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INTRODUCTION 

Chapter 1 
USEFULNESS OF DECISION MODELS TO GUIDE REPERFUSION 
THERAPY IN PA TIENTS WITH 
EVOLVING MYOCARDIAL INFARCTION 
4 CHAPTER 1 
Myocardial infarction is one of the leading causes of death among adults in the 
Western World. In The Netherlands, yearly approximately 20,000 men and 
10,000 women are admitted with this disease, which is responsible for circa 
12% of annual mortality (figure).[1.2l Myocardial infarction is an acute 
coronary syndrome, which may happen during the chronic process of 
coronary atherosclerosisp·4l At a certain stage in this process fissuring and 
disruption of the growing atherosclerotic plaque may occur, initiating 
intraluminal thrombus formation. Such thrombi may cause total occlusion of 
the coronary artery, so that oxygen delivery to the myocardium is blocked. IE 
th is situation persists for more than 30 minutes, irreversible damage to the 
myocardium, i.e. myocardial infarction, will occur.[Sl Prolonged duration of 
coronary occlusion results in a progressive increase of the infarcted area, until 
the whole area at risk becomes necrotic. Generally, after approximately six 
hours of continuous occlusion the infarct has reached its full extension.[5l 
Although the notion that myocardial infarction is caused by acute 
coronary thrombosis was already advanced in the beginning of this century,l6l 
the correctness of this idea was demonstrated only in the early 1980s, by 
studies of DeWood et al.[7] Since that time, treatment strategies have been 
introduced that aimed at rapid and lasting restoration of the coronary blood 
circulation. The overall benefits of these 'reperfusion' strategies have been 
established unequivocally.[8l Timely reperfusion therapy interrupts the process 
of evolving myocardial necrosis, which results in salvage of viabie 
myocardium, preservation of left ventricular function and, consequently, 
improved survival. Nowadays, physicians can choose among different 
thrombolytic drug regimens based on streptokinase, reteplase and altepiase. In 
some hospitals also direct angioplasty is an alternative. 
The beneficial effect of reperfusion therapy depends on patient's 
demographic characteristics, the location and extend of the jeopardised 
myocardium, and the duration of the coronaly occlusion.[9l Furthermore, the 
different treatment options have their intrinsic properties, effects and costs. 
Key questions in clinical practice are therefore, how widely thrombolytic 
therapy should be used, and whether different reperfusion strategies should be 
chosen for different types of patients and in different clinical circumstances. 
This is even more of an issue when medical resources are limited. Since the 
first six hours of symptom onset are of vital importance in treatment of 
myocardial infarction patients,[lOl time to weight potential benefits, risks and 
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costs in individual patients is fairly limited. In th is situation a decision model 
which integrates all relevant aspects might be very useful. 
The present thesis reflects the development of such clinical decision modeIs, 
with the foundation laid in the 'Premises' and the upshot given in the part on 
'Practical decision models' . Chapter 2 presents an overview of the most 
relevant randomised trials which studied the effects of various reperfusion 
strategies in myocardial infarction. Chapter 3 describes the relationship 
between treatment delay and -benefit. Chapter 4 evaluates to which degree 
consensus exists about factors that determine efficacy and applicability of 
reperfusion therapy in clinical practice among several groups of investigators. 
In chapters 5 and 6 the ingredients as described in the 'Premises' are moulded 
into reperfusion treatment modeIs. Sets of tables are presented which 
summarise treatment effects in individual patients. These can be implemented 
in clinical care for rapid and consistent decision making. Disu'ibution of 
available resources with help of these tables is evaluated in an actual cohort of 
20% 
• Male 
~ Female 
0% 
25-34 35-44 45-54 55-64 65-74 75-84 <:85 
Age (years) 
Figure: Mortality due to myocardial infarction as a percentage of overall mortality, 
.ccording to age, in the Dutch population of 1993 
6 CHAPTER 1 
Dutch myocardia! infarction patients. Sensitivity analyses are performed. In 
chapter 7 the importance of very early, pre·hospita! reperfusion therapy is 
recognised. Benefits and risks of severa! pre· hospita! thrombolysis strategies 
are studied. A genera! discussion of the resu!ts is presented in chapter 8, in 
which a!so practical and ethica! consequences of medicine according ra 
protocol are addressed. 
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Chapter 2 
AN OVERVIEW OF THE CLINICAL EFFICACY OF CURRENTLY 
A VAILABLE REPERFUSION TREATMENT OPTIONS IN 
MYOCARDIAL INFARCTION 
Boersma E, Simoons ML 
Evidence-based ca,.diology. Reperfusion strategies in acute myoca,.dial infa,.ction 
Eur HeartJ 1997; 18: 1703-11 
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INTRODUCTION 
The understanding that a myocardial infarction is usually caused by an acute 
thrombotic obstruction of a coronary artery has led to a major change in the 
approach of this diseasePl Since the early 1980s, pharmacological and 
mechanical interventions have been introduced that aimed at rapid and 
sustained restoration of blood flow in the occluded artety. This approach has 
been successful, and considerable progress hàs been achieved since that time. In 
The Netherlands, in 1980, in-hospital mortality aftel' myocardial infarction 
was approximately 15.6% (24.3%) in male (female) patients, whereas nowadays 
this figure is markedly reduced to about 11.3% (18.5%).[2] 
The effects of various treatment strategies have been evaluated in a 
number of randomised trials. Speeially attention was paid te the properties of 
thrombolytic, antiplatelet and anticoagulant therapy, alone and in 
combination, and more recently direct angioplasty was studied. The present 
paper presents a survey of the most relevant results observed in these trials, 
and reviews whether and te what extent evidence for benefit can be claimed 
for different reperfusion strategies. An overview of other review articles is 
presented in table 1. 
THROMBOL YTIC THERAPY 
Treatment witbin six baars of symptam anset 
Restoration of blood flow to the jeopardised myocardium within 6 h of 
symptom onset preserves viabie myocardial tissue, which protects left 
ventricular function, and consequently reduces mortality (we appreeiate, that 
this reasoning simplifies complex biochemical processes, and disregards the 
paradoxical fact that early reperfusion might also cause some cellular injury, 
even though the overall effects are clearly benefieial)Pl By intracoronary 
infusion of streptokinase recanalisation can be achieved in approximately 80% 
of patients,l'·5l At the same time the enzymatic infarct size is reduced by 20%-
35% compared with control therapy, and left ventricular function is 
preserved.[6.7J Mortality aftel' intracoronary streptokinase was evaluated in a 
couple of relatively small randomised controlled clinical trials. Pooled analysis 
of the results of these trials (including approximately 1,000 patients) indicate 
that use of intracoronary streptokinase results in a non-significant 15% relative 
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Theme of the overview Keywords Author Year ol 
publication 
Mortality, reinfarction and thrombolytic therapy, Yusul et al[8J 1985 
adverse events af ter intra- intracoronary infusion, 
coronar}' and intravenous intravenO\ls infusion 
thrombolysis 
Development of routine thrombolytic therapy, Yusul et al[57J 1990 
medical management aspirin, heparin, beta-
blockers, calcium blockers, 
nitrates 
All randomised trials thrombolytic therapy, Fibrinolytic 1994 
between librinolytic and overall evidence, subgroup Therapy Trialists' 
control therapy which analysis Collaborative 
include at least 1,000 Group[20J 
patients 
Prolonged antiplatelet antiplatelet therapy, Antiplatelet 1994 
therapy (in myocardial vascular death, Trialists' 
infarction patients among reinfarction, stroke Collaboration[4lJ 
others) 
Effects ol anticoagulant heparin, aspirin, Collins et alP'J 1996 
therapy in coherence with reinfarction, stroke, 
antiplatelet treatment pulmonary emboHsm 
Effects ol thrombolytic thrombolytic therapy, Boersma et a1.[21J 1996 
treatment delay on moe- time to treatment 
tality in randomised trials 
which include at least 100 
patients 
Randomised clinical trials thrombolytic therapy, Collins et aIP'J 1997 
of aspirin, heparin and aspirin, heparin 
librinolytic therapy 
Comparison of thrombo- thrombolytic therapy, \'{T eaver et al.{49] 1997 
lytic therapy vs. primary angioplasty 
coronary angioplasty 
Table 1: Review·articles which address mortality based Oll randomised trials on 
reperfusion therapy in acute myocardial infarction 
-tv 
Comparison Study N Antiplatelet Anticoagulant Timeto Follow-up Year of 
therapy therapy therapy publication 
N-SK vs. standard therapy GISSI-l [101 11,806 no no 0-12 h 21 days 1986 
N-SK vs. placebo and ISIS.i"1 17,187 ASA (50%) no 0-24 h 35 days 1988 
ASA vs. placebo 
N-SK vs. placebo ISAM'I 1,741 ASA N_Hep(l) 0-6 h 21 days 1986 
EMERAS[231 4,534 ASA no >6-24 h in hospita! 1993 
APSAC vs. placebo AIMS[161 (2) 1,254 no N-Hep 0-6 h 30 days 1988 
rt-PA vs. placebo ASSET[l7] 5,012 no N-Hep 0-6 h 1 month 1988 
LATE[241 5,711 ASA N-Hep (64%)(3) >6-24h 35 days 1993 
N-UK vs. standard therapy USIM[591 2,201 no N_Hep(4) 0-6 h in hospita! 1991 
N-SK vs. rt-PA (lSIS-3: vs. GISSI-i28)'1 20,749 ASA SC-Hep (50%) 0-6 h in hospita! 1990 
APSAC) and Hep vs. non-Hep ISIS-3[301 (5) 41,299 ASA SCHep (50%) 0-24h 35 days 1992 
N-SK vs. rt-PA vs. GUSTO-l[3J1 (6) 41,021 ASA Hep (SC 25% 0-6 h 30 days 1993 
combination and N 75%) 
N-SK vs. r-PA INJECT[37] 6,010 ASA N-Hep 0-12 h 35 days 1995 
rt-PA vs. immediate PTCA GUSTO-2b[4S1 (7) 1,138 ASA N-Hep (50%) 0-12 h 30 days 1996 
Hirudin (50%) 
rt-PA vs. r-PA GUSTO-3 [3S1 (8) 15,100 ASA N-Hep 0-6h 30 days 1996 
(") 
Table 2: Characteristics of all randomised trials on short-term mortality after reperfusion therapy in acute myocardial ~ 
infarction that include at least 1,000 patients t;J 
'" tv 
SK = streptokinase; APSAC = anisoylated plasminogen streptokinase activator; UK = urokinase; tt-PA = altepIase; r-PA = 
reteplase; PTCA = percutaneous transluminal coronary angioplasty; ASA = aspirin; Hep - heparin; IV = intravenous; SC = 
subcutaneous 
If no comments are made, treatment schedules were used as follows: SK: 1.5 MU over 1 h; UK: 1 MU bolus, repeated after 1 h; tt-
PA: 10 mg bolus + 50 rog over 1 h + 20 mg over each of next 2 h; APSAC: 30 U over 3-5 min; r-PA: two boluses of 10U given 
30 min apart; ASA: 160-325 mg/day; SC-Hep: 12,500 U twice dayly; IV-Hep: 5,000 U bolus + 800-1,200 U/ho 
(1) Additional oral anticoagulant therapy; (2) AlMS planned to include 2,000 patients, but tenninated prematurely because of an 
extreme mortality reduction by APSAC observed in an interim analysis half-way the trial; no Hep bolus was given, but instead 
1,000-1,500 U/h; additional oral anticoagulant therapy; (3) after protocol amendment; some patients received 2 boluses of 5,000 
U; (4) 10,000 U bolus; (5) tt-PA regimen: 0.04 MU/kg bolus + 0.36 MUlkg over 1 h + 0.067 MU/kg over next 3 h; (6) 
comparison of 4 groups: IV-SK, SC-Hep vs. IV-SK, IV-Hep vs. tt-PA (15 mg bolus + 0.75 mg/kg over 30 min + 0.5 mg/kg over 
ne"-"t hl, IV-Hep vs. tt-PA (0.1 mg/kg bolus + 0.9 mg/kg over 1 hl, IV-SK (1.0 MU over 1 hl, IV-Hep; (7) primary study endpoint 
was a composite of death, non-fatal reinfarction and non-fatal disabling stroke; the tt-PA regimen is equa! to GUSTO-l; patients 
were randomised to IV-Hep or hirudin (0.1 roglkg bolus + 0.1 rog/kg/hl; (8) the tt-PA regiroen is equal to GUSTO-1. 
tti 
-< 
:>-
~ 
fil 
~ 
I 
,... 
<.N 
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reduction in one-year mortality, from 14.7% to 12.5% [odds ratio (OR) 0.82 
and 95% confidence interval (Cl) 0.56-1.19; chi-square-test for 2x2 contingency 
table p~0.32].[8J 
Intracoronary drug infusion requires angiography, which is laborious, 
expensive and causes further treatment delay. Therefore, subsequent 
investigations concentrated on intravenous infusion of streptokinase. The 
largest trials in this context, GISSI-1, ISAM and ISIS-2, comprehend 30,600 
patients, who were randomised to either intravenous streptokinase or control 
therapy (tabie 2)P-IIJ In the patients treated within 0-6 h of onset of symptoms 
(N ~22,200), mortality at one month was significantly reduced by intravenous 
streptokinase from 12.0% to 9.2% [23% reduction; OR 0.74 and 95% Cl 0.68-
0.81; p < 0.0001], figure 1. 
The most feared complication related to thrombolytic therapy is the 
occurrence of intracranial haemorrhage, which leads to death in half of the cases 
and to severe disability in another quarter.[12J Embolie stroke rates are reduced 
in patients receiving thrombolytic therapy. The occurrence of any 
cerebrovascular accident in the GISSI-1, ISAM and ISIS-2 trials was slightly, but 
not significantly increased, from 0.74% in the control group to 0.79% in the 
intravenous streptokinase group (figure 1). 
Other intravenous thrombolytic drugs have been developed that might 
produce more rapid thrombolysis than streptokinase, resulting in higher early 
coronary patency rates.[13-15J One such second-generation drug, anisoylated 
plasminogen streptokinase activator (APSAC), has the additional advantage of 
a relative long half life, so that a single injection would be sufficient. This 
thrombolytic was evaluated in the placebo controlled AIMS study (1,000 
patients randomised within 0-6 h; table 2),[16J which reported a 6.4% mortality 
at one month in the APSAC group compared with 12.2% in placebo [48% 
reduction; OR 0.48 and 95% Cl 0.30-0.70; p~O.OOl]. No excess 
cerebrovascular accidents occurred in the active group. The ASSET trial (tabie 
2) studied recombinant tissue-type plasminogen activator (rt-PA),r17J which has 
the advantage over streptokinase and APSAC of being non-antigenic. 
Approximately 5,000 patients were randomised within 0-6 h, and mortality at 
one month was 26% reduced, from 9.8% to 7.2% by rt-PA compared with 
placebo [OR 0.72 and 95% Cl 0.58-0.88; p~O.OOl]. Stroke rates were similar in 
both groups. 
Ev ALUATION OF THE EVIDENCE 
12% 
10% 
8% 
6% 
4% 
2% 
0% 
2% 
p<O.OOOI 
12.0% 
NS 
Placebo SK 
GISSI-jllOI,ISAMl'1 
and ISIS-2[1l] 
N~22,2OO 
NS 
p<O.OOI 
SK 
ASA 
rt-PA APSAC 
ASA ASA 
GISSI_2[28,29] 
and ISIS-3[301 
N~46,600 
p~O.OI 
p~0.02 
1.98% 
p~O.Q3 p~0.007 
SK 
ASA 
Ace rt-PA Lytic PTCA 
ASA 
SQ Hep IVHep 
GUSTO-ll3J] Weaver et aU"] 
N~20,100 N-2,600 
15 
Figure 1: One-month mortality and stroke rates aftel' thrombolytic therapy or 
immediate angioplasty in patients with suspected myocardial infaretion treated 
within 0·6 h of onset of symptoms 
Grey bars represent mortality in the 0·6 h patients. Black bars represent stroke·rates 
(haemorrhagie or embolie) in all patients. Mortality data lrom the overview ol Weaver 
et al. is also flot restricted to the 0-6 h cohort. 
SK = streptokinase; APSAC = anisoylated plasminogen streptokinase activatorj rt-PA 
= recombinant tissue type plasminogen activatorj PTCA = percutaneous transluminal 
coronary angioplastyj ASA = aspirin; Hep = heparin 
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Very eady treatment 
Experimental data and measurements of myocardial enzymes in hu mans 
suggest that most of the irreversible damage to the myocardium occurs 
between 1 and 2 h after coronary occlusion.[18,19J Thus, appreciable additional 
benefit might be expected from very eady thrombolytic therapy. However, in 
a pooled analysis of the large trials (N =58,600) by the Fibrinolytic Therapy 
Trialists (pTT analysis) there was no marked discontinuity in mortality 
reduction as a result of thrombolytic therapy with regard to time of symptom 
onsetpoJ Recently, this analysis has been criticised, and it has been 
demonstrated that the beneficial effect of fibrinolytic therapy is indeed 
substantially higher in patients presenting within 2 h of symptom onset 
compared to those presenting later.[21J This 'golden hour' concept, however, is 
stil! controversial.[6J 
Treatment aftel' six hOI/I's 
Thrombolytic treatment af ter 6 h of continuous coronary occlusion is 
unlikely to prevent myocardial necrosis. Nevertheless, there are some reasons 
for a beneficial effect on post-infarct survival in patients presenting relatively 
late after onset of symptoms.[6,22J One argument is, that many patients suffer 
from intermittent occlusions rather than one continuous occlusion - coronary 
thrombus formation and resolution is adynamie process - so that partial 
salvage of ischaemic myocardium may stil! be achieved. Furthermore, existing 
collaterals may preserve some blood flow to the jeopardised area. FinaHy, even 
relatively late opening of the occluded artery wil! improve the healing process 
of the infarction and reduce left vent ri cu lar remodelling and dilatation. 
The combined results of the GISSI-1, ISIS-2 and EMERAS trials indicate 
that treatment with intravenous streptokinase within 6-12 haf ter onset of 
symptoms (N=8,100) wil! reduce one-month mortality by 11% compared 
with control therapy, from 13.9% to 11.9% [OR 0.87 and 95% Cl 0.76·0.99; 
p=0.04],llO,l1,2JJ which is half the reduction observed in the 0-6 h period. The 
LA TE trial of rt-PA vs. placebo (tabie 2) reported a 26% mortality reduction, 
from 12.0% to 8.9% [OR 0.12 and 95% Cl 0.53-0.96; p=0.02] in the relatively 
small 6-12 h cohort (N =2,100).[24J In patients randomised within 12-24 h of 
symptom onset (N =9,000 in the FTT-analysis) no significant reduction in one-
month mortality was observed following thrombolytic therapy.[20J 
EVALUATION OF THE EVIDENCE 17 
Overall clinical benefit of thrombolytic therapy 
From 1980 over 61,000 patients with suspected myocardial infarction 
participated in trials that randomised between thrombolytic therapy and 
control, within 24 h of onset of symptoms. The FTT analysis, which covers 
about 95% of the data, indicates a highly significant 17% one-month mortality 
reduction by t1uombolysis from 11.5% to 9.6% [OR 0.82 and 95% Cl 0.78· 
0.87; p<O.OOOl], which corresponds to an avoidance of 18 lSD 3] deaths per 
1,000 patients treated.(6.20J Thrombolytic therapy increases the occurrence of 
cerebrovascular accidents from 0.76% to 1.16% [OR 1.52 and 95% Cl 1.28- 1.81; 
p<O.OOOl], reflecting a small excess of about 4 [1] strokes (mainly intracranial 
bleedings) per 1,000 treated. It should be realised that half of this excess is 
already accounted for in the mortality data. Follow-up studies show that the 
mOltality reduction produced by thrombolytic therapy is sustained throughout 
at least four to ten years.[25.26.27J 
Comparison of thrombolytic regimens 
Superficial comparison of the results described above suggests, that APSAC 
(single injection of 30 U) and, to alesser extent, rt-PA (100 mg infusion over 3 
h) might be more effective than streptokinase (infusion of 1.5 MU over 1 hl. 
However, direct comparisons in patients randomised within 0·6 h in the 
GISSI-2 (streptokinase vs. rt-PA, N ~20,800) and ISIS-3 trials (streptokinase vs. 
rt-PA vs. APSAC, N~25,800; table 2)pSo30J showed no significant difference in 
one-month mortality between streptokinase and non-streptokinase regimens 
(figure 1). On the other hand, cerebrovascular accidents were slightly, but 
significantly, more frequent in the non-streptokinase groups [stroke rate 1.39% 
in rt-PA vs. 1.04% in streptokinase; OR 1.37 and 95% Cl 1.15-1.62; p<O.OOl]. 
Thus, the chosen rt-PA and APSAC regimens in GISSI-2 and ISIS-3 appeared 
not to be superior to streptokinase. There were some indications, however, 
that a soocalled 'accelerated' rt-PA infusion - i.e. over 1.5 h, with two thirds of 
the dose given in the first 30 min - williead to greater infarct artery patency, 
which can be sustained with intravenous heparin infusionp,,32J The 
accelerated rt-PA regimen has been evaluated in the GUSTO-1 trial, which 
randomly assigned 41,000 patients (within 0-6 h of symptom onset) to four 
different thrombolytic strategies (tabie 2). Treatment with accelerated rt-PA 
and intravenous heparin significantly reduced one-month mortality compared 
with streptokinase and subcutaneous heparin, the 'standard' streptokinase 
regimen, from 7.2% to 6.3% [13% reduction; OR 0.87 and 95% Cl 0.78-0.97; 
18 CHAPTER2 
p~O.Ol], figure 1.[3J] This mortality reduction was sustained throughout at 
least one year.[34] Left ventricular function was also better in patients 
randomised to accelerated rt-PAPS] Conversely, the incidence of 
cerebrovascular accidents was increased from 1.19% to 1.55% [OR 1.31 and 
95% Cl 1.02-1.67; p~0.03]p2] Thus, the accelerated rt-PA regimen produces a 
clear, albeit modest, overall clinical benefit compared with 'standard' 
streptokinase. This conclusion, however, is not shared by all investigators in 
the field.[6,16] 
Nowadays, to prove that new thrombolytic agents significantly reduce 
mortality compared with established strategies, trials require inclusion of tens 
of thousands of patients. To demonstrate, however, that the properties of new 
drugs are similar to established therapies, considerably fewer patients are 
needed. One such 'equivalence' trial is INlECT (N ~6,000; table 2). This trial 
demonstrated that the two boluses of 10 MU reteplase regimen is at least 
equivalent to 'standard' streptokinase: mortality at one month was 9.0% and 
9.5%, respectively, whereas stroke rates were 1.23% and 1.00%.[37] The recent 
GUSTO-3 trial (N ~ 15,100; table 2) compared reteplase with the GUSTO-1 
accelerated rt-PA regimen, and observed no statistically significant differences 
in 30-day mortality (7.2% after accelerated rt-PA and 7.4% after reteplase) or 
cerebral complications (stroke rates were 1.83% and 1.67%, respectively)PS] 
Thus, clinical effects of reteplase seem to be in between 'standard' 
streptokinase and accelerated rt-PA. 
ANTIPLA TELET AND ANTICOAGULANT THERAPY 
Immediate and tempo1'a>y IIse 
ISIS-2 (N ~ 17,200) assessed the value of antiplatelet therapy in acute 
myocardial infarctionPI] Patients were randomised not only to intravenous 
streptokinase or placebo, but also to oral aspirin (162.5 mg daily for one 
month) or placebo (tabIe 2). Aspirin significantly reduced one-month 
mortality from 11.8% to 9.4% [20% reduction; OR 0.77 and 95% Cl 0.70-0.85; 
p<O.OOOl], figure 2. The occurrence of cerebrovascular accidents was also 
significantly reduced, from 0.94% to 0.55% [41% reduction; OR 0.58 and 95% 
Cl 0.40-0.84; p~0.003], while intracranial haemorrhage rates were similar. In 
patients allocated both intravenous streptokinase and aspirin one-month 
mortality was 8.0% compared with 13.2% in those allocated both placebo 
Ev ALUAT10N OF THE EVIDENCE 
14% 
12% 
10% 
8% 
6% 
4% 
2% 
p<O.OOOI 
14.9% 
0% f-......... rif-.... f--
2% 
Placebo ASA 
IS1S·2[1I] 
N~17,200 
2.14% 
Placebo Hep 
Collins et aU"] 
N~5,000 
p<O.OOOI 
Both SK 
placebo ASA 
ISIS·2[1I] 
N~8,600 
8.8% 
NS 
SK 
ASA 
SK 
ASA 
Hep 
Collins et aU"] 
N~63,300 
19 
Figure 2: One-month mortality and stroke rates aftel' antiplatelet or anticoagulant 
therapy in patients with suspected myocardial infaretion 
Grey bars represent mortality and bJack bars represent stroke rates (haemorrhagic or 
embolie). 
SK = streptokinase; APSAC = anisoylated plasminogen streptokinase activator; rt-PA 
= recombinant tissue type plasminogen activator; PTCA = percutaneous transluminal 
coronary angioplasty; ASA = aspirinj Hep = heparin 
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[39% reduction; OR 0.56 and 95% Cl 0.48·0.66; p<O.OOOll, figure2. Thus, 
streptokinase and aspirin show additive effects. 
The properties of anticoagulant therapy in the absence of antiplatelet 
therapy are evaluated in a couple of randomised trials, covering about 5,000 
patients (all of them received heparin, but doses and mode of administration 
varied).l39] Heparin decreased short-term mortality to 11.4% compared with 
14.9% aftel' control treatment [23% reduction; OR 0.74 and 95% Cl 0.62-0.87; 
p~0.0003l, figure 2, and cerebral complications were reduced from 2.14% to 
1.14% [47% reduction; OR 0.53 and 95% Cl 0.31-0.90; p~O.Ol]. These results 
are comparable with aspirin in the absence of anticoagulant therapy. There are 
very few data about the combination of thrombolytic and anticoagulant 
therapy in non-aspirin patients.l39] 
The value of anticoagulant treatment added to the combination of 
thrombolytic and antiplatelet therapy was evaluated in about 63,300 patients, 
who were randomised to subcutaneous heparin (the GISSI-2 and ISIS-3 
regimen, table 2) or control therapy.l39] A small non-significant 4% short-term 
mortality reduction was observed in the heparin group (mortality 8.8% in the 
heparin group and 9.2% in controls [OR 0.95 and 95% Cl 0.90-1.01; p~0.09l, 
figure 2). Stroke rates were 1.22% and 1.15% in heparin vs. non-heparin 
patients, respectively [OR 1.07 and 95% Cl 0.92-1.24; p~0.37l. In the 
GUSTO-1 study, no significant difference was observed between subcutaneous 
and intravenous heparin in patients treated with streptokinase. Thus, it may 
be concluded from the GISSI-2, ISIS-3 and GUSTO-1 studies that neither 
subcutaneous nor intravenous heparin adds much to the outcome in 
streptokinase patients. Therefore, recent guidelines do not recommend 
heparin as adjunctive therapy in myocardial infarction patients treated with 
streptokinase and aspirin.l40] 
Angiographic studies indicate that coronary patency is improved by 
adding intravenous heparin to rt_PApt,J2] As described above, the GUSTO-1 
accelerated rt-PA regimen, which included intravenous heparin, was 
significantly better than 'standard' streptokinase. Thus, although there are no 
large randomised trials that assess the clinical benefit of adding heparin to rt-
PA, the available data support the use of intravenous heparin for two or three 
days in patients receiving tt-PA. 
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Secondaly prevention 
Approximately 19,800 patients with recent myocardial infarction participated 
in trials that randomised between prolonged use, i.e. at least for one month, of 
aspirin or other antiplatelet agents (such as dipyridamole and sulfinpyrazone) 
and control therapy.[41] Antiplatelet therapy significantly reduced long-term 
mortality by 12%, from 10.4% to 9.2% [OR 0.88 and 95% Cl 0.80-0.96; 
p~0.006], non-fatal myocardial reinfarction by 28%, from 6.5% to 4.7% [OR 
0.70 and 95% Cl 0.62-0.80; p<O.OOOl] and non-fatal stroke by 33%, from 1.5% 
to 1.0% [OR 0.63 and 95% Cl 0.47-0.84; P < 0.001]. 
Two recent randomised trials evaluated the value of long-term oral 
anticoagulant treatment (warfarin or coumadin vs. placebo) in about 4,600 
survivors of myocardial infarction.[42,43] Mortality at three years was 11.4% in 
the anticoagulant group and 13.5% in the placebo group, which implies a 
reduction of 15% [OR 0.83 and 95% Cl 0.69-0.99; p~0.03]. Recurrence of 
myocardial infarction was reduced by 46%, from 15.8% to 8.5% [OR 0.49 and 
95% Cl 0.41-0.60; P < 0.0001], as was the occurrence of cerebrovascular 
accidents, from 4.6% to 2.5% [OR 0.53 and 95% Cl 0.37-0.74; p~O.OOOl]. 
Thus, prolonged use of aspirin or coumadin prevent reinfarction, stroke 
and mortality af ter myocardial infarction. The salutary effects of coumadin 
seem somewhat largel', but direct comparisons of antiplatelet and 
anticoagulant therapy are lacking. One trial recently reported that aspirin and 
low-dose coumadin resulted in similar effects.[44] However, that trial was 
stopped prematurely because outcomes in the two groups were virtually 
identÎcal. Other trials comparing high dose coumadin and aspirin are ongoing. 
IMMEDlATE ANGIOPLASTY 
The most important conceptual deficit of thombolytic therapy in patients 
with evolving myocardial infarct ion is, that such pharmacological intervention 
only aims to dissolve the acute coronary th rombus. On the other hand, 
mechanical intervention by means of immediate coronary angioplasry also 
treats the underlying atherosclerotic plaque. Thus, recurrence of ischaemia and 
reocclusion are less likely af ter angioplasty than aftel' thrombolysis. 
Additionally, less serious (cerebral) bleeding complications are to be expected. 
Whereas routine angioplasty aftel' thrombolytic therapy appeared not be 
successful,l14,45] clinical trials that randomised between direct angioplasty and 
22 CHAPTER2 
thrombolytic therapy initially reported excellent (extreme) results in support 
of the invasive strategy.(46,47J However, results of the recent larger GUSTO-2b 
angioplasty substudy (N ~ 1,100; table 2), which applied the GUSTO-l 
accelerated rt-PA regimen, were less favourable.(48J Overall, among the 2,600 
patients randomised in all of the angioplasty trials, short term mortality was 
significantly reduced from 6.5% af ter thrombolytic treatment to 4.4% af ter 
primary angioplasty [33% reduction; OR 0.66 and 95% Cl 0.46-0.95; p~0.02l, 
figure l.(49J The risk of stroke was reduced from 1.98% to 0.70% [65% 
reduction; OR 0.35 and 95% Cl 0.14-0.77; p~0.007l. The wide confidence 
intervals reflect the relative small number of patients randomised, which 
necessitates a careful interpretation of the estimates of benefit. Furthennore, it 
should be realised that these results are obtained by high volume angioplasty 
operators and experienced teams. Nevertheless, direct angioplasty might be 
considered the treatment of choice, particularly in patients at high risk of 
death or cerebral haemorrhage. 
Current trials address the issue whether implantation of coronary stents 
is associated with additional benefits,fsoJ Trials are also ongoing to establish the 
value of special catheter devices designed to remove thrombotic material by 
section or ultrasound in selected patients with a high dot burden. 
FUTURE DIRECTIONS 
DiI'eet thrombin inhibitors 
Heparin is an indirect thrombin inhibitor, requiring the presence of anti-
thrombin m. Direct thrombin inhibitors, like hirudin and hirulog, do not 
require this enzyme and might therefore be expected to be more effective. 
Direct thrombin inhibitors also act on platelet bound thrombin. However, 
two large randomised studies in patients with evolving myocardial infarction 
(TIMI-9 and GUSTO-2) did not show a significant advantage of hirudin over 
heparin in combination with thrombolysis.(51,s2J The high dose of hirudin 
initially used in these trials resulted in an unacceptable high rate of intracranial 
haemorrhage, which was also observed in the HIT trial.[S3J The subsequently 
low doses used, largely avoided these complications, but had little (GUSTO-
2b) or no (TIMI-9b) effect on survival.[S4,SSJ Studies with other thrombin 
inhibitors in combination with thrombolytic therapy are ongoing. 
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P/atelet glycoprotein IIb/IIIa receptor b/ockers 
Aspirin is a weak inhibitor of platelet aggregation. More extensive, or even full 
inhibition of platelet aggregation can be achieved with the new platelet 
glycoprotein nb/IDa receptor blockers. The first such agent, abciximab, has 
been shown to be very effective in patients undergoing coronary angioplasty, 
including angioplasty for myocardial infarction. Pre-treatment with abciximab 
while preparing for direct angioplasty may resolve the occlusive clot in some 
patients.l56l In animal experiments combined treatment with glycoprotein 
nb/IDa receptor blockers and thrombolytics has been shown to facilitate clot 
lysis. Studies assessing the clinical value of such treatment in patients with 
evolving myocardial infarction are ongoing. Again, it is possible that such 
combination treatment will improve reperfusion and reduce reocclusion rates, 
but it might also increase the bleeding risk. 
CONCLUSIONS 
• Thrombolytic treatment of suspected myocardial infarction within 0·6 h of 
onset of symptoms will avoid approximately 25 deaths per 1,000 patients, 
while 4 cerebrovascular complications will be caused. 
• The beneficial effect of thrombolytic therapy very much depends on the 
time of symptom onset. However, thrombolytic therapy is generally 
beneficial up to 12 haf ter the onset of symptoms, and in some patients 
(those with ongoing ischaemia) even up to 24 h. 
• Administration of antiplatelet or anticoagulant therapy will avoid about 20 
deaths and 5 cerebrovascular accidents per 1,000 patients. The beneficial 
effects of thrombolytic therapy and aspirin are largely independent. 
Subcutaneous heparin adds little to combination therapy with a 
thrombolytic agent and aspirin, while intravenous heparin is recommended 
in patients treated with (accelerated) altepiase. 
• There are moderate, but significant differences in outcome between several 
reperfusion strategies: direct angioplasty being most effective, and 
accelerated altepiase (with intravenous heparin) being slightly superior to 
streptokinase. However, most emphasis should be on rapid installation of 
some effective therapy without worrying overmuch about which strategy to 
choose. 
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• Secondary prevention with either antiplatelet or anticoagulant therapy has a 
modest effect on mortality, but substantially reduces the risk of recurrent 
myocardial infarction. 
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SUMMARY 
Background 
There is conclusive evidence from clinical trials that reduction of mortality by 
fibrinolytic therapy in acute myocardial infarction is related to the time elapsing 
between onset of symptoms and commellcement of treatment. However, the exact 
pattern of this relation continuous to be debated. This paper discusses whether or 
not appreciable additional gain can be achieved with very early treatment. 
Methods and findings 
The relation between treatment delay and short-term mortality (up to 35 days) was 
evaluated using tabulated data from all randomised trials of at least 100 patients 
(n~22; 50,246 patients) that compared fibrinolytic therapy with placebo or control, 
reported between 1983 and 1993. 
Benefit of fibrinolytic therapy was 65 [SD 14], 37 [9], 26 [6] and 29 [5]lives 
saved per 1,000 treated patients in the 0-1, <:1-2, ;>2-3 and ;>3-6 h intervals, 
respectively. Proportional mortality reduction was significantly higher in patients 
treated within 2 h compared to those treated later (44% [95% Cl 32-53] vs. 20% [15-
25]; p~O.OOl). The relation between treatment delay and mortality reduction per 
1,000 treated patients was expressed significantly better by a non-linear (19.4-
0.6x+29.3x·1) than a linear (34.7-1.6x) regression equation (p~0.03). 
Conclusion 
The beneficial effect of fibrinolytic therapy is substantially higher in patients 
presenting within 2 haf ter symptom onset compared to those presenting later. 
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INTRODUCTION 
The reduction in mortality that can be achieved with reperfusion therapy in 
patients with evolving myocardial infarction depends on the time elapsing 
between onset of symptoms and initiation of treatment or more specifically, 
on the duration of coronary occlusion before reperfusionP] Although earlier 
reperfusion yields a better clinical outcome, the relation between treatment 
delay and mortality reduction is still controversia!. A key question is whether 
or not a substantial additional reduction of the mortality risk can be achieved 
with very early treatment, i.e. within 2 to 3 haf ter onset of symptoms. The 
concept of a 'first golden hour,I'] is supported both by experimental studies 
and randomised trials comparing pre-hospital with in-hospital therapy.I2,J] By 
contrast, the Fibrinolytic Therapy Trialists' (pTT) Collaborative Group, in a 
pooled dataset of randomised trials of more than 1,000 patients,I4] reported 
onlya gradual decrease of benefit with longer delay. We present an alternative 
analysis of data from previous trials. 
Experimental stIldies 
The duration of coronary occlusion and the extent of collateral circulation are 
the main determinants of infarct size in pigs, dogs, cats and other animals.I5.7] 
In animals with a corona,y collateral circulation similar to that of humans an 
occlusion persisting for 15-30 min generally does not lead to significant 
myocardial damage.I6.7J Thus, necrosis can be prevented provided reperfusion 
is achieved within th is period.I8] A small area of necrosis usually occurs with 
reperfusion af ter 45 min occlusion, while the mid-endocardial and sub-
endocardial zones are still viable.I6] Longer durations of corona,y occlusion 
result in progressive growth of the infarction and reduction of the amount of 
salvageable myocardium. At 90 min the extent of cell death involves 40%-50% 
of the area at risk; less than half of the jeopardised myocardium remains viabie 
at that time point.I3,6] Six hours af ter the onset of continuous ischaemia the 
area at risk is fully infarcted such that myocardial salvage will be minima!. 
In humans, the thrombotic event frequently consists of multiple cycles of 
temporary occlusion and reperfusion. The degree of chest pa in (if present) 
varies among patients so that it is often difficult to determine the exact 
duration of the coronary occlusion. Nevertheless, data indicate that evolution 
of (enzymatically detectable) infarct size over time in humans shows a pattem 
similar to that in animals.I9] 
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Pre-hospital versus in-hospital thrombolysis 
Various clinical trials have showh that early resto rat ion of eoronary pateney 
improves survivalpO-13l Later reeanalisation mayalso be beneficial, partieularly 
in patients with sufficient eollateral flow and those with stuttering infarction. 
Randomised trials comparing pre-hospital with in-hospital therapyl4-21l have 
shown a substantial benefieial effect of very early thrombolytic therapy. 
Although these studies were too small to show statistieal significanee, such 
significanee was reached in pooled analyses of the datap,22l The largest EMIP 
trial, with 5,469 randomised patients, reported 15 lSD 8] additional patients alive 
at 30 days per 1,000 patients as a result of one hour earlier treatment.[21l Figure 1 
shows the weighted regression line of all 8 randomised studies.[H-21l In these 
studies, the average delay from symptom onset to initiation of therapy was 2.1 h 
in the pre-hospital patients and 3.1 h in the in-hospital patientsP2l One hour 
earlier treatment within 3 h of symptom onset is assoeiated with a benefit of 
21 [6]lives per 1,000 treated (p~0.002). 
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Figure 1: Mortality at 35 days in randomised studies comp.ring pre-hospita! (circles) 
with in-hospita! (squares) thrombo!ytic therapy 
AU trials (except Ca5taigne) showed a trend favouring pre-ho5pita! thrombo!ysis. The 
regression line (bold, wcighted hy the number of patients included in the mortality 
resu!t) was main!y determined by the EMIP[ll] study. 
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PTT analysis 
The Fibrinolytic Therapy Trialists' Collaborative Group presented a 
systematic analysis of the pooled data from all unconfounded trials of 
fibrinolytic therapy vs. control or placebo that randomised at least 1,000 
patients with suspected myocardial infarction.[4J Nine trials were included 
with 58,600 patients, among whom 6,177 deaths (10.5%) were reported within 
35 days. The effect of treatment on mortality and morbidity was studied in 
various patient categories. One of the FTT subanalyses described the benefits 
of fibrinolytic therapy in 5 subgroups according to the delay from symptom 
onset to randomisation (0-1, d-3, ;:0,3-6, ;:0,6-12 and d2-24 h). Mortality 
reduction was highest among patients presenting in hospital within 1 h: the 
absolute benefit was 35 [11) additional patients alive per 1,000 treated. In 
patients presenting ;:0,1-3 and ;:0,3-6 h the benefits were 25 [5) and 19 [5) 
additional alive patients per 1,000 treated, respectively. 
In patients with ST elevation or bundie branch block (N ~45,000, 77% of 
the population) the absolute effects of fibrinolytic therapy were slightly larger. 
Benefits per 1,000 treated patients were 39 [12), 30 [5), 27 [6), 21 [7) and 7 [7) in 
the respective subgroups. The relation between these benefits and the average 
delay from symptom onset (0.98, 2.50, 4.79, 9.11 and 17.48 h, respectively) was 
described as a straight regression line. Every additional hour of treatment 
delay from onset of symptoms was associated with a reduction in benefit by 
approximately 1.6 [0.6)lives per 1,000 patients. 
The FTT investigators concluded from these data a gradually increasing 
benefit with earlier treatment, without significant additional treatment effect 
at 0-1 h. According to this analysis little would be gained by extra efforts to 
achieved very early, pre-hospital therapy. 
Alternative pl'esentation of the trial data 
Since the FTT analysis is at varianee with the experimental data, and with the 
larger benefit found in direct, randomised comparison of pre-hospital with in-
hospital therapy, an alternative presentation of the trial data may be 
appropriate. Furthermore, estimations of benefit for early treatment in the 
FTT analysis may have been influenced by the chosen framework for analysis. 
The inclusion-threshold of 1,000 patients for each of the 9 studies 
included in the FTT analysis is rather arbitrary. There is no good reason to 
exclude smaller trials. Although the number of patients in the smaller studies 
may not be sufficient to prove the effect of thrombolytic therapy, these studies 
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may nevertheless assist a more powerful estimation of treatment effects in 
subgroups of patients in a pooled dataset; more so, because several smaller 
studies excluded from the FTT analysis included a significant proportion of 
patients who were treated vely early, 
The statistical analysis was based on subdivision of patients according to 
delay from symptom onset with only two benefit estimations in the first three 
hours (at average delay times of 0,98 and 2,50 h, respectively), In th is way, part 
of a potential large effect in the first two hours may be obscured by a 
relatively small effect in the third hour, A more differentiated subdivision 
seems more appropriate to study the effect of very early therapy.f23J 
Furthermore, non-linear models might be developed and tested in addition to 
the linear FTT model. 
METHOOS 
For the reasons given, we studied the delay/benefit relation in a modified 
dataset, covering all randomised trials of fibrinolytic therapy vs, placebo or 
control which included at least 100 patients, These trials were reported 
between 1983 and 1993 and were indexed in the MEDLINE infonnation 
[24J Th 22 h 'I [12 IJ 25·44J Th 'd' , , f'b' I ' system. ere are suc tna s. ' , e In lcatlon lor 1 nno ytiC 
therapy in two of the trials may not have been appropriate: the USIM trial 
included a high proportion (32%) of patients with unstable angina, and the 
ISIS-3 uncertain indication group consisted of patients without or with only 
minor ST elevationi43.44J these patient subgroups are unlikely to benefit from 
fibrinolysis,[45.47J The USIM and ISIS-3 trials included 4,250 patients who were 
treated within 3 h of symptom onset and may therefore seriously bias benefit 
estimations for early treatment of those with confirmed infarction, 
Accordingly, we analysed data from previous trials both with and without 
inclusion of USIM and the ISIS-3 uncertain indication group, 
Tabulated data were collected on time from symptom onset and short-
term mortality (up to 35 days) , Mortality observations of the separate trials 
were positioned at the average treatment delay, if reported, and otherwise at 
the mid-point of the described time-window, The data of 11 trials were 
ff" I d 'I d b I" d'ff " I [12 IJ 27 29 31·33 41-44J su lelent y eta1 e to e sp 1t mto 1 erent time lnterva s. I , " • 
Patients were subsequently allocated to six subgroups according to treatment 
delay (0-1, <:1-2, ;:'2-3, ;:'3-6, ;:'6-12 and ;:'12-24 h from symptom onset to 
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randomisation). Absolute and relative mortality eHects of fibrinolytic therapy 
were evaluated in each of these categories. USIM and ISIS·3 uncertain 
indication patients were excluded from this analysis. 
Benefit was defined as the absolute mortality reduction, calculated as the 
diHerence in the percentage dying in the fibrinolytic group and the controls 
(we also calculated the SD and 95% Cl of this difference). Linear (a+ f3x) and 
non·linear (a+f3x+yx' and a+f3x+yx·1) regression analyses were performed to 
determine the relation between benefit and treatment delay. Regression 
functions were fitted in the tabulated data from the separate trials. Data were 
weighted by the inverse of the varianee of the absolute benefit described.[41 
Goodness of fit was expressed as the ratio of regression sum of squares and 
total sum of squares (R2·value). Regression analyses were performed both with 
and without USIM and ISIS·3 uncertain indication data. 
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Figure 2: Mortality at 35 days among fibrinolytic·treated and control patients, 
according to treatment delay 
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Figure 3: Proportional effect of fibrinolytic therapy on 35.day mortality aeearding 
to treatment delay 
Odds ratios, plotted with their 95% Cl on a log scale, are significantly different over the 
six groups (Breslaw-Day test, p~O.OOl) The areas of the blaek squares are propartianal 
to the amount of statistical information.(4] 
REsULTS 
The 22 trials included a totalof 50,246 patients, of whom 5,762 (11%) were 
randomised within 2 h of symptom onset and another 10,435 (21%) between 2 
and 3 h. Fibrinolytic therapy appeared to be beneficial up to at least 12 h 
(figure 2). The absolute reduction in mortality was greatest among patients 
who presented within 1 h of symptom onset (average delay 0.75 h). Benefit in 
this group was estimated at 65 [SD 14; 95% Cl 38-93]lives saved per 1,000 
treated patients, which is higher than the FTT estimation of benefit at nearly 
the same time point (0.98 h) of 35 [11]. Benefit was also higher in our analysis 
than in the FTT analysis among patients randomised in the second hour (37 [9; 
20-55] per 1,000 treated). The benefit per 1,000 treated in the subgroups 
presenting at d-3, ,,3-6, ~6-12 and d2-24 was respectively 26 [6; 14-37],29 [5; 
19-40], 18 [6; 7-29] and 9 [7; -5-22]. 
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Pigure 4: Absolute 35.day mortality reduction versus treatment delay 
Small c10sed dots: information from trials included in the PTT .n.lysis; open dots: 
information from additional trials; small squares: data beyond the scale of the x/y cross. 
The linear (34.7.L6x) and non·linear (19.4.0.6x+29.3x·1) regression lines are fitted within 
these data weighted by the inverse of the v.ri.nce of the absolute benefit in each 
datapoint,c4] Black squares: average effeets in six time·to-treatment groups (the areas of 
these squares are inversely proportional to the varianee of absolute benefit described. 
Similarly, the proportional mortality reduction was highest in the 1 h patients 
(48% [95% Cl 31·61]; figure 3), and significantly higher in patients treated 
within 2 h than in those treated later (44% [32-53] and 20% [15·25], 
respectively). By contrast with the FTT report, odds ratios differed 
significantly over the time·to·treatment groups (p-0.001, figure 3). 
The relation between absolute benefit of fibrinolytic therapy and 
treatment delay can be described by a linear function, similar to FTT, which 
shows a significant reduction in benefit of approximately 1.6 [0.5] lives per 
1,000 patients per hour of treatment delay (Ho: 13-0 rejected; p<O.OI; 
R'-0.22). This linear model was not significantly improved by addition of the 
term y/ (Ho: y-O not rejected; p-0.29; R'-0.25). However, the component 
yx.l of the second non-linear model had a significant contribution to the 
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regression function (Ho: y~O rejected; p~0.03). In fact, this latter model fits 
best with the data (R2~0.32), in particular with the early observations (figure 
4). Inclusion of the USIM and ISIS·3 uncertain indication data and exclusion of 
the intracoronary studies (\XI\XlashIC and ICIN)[26.28J did not essentially change 
these findings. Furtl,er analyses were performed including all trials with at 
least 1,000 (FTT dataset), 500 and 250 patients, respectively. In all cases, the 
second non-linear model was significantly better than the linear model. 
DISCUSSION 
In animals with a coronary circulation similar to that of hu mans, the amount 
of myocardial tissue that is salvageable directly depends on the duration of 
coronary occlusion. This dependency is non-linear. Very early reperfusion of 
the occluded coronary artery (within 30 min) may lead to full recovery of 
ischaemic tissue and thus prevent necrosis. In experimental modeIs most of the 
irreversible damage to the myocardium occurs between 1 and 2 h after the 
occlusion, and little or no salvage can be achieved after 6 h of occlusion. 
These findings correspond very weil with the relation between infarct 
size estimated by assay of cardiac enzymes and the delay in thrombolytic 
treatment, as measured in 1,334 patients with evolving myocardial 
infarction.[9J The cumulative release of myocardial a-hydroxybutyrate 
dehydrogenase during the first 72 h after infarction (Q72) was comparatively 
small in patients treated within 1 h from onset of symptoms. A very steep 
increase in the rate of enzyme release was noted between 1 and 2 h of 
treatment delay (the increase was relatively small thereafter). The life-saving 
effect of very early reperfusion therapy has been supported by pooled analyses 
of studies which randomised between immediate, pre-hospital initiation of 
therapy and delayed, in-hospital therapy (figure l)5'·22J 
This advantage of very early therapy in the pre-hospital studies is much 
larger than the effect of 1 h earlier treatment repOl'ted by the FTT investigators 
(1.6 lives per 1,000 treated), who compared in-hospital thrombolytic with 
placebo or conventional therapy.[4J We emphasise that patients with a short 
treatment delay tend to differ from those who wait longer before seeking 
medical help: many of the patients with very large infarcts (with the highest 
mortality risk and greatest treatment benefitJf48J report early, whereas elderly 
patients tend to wait longer.[49,50J Therefore, the randomised comparisons of 
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earlier vs. later therapy may provide better estimates of the delayl effect 
relation than comparison of different cohorts from the large randomised trials. 
Furthermore, the formal statistical approach has a major influence on the 
results of the FTT analysis. Results from previous investigations indicating a 
non-linear delay/benefit relation (e.g. the GISSI-1 clinical triaIJf12] were 
considered hypothesis-generating, whereas the outcomes of experimental and 
pre-hospital trials were dismissed.[4] In the combined trial data (summarised by 
five datapoints) no significant deviation of linearity was observed and thus the 
hypothesis of a linear delay/benefit relation was not rejected in the FTT 
analysis. By contrast, our altemative analysis supports a non-linear relation 
which is in agreement with the experimental and pre-hospital data (figure 4). A 
large reduction in mortality was detected in patients treated within 1 h of 
symptom onset (65 lSD 14] per 1,000 treated). The decrease in benefit in the 
0.75-1.6 h interval (51 min) was roughly 33 lives per 1,000 treated pel' h01l1' 
(from 65 [14] to 37 [9]), and declined rapidly to about 3.3lives per h in the 1.6-
4.0 h interval (from 37 [9] to 29 [5» and only 1.4 lives per h aftel' this period 
(from 29 [5] at 4.0 h to 9 [7] at 18.0 hl. The delay/benefit relation could be 
significantly better described by a non-linear (a+J3x+yx-l) rather than a linear 
(a+ J3x) function. Although the goodness of fit within the tabulated data of the 
separate trials remains limited (R2~0.32), the non-linear function does fit very 
weil with the benefit estimations in the six time-to-treatment groups (figure 4). 
The concept of a first golden hour in myocardial infarction is supported 
by our analysis, although our estimations may be biased by differences in 
baseline characteristics between time-to-treatment groups, the unknown delay 
between randomisation and actual initiation of therapy and coronary 
reperfusion, and the unknown individual delays within the repOlted studies. 
The benefit of thrombolytic therapy initiated within 30-60 min aftel' onset of 
symptoms Can be estimated at 60-80 additional patients alive at one month per 
1,000 treated compared with convent ion al therapy. The benefit of therapy 
within 1-3 h is in the range 30-50 per 1,000 treated. 
From a clinical standpoint, the challenge is to initiate fibrinolytic 
treatment within the first 2 to 3 h aftel' onset of symptoms. A first important 
step will be to increase public awareness of the need to reduce delay in seeking 
medical help for cardiac symptoms. Second, as an aid to rapid diagnosis when 
there is chest pain suggestive of infarction, the general practitioner or 
ambulance team should obtain - preferably on-site - a computer-interpreted 
standard 12-lead EeG.[Sl] With certainty of diagnosis, thrombolytic therapy 
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may be started quickly, before hospital admission. Patients in whom 
myocardial infarction cannot be confirmed on site, and those presenting 
directly to the emergency departinent, may still benefit from emergency room 
initiation of thrombolytic infusion. Avoidanee of unnecessaty treatment delay 
should be given top priority so as to improve the survival prospeets of patients 
with suspected evolving myocardial infarction.[52] 
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FACTORS THA T DETERMINE EFFICACY AND APPLICABILITY OF 
REPERFUSION THERAPY IN CLINICAL PRACTICE: 
A SEARCH FOR CONSENSUS 
The Reperfusion Therapy Consensus Group 
Clinical pel'spectives: 
Selection ofl'epelfllsion therapy for individllal patients with evo/ving 
myocardial infal'ction 
Eur HeartJ 1997; 18: 1371-81 
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INTRODUCTION 
The overall benefits of reperfusion therapy for acute myocardial infarct ion 
have been established unequivocally. Physicians can now choose among 
different thrombolytic regimens based on streptokinase and tissue 
plasminogen activator, while other regimens are under development (for 
example reteplase and saruplase). In some hospita Is, direct angioplasty is an 
alternative. 
Key questions in clinical practice are how widely should thrombolytic 
therapy be used, and whether different reperfusion strategies should be chosen 
for different types of patients and in different clinical circumstances. This is 
even more of an issue when medical resources are limited. Such decisions 
could be based on simple univariate criteria (older vs. younger patients, 
anterior vs. inferior infarction) or on more complex multivariate modelling. 
Moreover, some consideration of the cost/ effectiveness, the relative safety and 
the complexity (e.g. primary angioplasty) of different therapeutic options need 
to be taken into account. 
On 20 and 21 February 1995, a colloquium involving several groups of 
investigators was organised to review these issues (Appendix). Prior to the 
meeting, several questions were posed to guide the discussion and to attempt 
to obtain consensus: 
1. Reperfusion therapy preserves viabie myocardial tissue and reduces 
mortality in acute myocardial infarction patients. Are left ventricular ejection 
fraction and infarct size adequate 'surrogate' measures for the effects on 
mortality and morbidity? 
2. Mortality with or without reperfusion therapy can be predicted by 
individual characteristics. What are the short-term effects of reperfusion 
therapy in different subgroups of patients? 
3. Improved survival with reperfusion therapy is sustained aftel' the first year. 
What are the determinants of the long-term survival advantage aftel' 
reperfusion therapy? 
4. The mortality reduction produced by reperfusion therapy is related to the 
time from symptom onset to treatment. What is the nature of th is 
relationship? Is there a first 'golden hour' aftel' symptom onset in which 
treatment benefits are particularly large? 
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5. Do patients treated late after onset of symptoms - between 12 and 24 hours -
also benefit from reperfusion therapy? 
6. A negative aspect of thrombolytic therapy is the possible occurrence of 
intracranial haemorrhage. What are the most important predictors of 
intracranial haemorrhage and excess of stroke with thrombolytic treatment? 
7. Commonly used modes of reperfusion therapy in clinical practice include 
different thrombolytic regimens with streptokinase or (accelerated) tissue 
plasminogen activator, and direct angioplasty. What is the relationship 
between survival bene fits, cerebral bleeding risks and costs for these three 
options? 
8. How can the benefits, risks and costs of different reperfusion strategies be 
integrated into clinical decision making? 
A summary of the discussion of each of these issues is provided in the 
following sections. Although there was a consensus on most topics, in some 
areas agreement could not be reached and the alternative views are 
summarised. The occurrence of contrasting viewpoints can partly be explained 
by differences in emphasis on pathophysiological concepts and results of large 
trials. It should be appreciated, however, that these differences in interpre-
tation do not lead to major differences in routine treatment strategies. 
1. REPERFUSION THERAPY PRESERVES VIABLE MYOCARDlAL TISSUE AND 
REDUCES MORTALITY IN ACUTE MYOCARDlAL INFARCTION PATIENTS. 
ARE LEPT VENTRICULAR EJECTION FRACTION AND INFARCT SIZE 
ADEQUATE 'SURROGATE' MEASURES FOR THE EFFECTS ON MORTALITY 
AND MORBIDITY? 
Infarct size can be measured from the total quantity enzymes or other proteins 
released from the myocardium. Early reperfusion therapy results in rapid 
protein release.[l,,] The total quantity of proteins released (indicating infarct 
size) is reduced by 20%-35% with thrombolytic therapy compared with 
control.[l,J-S] Similarly, more effective reperfusion therapy yielded smaller 
infarct size than standard therapy.[6,7J In patients with a first infarct, infarct 
size is inversely correlated with residualleft ventricular function.[7,8] However, 
in most randomised controlled trials, differences in left ventricular ejection 
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fraction between patients recelvmg reperfusion therapy and controls were 
smalI, although generally in favour of the treated group (pooled left 
ventricular ejection fraction 54% in treated patients vs. 51% in controls),f9l 
whereas substantial survival benefits are demonstrated by large-scale 
randomised trials.(IO·lll In the Fibrinolytic Therapy Trialists' (FT1) 
collaborative overview of the nine largest comparisons of thrombolytic 
therapy vs. control, this benefit was estimated to be 30 fewer deaths per 1,000 
patients with ST elevation or bundIe branch block treated within about 6 h 
from symptom onset.(12l 
Physiological studies might heighten our understanding of the possible 
mechanisms of the action of thrombolytic treatment - for example, the 
relationship between eady coronary patency (TIMI-3 flow in the infarct 
related artery) and infarct size. Moreover, several studies have documented a 
close relationship between infarct size, residual left ventricular function, 
coronary patency and long term survival.(13,14l Although studies measuring 
early coronary patency, enzymatic infarct size and ventricular function may 
give an indication of the effect of (new) reperfusion strategies, such studies 
cannot reliably determine the net clinical benefit of reperfusion therapy. 
Survival af ter myocardial infarction depends not only on early patency but 
also on slistained coronaly patency and the healing process of the infarction. 
Furthermore, the risk of intracranial haemorrhage with treatment is largely 
independent of infarct size and left ventricular ejection fraction. Hence, 
determination of the balance between survival benefit and cerebral bleeding 
risk with different treatment strategies requires large mortality trials. 
Conell/sjons 
• Coronary artery patency, left ventricular ejection fraction and infarct size 
(as determined by cumulative myocardial protein release) can be used to 
make initial assumptions of the efficacy of reperfusion regimens . 
• Subsequently, large mortality trials are required to assess reliably the 
survival benefits and bleeding risks of reperfusion strategies. 
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2. MORTALITY \VITH OR WITHOUT REPERFUSION THERAPY CAN BE 
PREDICTED BY INDIVIDUAL CHARACTERISTICS. WHAT ARE THE SHORT 
TERM EFFECTS OF REPERFUSION THERAPY IN DIFFERENT SUBGROUPS OF 
PATIENTS? 
Several studies have shown that the risk of death from acute myocardial 
infarct ion can be predicted at the time of hospital admissionPS-21] Some 
determinants of mortality cannot be altered by thrombolytic therapy, such as 
sex, age, baseline left ventricular function, a history of infarction and location 
of the current infarct PS] The area of myocardium at risk can be estimated 
from total ST elevation on the presenting ECG and Killip class. Infarct size, as 
a proportion of the area at risk, can be influenced by reperfusion therapy, 
with greater salvage by earlier treatment. Thrombolytic therapy has been 
shown to improve survival in patients presenting with either ST elevation or 
bundie branch block within 12 h of symptom onsetP'] In an overview of the 
large trials there was no significant heterogeneity between the proportional 
mortality reductions in the different subgroups of patients studied. 
Consequently, the absolute number of deaths avoided by thrombolytic 
treatment appears to be greater in those groups with a higher mortality risk. 
Moreover, there was no support for withholding thrombolytic therapy on the 
basis of age alone as the survival advantages were similar in young and old: 15 
[SD 4]lives saved per 1,000 treated aged <55 years, 21 [5] aged 55-64, 37 [6] 
aged 65-74 and 13 [14] aged 275 years, respectively. It should be appreciated, 
however, that the estimate of benefit in patients aged 75 years or over is 
imprecise due to the relative small number of patients, and thus additional 
information from controlled trials would be valuable. 
It is less clear whether there are worthwhile benefits among patients 
presenting with ST depression but without ST elevation or bundie branch 
block. Some of these patients have coronary occlusion and evolving posterior 
infarction and are at high risk of death, and so may weil benefit from 
thrombolytic therapy. Others may be suffering from unstable angina pectoris, 
with extensive ischaemia but without occlusion of a major coronaly artery, 
although a significant (non-occluding) stenosis may be present. In these 
patients coronary angiography and coronary angioplasty or bypass surgery are 
often indicated, but thrombolytic therapy is less likely to be usefu!' Further 
trials are warranted to identify patients with ST depression who do benefit 
from early reperfusion therapy. 
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Another, not completely understood, phenomenon is the excess of deaths in 
thrombolytic treated patients on the first day, particularly in patients treated 
relatively late aftel' onset of symptomsP'] If there is a physiologicalreason for 
this early hazard which could be prevented then the benefits of thrombolytic 
therapy might be increased substantially. 
ConclIlsions 
• Almost all patients with evolving myocardial infarction presenting with ST 
elevation or bundIe branch block up to at least 12 h from symptom onset 
will benefit from thrombolytic therapy. 
• The proportional improvement in short-term survival produced by 
reperfusion therapy is generally similar in different subgroups of patients. 
Consequently, in absolute terms, high-risk patients (e.g. older patients, 
those with a history of infarction, anterior location of the current infarct, 
extensive ST elevation or shock) may benefit most from such therapy. 
• More information is needed to define more accurately the survival benefit 
in the very elderly (age 75 years or over), and in patients with ST segment 
depression on the presenting ECG without ST segment elevation. 
3. IMPROVED SURVIVAL WITH REPERFUSION THERAPY IS susTAINED 
AFTER THE FIRST YEAR. WHAT ARE THE DETERMINANTS OF THE LONG-
TERM SURVIVAL ADVANTAGE AFTER REPERFUSION THERAPY? 
Follow-up studies confirm that reperfusion therapy provides sustained survival 
benefit at 4, 5 and 10 years.[14,18.23.24] In 1SIS-2, streptokinase produced an 
absolute improvement in survival at 35 days of 29 [5] fewer deaths per 1,000 
treated patients, while the absolute benefit was 28 [7] fewer deaths per 1,000 at 
4 years. Hence, following the large divergence in survival during days 0-35, 
there waS no significant divergence or convergence thereafter. The absolute 
benefit at 4 years among patients randomised within 0-3 or ~3-6 h of symptom 
onset (48 [13] and 18 [12], respectively) were similar to those at day 35 (44 [9] 
and 25 [8]). The greater absolute benefits observed at one month in patients at 
higher risk of death were also sustained: for example, among patients 
presenting with anterior ST elevation there were 71 [11] and 62 [15] fewer 
deaths per 1,000 at 35 days and 4 years, respectively. Other reports confirm 
h b . [141824] BI" I' I . I b tese 0 servatlons. ,. y mu tlvanate ana yS1S, ong-term surVlva can e 
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predicted from measurements at the time of hospital discharge including leEt 
ventricular function, enzymatic infarct size, number of diseased vessels, and 
TIMI perfusion grade.[B.l4.24] When such information is included, the initial 
therapy (thrombolysis or conventional) appeared not to be an independent 
predictor of long-term outcome. Thus the bene fits of reperfusion therapy are 
obtained early af ter initiation of therapy, and are maintained thereafter. 
One reservation expressed about the use of thrombolytic therapy in 
elderly patients is that any short-term survival advantage might be only 
transitory because of the high underlying mortality. However, although 4-year 
survival among patients aged 70 years or over at entry into ISIS-2 was only 
about 50%, the absolute reduction in 4-year mortality with streptokinase was 
as least as great among these patients (45 [19)lives saved per 1,000) as among 
those aged less than 70 years (23 [7)lives saved per 1,000). Thus, long-term 
benefits of reperfusion therapy are also apparent in elderly patients. 
ConclIlsions 
• The absolute mortality reduction produced by reperfusion therapy is 
sustained after the first year, but there is no evidence that it increases with 
more prolonged follow-up. 
• Multivariate analysis of large trial databases may give more insight into the 
underlying relationships between patient characteristics and the effects of 
thrombolytic therapy on early and long term survival. 
4. THE MORTALITY REDUCTION PRODUCED BY REPERFUSION THERAPY IS 
RELATED TO THE TIME FROM SYMPTOM ONSET TO TREATMENT. WHAT IS 
THE NATURE OF THIS RELATIONSHIP? Is THERE A FIRST 'GOLDEN HOUR' 
AFTER SYMPTOM ONSET IN WHICH TREATMENT BENEFITS ARE 
PARTICULARLY LARGE? 
All the participants agreed that the earlier reperfusion therapy is initiated, the 
larger the survival advantagepO-12·lS.2S] There was disagreement, however, as to 
whether the benefits of treatment within the first hour after symptom onset 
are substantially greater (that is a 'golden hour') than slightly later 
treatmentpS] or whether there is only a gradual diminution of benefits with 
later treatmentP2] 
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Figure 1: Absolute reduction in 35.day mortality versus treatment de1ay as reported 
by the FTT investigatorsl121 
The loss of benefit per hour of de1ay to randomisation was estim.ted at 1.6 lSD 0.6] per 
1,000 patients. The black squares represent the average effects in five time-to-treatment 
groups. The areas of these squares are inversely proportional to the varianee of absolute 
benefit it describes. 
First viewpoint 
One view was that although earl ier thrombolytic treatment dearly produces 
greater benefit, the FTT overview of all relevant data from all nine trials that 
induded more than 1,000 patients (involving a total of 46,000 randomised 
patients) indicated that the decrease in the absolute benefit with increasing 
delay was fairly shallow, and was not significantly steeper in the first few 
hours than in subsequent hours (figure 1)P2J A retrospective subgroup analysis 
of GISSI-1 had suggested that fibrinolytic therapy might be especially effective 
when started within one hour from symptom onset, but this was not 
supported by the other large trials. Indeed, if GISSI-1 was exduded then the 
apparent benefit in those randomised in hours 0-1 was slightly below the 
sloping line in figure 1. Each hour of delay recorded among patients with ST 
elevation or bundIe branch block was associated with a reduction in benefit of 
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about 1.6 [0.6) deaths per 1,000 patients. This estimate may have been 
somewhat diluted by inaccuracies in assessing the delays, and so the real effect 
of each additional hour of delay may well be slightly greater, involving 
perhaps 2 (or even 3) extra deaths per 1,000, per hour. (The results of an 
analysis that included all smaller trials, i.e. at least 100 patients,[35] may be 
biased because results for patients randomised within 0-1 h of symptom onset 
were not listed separately for several of these smaller trials, and those smaller 
trials that did report such information may have done so because their results 
were extreme.) In principle, the trials of pre-hospital vs. in-hospital fibrinolytic 
therapy could provide directly randomised evidence of the relevance of an 
extra hour of delay, but even in aggregate they are far too small to measure 
reliably differences of only a few deaths per 1,000, and their combined results 
are consistent with their being little or no improvement in outcome with 
slightly earl ier treatment. Moreover, with respect to assessing the effects of 
very early treatment, the slight non-significant benefit of about one hour 
earl ier treatment in the largest trial (EMIP) was observed in those randomised 
3-6 h after symptom onset, and not in those entered within 3 h.[26] 
Second view point 
In contrast to this first view, it was pointed out that an occlusion of less than 
30 min in animaIs generally does not lead to irreversible myocardial damage,l"-
29] and small observational studies in humans support the plausibility of similar 
patternsPO,31] Studies comparing pre-hospital and in-hospital therapy suggest a 
greater effect with earlier treatment.[26,32,JJ] For example, the largest study 
(EMIP) reported 15 fewer deaths per 1,000 treated at a median of 2.2 h instead 
of 3.2 h after onset of symptoms (95% Cl: 27 fewer deaths to 1 additional 
death per 1,000 treated, not significant), albeit that most of this benefit was 
realised in patients treated between 3-6 haf ter onset of symptoms.[26] Although 
the pre-hospital trials were relatively small and the individual results were not 
statistically significant, significance was reached in pooled analyses of the 
data.[25,J4] 
The concept of a first 'golden hour' is supported by a re-analysis of the 
large trials in the FTT report in combination with data from smaller trials (at 
least 100 patients) that randomised patients between fibrinolytic therapy and 
control.[35] This analysis showed that the delay/benefit relation could be 
significantly better described with a non-linear than with a linear function (see 
figure 2). The decrease in benefit up to approximately 1.5 h from symptom 
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Figure 2: Absolute 35·day mortality reduction versus treatment delay as reported by 
a re-analysis of the PTT data in combination with data from smaller trials (at least 
100 patients) that randomised between fibrinolytic therapy and control or 
placebol35] 
The small closed dots represent information from trials included in the FTT analysis, 
the open dots represent information from additional trials. The small squares mark data 
beyond the scale of the y-axis. Linear (34.7-1.6x) and non-linear (19.4-0.6x+29.3x·') 
regression lines are fitted within these data. The best fit was obtained with the non-linear 
mathematical function (significant contribution of the x·i.component; largest R2 -value). 
The black squares represent the average effects in six time-to-treatment groups. The areas 
of these squares are inversely proportional to the variance of absolute benefit it 
describes. 
onset was about 30 lives per 1,000 treated per hour, and declined rapidly to 
approximately 3 lives per hour in the 1.5-4.0 h interval and only 1.4 lives per 
hour af ter this period. Thus an extra effort to treat earl ier (e.g. pre-hospital 
identification and therapy, and optimisation of in-hospital logistics) wil! be 
particularly effective for patients reporting within the first hours after 
symptom onset, while some additional delay is less harmful in patients 
presenting late. 
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ConclIlsions 
• It is clear that the earl ier reperfusion therapy is started af ter the onset of 
symptoms, the larger the mortality reduction. 
• There is no agreement as to the shape of the association between the 
mortality benefit and time from symptom onset to treatment for patients 
treated within the first few hours, and of the existence of a first 'golden 
hour'. 
5. Do PATIENTS TREATED LATE AFTER ONSET OF SYMPTOMS - BETWEEN 
12 AND 24 HOURS - ALSO BENEFIT FROM REPERFUSION THERAPY? 
Approximately 30% of patients with acute myocardial infarction arrive in 
hospital beyond the currently accepted time limit for reperfusion therapy, that 
is, more than 12 h from symptom onsetP6] Pharmacological or mechanical 
achievement of patency is possible in these late arrivals'p7l and vessel patency 
may help to preserve left ventricular function or improve infarct healing and 
recovery, although significant myocardial salvage will probably not occur.[38] 
Overall, 7,000 patients with ST elevation or bundie branch blo ck 
presenting between 12 and 24 h from symptom onset have been randomised 
between fibrinolytic therapy and control.[11,22,36,39] Although the absolute 
benefit of 7 [7) fewer deaths per 1,000 treated observed among these patients 
was non-significant'p2] benefit with earlier treatment and the gradual 
diminution of benefit with later treatment (see figures 1 and 2) does suggest 
that worthwhile net benefits may await discovely among patients who present 
within 12-18 h or so af ter onset, especially if there are signs of ongoing 
ischaemia, 
This suggestion is supported by subgroup observations in the LATE trial. 
Patients presenting af ter 12 h who were treated soon af ter admission, generally 
because of clear evidence of ischaemia, showed a 22% relative mortality 
reduction with recombinant tissue plasminogen activator (rt-PA)p6] In 
contrast, among those patients in whom the decision for therapy was delayed 
until an observational period of 3 h or longer, no beneficial effect was 
observed, Thus, patients presenting more than 12 h from symptom onset with 
clear indications of immediate thrombolytic therapy, i.e. ongoing chest pain 
or other signs of ongoing ischaemia (EeG), may benefit. Perhaps this is 
because some of these patients do not have continuous coronary occlusion, but 
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rather intermittent occ1usions - a'stuttering infarction' - so that partial salvage 
of ischaemic myocardium may be achieved in them.f40.411 
ConclIlsions 
• Reperfusion therapy may be justified in patients with signs of ongomg 
isehaemia presenting between 12 and 24 h after symptom onset . 
• Further study of the effect of reperfusion therapy in patients presenting late, 
and the meehanism of sueh effect, is needed. 
6. A NEGATIVE ASPECT OF THROMBOLYTIC THERAPY IS THE POSSIBLE 
OCCURRENCE OF INTRACRANIAL HAEMORRHAGE. WHAT ARE THE MOST 
IMPORTANT PREDICTORS OF INTRACRANlAL HAEMORRHAGE AND EXCESS 
STROKE WITH THROMBOLYTIC TREATMENT? 
Intraeranial haemorrhage is a rare event in patients with myocardial infarction 
receiving conventional therapy. Thrombolytic therapy does increase the rate of 
intraeranial haemorrhage, despite attempts to avoid treating patients with an 
increased bleeding risk (panicularly those with a recent cerebrovascular accident 
or with a cranial trauma). On the other hand, embolie stroke rates may be 
slightly reduced in patients receiving thrombolytic therapy, perhaps because of 
infarct size reduction and the anticoagulant effects of thrombolytic agents. 
Overall, the excess of any stroke (haemorrhagie or embolie) with thrombolytic 
therapy appears te be smalI, averaging about 4 [0.8] per 1,000 patients treated in 
the large studiesp21 About half of these strokes were fatal. Of the survivors 
about half were moderately or severely disabled while the others experienced 
little or na disability.[431 
A few independent predictors for intracranial haemorrhage were identified 
by a case control study inc1uding 150 patients with such bleeding and 294 
matehed controls from various trials. These predictors were age over 65 years, 
body weight below 70 kg, hypenension (defined as blood pressure greater than 
165/95 mm Hg) on hospital admission and the use of altepiase (vs. 
streptekinase).[421 These findings were supponed by analyses of the GUSTO-1 
database, which found age (median age of patients without and with 
haemorrhagic stroke was 61 and 70 years, respectively) and previous 
cerebrovascular disease to be risk factors for intracranial bleeding (although the 
latter was an exc1usion criterion in the trial).[431 
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Even though it is possible to identify subgroups of patients with increased 
intracranial bleeding risk from observational data, the large randomised trials 
did not demonstrate a significant excess risk due to thrombolytic therapy in 
these subgroupsP2l In the FTT analysis an excess of strokes with thrombolytic 
therapy occurred during day 0-1, and was mainly due to increase in intracranial 
haemorrhage. This early excess appeared to be somewhat greater in patients 
aged 75 years and above, but it was not significantly greater than in those aged 
55-74 years (and strokes were rare among those under 55 years). The excess of all 
strokes (haemorrhagic and embolie) during the hospital stay was also not 
strongly related to age, blood pressure or other patient characteristics. 
The available evidence, therefore, supports the use of thrombolytic 
therapy in most patients presenting with ST segment elevation or bundIe branch 
block within 12 h of symptom onset unless a markedly increased bleeding risk 
can be identified. In each individual patient the likely benefits and risks of 
thrombolytic therapy should be weighed carefully. But risks should not be 
exaggerated as this may result in inappropriate under-treatment. 
ConclIlsions 
• Thrombolytic therapy cames an increased risk for intracranial 
haemorrhage, while embolie strokes are slightly reduced. Overall, 
thrombolytic treatment is associated with about 4 extra strokes per 1,000 
patients treated. However, in all categories of patients presenting with ST 
segment elevation or bundIe branch bloek within 12 h that have been 
studied, the survival benefits of thrombolytic therapy outweigh the risks. 
• Advanced age, a history of cerebrovascular disease, low body weight, 
hypettension on hospital admission as weil as a recent head trauma are 
important risk factors for the occurrence of intracranial bleeding 
complications. However, the excess risk of early strokes (mainly intracranial 
haemorrhage) or of total strokes due to thrombolysis are not strongly related 
to age, blood pressure or other patient characteristics. 
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7. COMMONLY USED MODES OF REPERFUSION THERAPY IN CLINICAL 
PRACTICE INCLUDE DIFFERENT THROMBOLYTIC REGIMENS WITH 
STREPTOKINASE OR (ACCELERATED) TISSUE PLASMINOGEN ACTIVATOR, 
AND DIRECT ANGIOPLASTY. WHAT IS THE RELATIONSHIP BETWEEN 
SURVIVAL BENEFITS, CEREBRAL BLEEDING RISKS AND COSTS FOR THESE 
THREE OPTIONS? 
COMPARISONS OF DIFFERENT THROMBOLYTIC REGIMENS 
Different thrombolytic regimens - whether based on streptokinase, 
(accelerated) tt-PA or anisoylated plasminogen streptokinase activator 
complex (APSAC), have all been shown to produce substantial improvements 
in survival. There was no agreement, however, as to whether there was any 
worthwhile net difference in clinical outcome between the different 
thrombolytic regimens that have been studied. 
Fitst viewpoint 
Neither the GISSI-2/International trial nor ISIS-3 found a survival difference 
between streptokinase (1.5 MU infused over 1 h, either with or without 
subcutaneous heparin) or tt-PA (alteplase/duteplase infused over 3-4 h, also 
with or without heparin).lJ9.44.45] The GUSTO-1 investigators, however, 
reported a significant reduction in 30·day mortality of 10 [3] per 1,000 patients 
treated with accelerated administered rt-PA (alteplase infused over 1.5 h, 
combined with intravenous heparin) compared with the 'standard' 
streptokinase regimen (either with subcutaneous or intravenous heparin).l461 
This benefit was maintained for at least 1 year,l47l and was observed in almost 
all subgroups, including elderly patients, and those presenting after 3 h. Some 
questions have been raised about supposed differences in outcome between 
U.S.A. and non-U.S.A. patients, but these non-significant differences could 
largely be eXplained by differences in baseline characteristics between patients 
enrolled in these two continents.l48] 
The risk of non-fatal stroke (especially of intracranial haemorrhage) is 
increased with rt-PA compared with streptokinase. In GUSTO-1, a significant 
absolute increase in total stroke was repotted of 2.6 [1.5] per 1,000 patients 
treated with accelerated rt-PA. Nevertheless, the absolute net clinical benefit, 
of the combined end point of 30·day mortality or non-fatal stroke was still 9 
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[3) patients per 1,000 treated with accelerated rt-PA_ Thus, acce[el'ated rt-PA 
has been shown to be clearly superior to streptokinase. 
In spite of the favourable outcome with accelerated rt-PA, application in 
clinical practice remains limited by the relative high costs. A cost-effectiveness 
study of the GUSTO data estimated the additional costs of accelerated rt-PA 
compared with streptokinase at $27,369 per life year added, based on the cost 
of rt-PA in the U.S.AY'] Accordingly, accelerated rt-PA was recommended in 
patients who might benefit greatly from reperfusion therapy, i.e. those with a 
high mortality risk without thrombolysis.[18] 
Second view point 
In contrast with this first view, it was argued that, when the totality of the 
clinical trial evidence is considered, there is no good evidence that any 
particular thrombolytic regimen is clearly better. More intensive regimens, 
generally based on tissue plasminogen activator, do not increase the overall 
proportion of arteries eventually opened within the first few hours, but they 
do work slightly more rapidly. Although opening the arteries half an hour or 
one hour earlier should produce some cardiac benefit, the fundamental 
question is whether any cardiovascular advantages of more intensive 
thrombolytic regimens outweigh any cerebrovascular disadvantages. 
In the three large trials of the 'standard' 1 h 1.5 MU streptokinase 
regimen vs. rt-PA-based fibrinolytic regimens, patients were entered on an 
average of about 2-3 haf ter the onset of symptoms in GISSI-2, 4 h in IS1S-3 
and 2 h in GUSTO_1.[39,44.46] In each, the rt-PA-based regimens were designed 
to ensure appreciably better 90 min coronary artery patency than the 
'standard' streptokinase regimen with which they were compared, and the 
accompanying dose of aspirin was sufficiently large to contribute substantially 
towards the maintenance of that early patency. Moreover, both of the rt-PA-
based regimens in GUSTO-1 were very similar to each other in terms of the 
total dose given in the first hour (82 mg of altepIase with the accelerated rt-PA-
alone regimen and 78 mg of altepIase with the other rt-PA-based regimen) and 
in terms of 90 min TIM1 2/3 patency. Hence, it is most appropriate - in order 
to avoid selective emphasis on particular trial results - to consider all three 
trials together.[SO] 
Overall in these trials, there was a highly significant excess of 3.3 [0.8) 
strokes per 1,000 treated with rt-PA compared with streptokinase.[SO] Most of 
this excess occurred within the first day of giving rt-PA, and was attributed to 
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an even more definite excess of 2.9 [0.5] cerebral haemorrhages per 1,000. 
These excesses with the rt·PA regimens increased with increasing age and 
blood pressure. Overall, the rt·PA-based regimens were associated with 4.9 
[1.8] fewer non-stroke deaths per 1,000 compared with streptokinase, but the 
95% Cl for this estimate spans a wide range from about 1 to about 9 fewer 
non-stroke deaths per 1,000. When taken all together, the directly randomised 
comparisons suggest such rt-PA-based regimens might confer a non-significant 
improvement of only one or two per 1,000 in net clinical outcome. But, 
whereas the hazard is definite (about 3 additional cerebral haemorrhages per 
1,000) any excess of benefit over hazard is uncertain. 
COMP ARISON OF THROMBOL YTIC THERAPY VERSUS PRIMARY ANGIOPLASTY 
Preliminary results from a pooled analysis of data from three small trials of 
thrombolytic therapy (405 patients; 256 rt-PA and 149 streptokinase) vs. 
angioplasty (394 patients) indicated a favourable outcome of the latter strategy 
(6.4% vs. 2.6% in-hospital mortality; reduction of 39 per 1,000, with 95% Cl of 
10·68, p_0.01).[7.51.54] This apparent mortality advantage of primary 
angioplasty was observed largely among patients at somewhat higher risk 
(elderly, anterior infarction, increased heart ratel, and appeared to be 
assoeiated with fewer strokes, although these apparent bene fits are uncertain 
due to the small numbers of patients studied in these trials. In the recently 
completed larger (n-1138) GUSTO-2b substudy of accelerated rt-PA vs. direct 
angioplasty, however, the observed differences in survival were less striking: 
30·day mortality was 5.7% in the direct percutaneous transluminal coronary 
angioplasty group vs. 7.0% in thrombolytic-treated patients (a non-significant 
difference with 95% Cl of 15 more to 40 fewer deaths per 1,000 angioplasties). 
The combined 30-day end point of death, re-infarction or disabling stroke was 
significantly lower in patients treated with direct PTCA (9.6%) compared with 
thrombolytic therapy (13.7%; reduction of 41 per 1,000, but with 95% Cl of 3-
78, p_0.033).[55] 
The initial costs of an angioplasty procedure are relative high. However, 
some of these costs may be offset during follow-up. Costs af ter thrombolytic 
therapy may be higher, due to a higher number of interventions and re-
admissions. [56] 
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ConclIlsions 
• Any differences in outcome between reperfusion strategies are likely to be 
small in comparison with the differences in outcome between reperfusion 
therapy and no reperfusion therapy. Hence, most emphasis should be on 
ensuring that eligible patients receive some effective reperfusion therapy as 
rapidly as is practical without worrying overmuch about which strategy to 
choose. 
• Tissue plasminogen activator-based therapy produces a higher rate of early 
coronary patency and, probably, some improvement in cardiac mortality. 
On the other hand, treatment with rt-PA is associated with a greater risk of 
early intracranial haemorrhage compared with the 'standard' streptokinase 
regimen. The balance of advantages (survival) and disadvantages (cerebral 
bleeding) of rt-PA is judged differently. Some investigators are convineed 
that the use of accelerated altepIase with intravenous heparin yields a 
significant net clinical benefit over streptokinase, while others consider that 
whereas the hazard with rt-PA is definite any excess of benefit over hazard 
is uncertain. 
• Direct angioplasty may be more effective at reducing mortality than 
thrombolytic therapy, although the current estimates of benefit are unclear 
due to the relatively small number of randomised patients studied. Primary 
angioplasty may be offered as an alternative of thrombolytic therapy in 
centres with adequate facilities and experience, particularly in patients with 
large infarcts and increased cerebral bleeding risk. 
• Additional much larger studies are needed to compare the (cost-)efficacy of 
direct angioplasty and thrombolytic therapy reliably. 
8. How CAN THE BENEFITS, RISKS AND COSTS OF DIFFERENT REPER-
FUSION STRATEGIES BE INTEGRA TED INTO CLINICAL DECiSION MAKING? 
In clinical practice a physician must choose for each individual patient 
between different therapies with different costs ond efficacy. This choice is 
often restricted by limited resources or organisational constraints (e.g. 
availability of direct angioplasty). Since the effect of reperfusion therapy is 
strongly related to treatment delay, in the acute setting there is linIe time in 
which to weigh up the potential benefits and risks of different treatment 
regimens in an individual patient. In this situation a treatment protocol may 
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be a powerful tooi to help rapid decision-making in a consistent manner, 
although this can not replace the physician's clinical impression of the patient. 
A range of treatment guidelines for individual patients has been 
developed. Ideally such protocols would first provide reliable estimates of the 
expected treatment benefit, for example the gain in one-year survival, based on 
a limited number of relevant individual characteristics (such as the duration of 
symptoms, age and ECG changes). Secondly, a reliable estimate of the 
patient's (cerebral bleeding) risk from treatment would be estimated. Finally, 
benefits and risks would be weighed, and advice given on whether or not to 
use reperfusion therapy and possibly on the choice of therapy. Such 
reperfusion treatment protocols might be presented on simple paper charts, or 
. h' I h' f [182057-62] mig t mvo ve t e asslstance 0 a computer program. . . 
ConclllsÎons 
• Areliabie reperfusion treatment protocol may be a powerful tooi to assist 
in the optimal and consistent treatment of acute myocardial infarction 
patients. 
• Protocols need to be evaluated, improved and extended. Analysis of large 
databases from clinical trials, as weil as from prospective studies and 
registries in clinical practice, would help in th is task. 
FUTURE DIRECTIONS 
The introduction of reperfusion therapy has considerably improved the 
prognosis of patients with evolving myocardial infarction during the last 
decade. Mortality at one month is reduced by approximately 30 deaths per 
1,000 patients treated within 6 h from symptom onset, despite a small excess of 
cerebral bleeding complications (approximately 4 per 1,000). 
Analysis of existing trial data has shown that the absolute benefit of 
reperfusion therapy is largely dependent on the patient's baseline mortality 
risk and the time elapsed from onset of symptoms. Therefore, future 
investigations should concentrate on: 
• early initiation of thrombolytic therapy and further evaluation of the 
effectiveness and costs of pre-hospital thrombolytic treatment; 
• evaluation of the effects of thrombolytic therapy in those patient slIbgrollps 
for which uncertainty about clinical benefit exists (e.g. those presenting 
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af ter 12 h from symptom onset and those without ST elevation or bundie 
branch bloek); 
• development of better thrombolytic regimens, that produce coronary 
pateney rapidly without inereasing the risk of eerebral haemorrhage (e.g. 
combination of thrombolytic drugs and powerful anti-thrombotic agents, 
sueh as the glycoprotein IIb/illa receptor blockers); 
• evaluation of the effects of newer antithromboties on slIstained pateney; 
• study of the mechanisms of the early mortality associated with thrombolytie 
therapy and of ways to avoid it; 
• further analysis of primary pereutaneous transluminal eoronary angioplasty 
(perhaps in combination with eoronary stenting) as an alternative for 
thrombolytie therapy. 
REFERENCES 
1. Simoons ML, Serruys P\V, Brand van den M, et al., for thc working group 011 
thrombolytic therapy in acute myocardial infarction of the Netherlands Interuniversity 
Cardiology Institute. Early thrornbolysis in acute myocardial infarctÎon: limitatÏon of 
infarct size and improved survival. JAm eoU Otrdio11986; 7: 717-28. 
2. The LS.A.M. Study Group. A prospective trial of intravenous streptokinase in acute 
myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Eng! 
] Med 1986; 314: 1465-71. 
3. Anderson JL, Marshall mv, Bray BE, et al. A randomized trial of intracoronary 
streptokinase in the treatment of acute myocardial infarction. N Engl ] Med 1983; 308: 
1312-18. 
4. The Thrombolysis Early in Acute Heart Attack Trial study group. Very early 
thrombolytic therapy in suspected acute myocardial infarction. Am] Cardiol 1990; 65: 
401-07. 
5. Hermens \VI, \'7illems GM, Nijssen KM, Simoons ML. Effect of thrombolytic treatment 
delay on myocardial infarction size. Letter to the editor. Lancet 1992; 340: 1297. 
6. Baardman T, Hermens \'{fT, Lenderink T, et al. Differentîal effects of tissue plasminogen 
activator and streptokinase on infarct size and on rate of enzyme release: influence of 
early infarct related artery patency. The GUSTO enzyme substudy. ElIr HeartJ 1996; 17: 
237-46. 
7. Boer de M], Suryaprallata H, Hoorntje ]CA, et al. Limitation of infarct size and 
preservation of left ventricular function after primary coronary angioplasty cornpared 
with intravenous streptokinase in acute myocardial infarction. Circulation 1994; 90: 753-
61. 
64 CHAPTER4 
8. Laarse van de A, Kerkhof PLM, Vermeer P, et al. Relation between infarct size and left 
ventricular performance assessed in patients with first acute myocardial infarction 
randomized to intracoronary thrombolytic therapy or to conventional treatment. Am] 
Cardio/1988; 61: 1-7. 
9. Granger eB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of 
coronary arterial patency alld left ventricular funedon after intravenous thrombolysis for 
acute myocardial infarctÎon. Am J Cardio11994; 74: 1220-28. 
10. Gruppo ltaliano per la Studio della Streptochinasi nell'Infarto miocardico (GISSI). 
Effeetiveness of intravenous thrombolytic treatment in acute myocardial infarction. 
Lancet 1986; i: 397-401. 
11. 1S15-2 (Second International Study of Infarct Survival) Coltaborative Group. Randomised 
trial of intravenous streptokinase, oral aspirin, bath, or neitller among 17,187 cases of 
suspected acute myocardial infarctian: ISIS·2. Lancet 1988; ii: 349-60. 
12. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic 
therapy in suspected acute myocardial infarction: collaborative overview of early 
mortality and major marbidity results from all randomised trials of more than 1,000 
patients. Lancet 1994; 343: 311-22. 
13. \'{lhite HD, Cross DB, Elliatt JM, Narris RM, Yee TW. Long-term prognostic 
impartance af patency of the infarct-related corollary artery af ter thrombolytic therapy 
for acute myocardial infarction. CirCIIlation 1994; 89: 61-67. 
14. Lenderink T, Simoons ML, Es van GA, \'{lerf van de F, Verstraete M, Arnold AER, for 
the European Cooperative Study Group. Bellefit of thrombolytic therapy is sustained 
thraughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at 
discharge. Circulation 1995; 92: 1110-16. 
15. Vermeer F, Simoons ML, Bär FW, et al. Which patients benefit mast from early 
thrombolytic therapy with intracoronary streptokinase? CirclllatioJl 1986; 74: 1379-89. 
16. Arnald AER, Simoons ML, \'{Ierf van de F, et al., for the European Cooperative Study 
Group. Recombinant tissue-type plasminogen acdvator and inunediate angioplasty in 
acute myocardial infarction. CirCIIlation1992j 86: 111-20. 
17. Mueller HS, Cohen LS, Braunwald E, et al., for the TIMI investigators. Predictors of early 
morbidity and mortality after thrombolytic therapy of acute myocardial illfarction. 
Analyses of padent subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, 
Phase II. CirC/tfation 1993; 88: 416-29. 
18. Simoons ML, Arnold AER. Tailored thrombolytic therapy. A perspective. CirCII/atioll 
1993; 88: 2556-64. 
19. Lee KL, \'{loodlief LH, Topoi EJ, et al., far the GUSTO-I investigators. Predictors of 30-
day mortality in the era of reperfusion for acute myocardial infarctÏon: results from an 
international trial of 41,021 patients. CircIIlatio111995; 91: 1659-68. 
20. Califf RM, \'{laodHef LH, Harrell FE, et al., for the GUSTO-I investigators. Selection of 
thrombolytic therapy far individual patients: development of a clinical model. Am Heart J 
1997; 133: 630-39. 
21. Volpi A, De Vita C, Franzosi MG, et al., the ad hoc working group of the Gruppa 
Italiana per 10 Studio delta Sopravvivenza nell'Infarto Miocardico (GISSI)-2 data base. 
Determinants of 6-month mortality in survivors of myocardial infarction after 
thrombolysis. Results of the GISSI-2 data base. CirclIlatiotl 1993; 88: 416-29. 
22. E:MERAS (Estudio Multicéntrico Estreptoquinasa Repu.blicas de América del Sur) 
Collahorative Group. Randomised trial of late thromholysis in patÏents with suspected 
acute myocardial infarction. Lancet 1993; 342: 767-72. 
A SEARCH POR CONSENSUS 65 
23. Baigent C, Collins R, for the 1515 Collaborative Group. 1515-2: 4-year mortality follow-up 
of 17,187 patients af ter fibrinolytic and antiplatelet therapy in suspected acute myocardial 
infarction. Circulation 1993; 88(suppl): 1-291. 
24. Sirnoons ML, Vos JJ Tijssen JGP, et al. Long-term benefit of early thrombolytic therapy 
in patients with acute myocardial infarction: a 5 year follow-up of a trial conducted by the 
Interuniversity Cardiology Institute of the Netherlands. ] Am ea/l Otrdio/1989j 14: 1609-
15. 
25. \Veaver WD. Time to thrombolytic treatment: factors affecting delay and their influence 
on outcome. JAm Col/ Cardio/ 1995; 25 (suppl): 3S-9S. 
26. Tiefenbrullli AJ, Sabel BE. Timing of coronary recanalization. Paradigms, paradoxes, and 
pertinence. Circulation 1992; 85: 2311·15. 
27. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of 
ischemie ceU death. 1. M)'ocardial infarct size versus duration of eoronar)' occlusion in 
dogs. Cimdation 1977; 56: 786-94. 
28. Schaper \YI, Binz K, Sass S, \Vinkler B. Influence of collateral blood flow and of variations 
in :MV02 on tissue·ATP content in ischemie and infarcted myocardium. ] Moll Cell 
Cardio/ 1987; 19: 19-37. 
29. Davies GJ, Chierchia S, Maseri A. Prevention of myocardial infarction by very early 
treatment with intracoronary streptokinase. N Eng/ ] Med 1984; 311: 1488-92. 
30. McNeill AJ, Flanllery DJ, Wilson CM, et al. Thrombolytic therapy within one hour of 
the onset of acute myocardial infarction. QJ Med 1991; 79: 487-94. 
31. \Yleaver \'{ID, Cerqueira M, Hallstrom AP, et al., for the Myocardial Infarction Triage and 
Intervention Project Group. Prehospital.initiated vs hospital.initiated thrombolytic 
therapy. The Myocardial Infarction Triage and Intervention trial. JAMA 1993; 270: 1211-
16. 
32. GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general 
practitioners: Grampian region early anistreplase trial. Br MedJ 1992; 305: 548-53. 
33. The European Myocardial InfarctÏon Project Group. Prehospital thrombolytic therapy in 
patients with suspected acute myocardial infarction. N Engl ] Med 1993; 329: 383-89. 
34. Fath·Ordoubadi F, AI-Mohammad A, Huehns TY, Beat KJ. Meta-analysis of randomised 
trials of prehospital versus hospital thrombolysis. CirC/llatioll 1994; 90 (suppl): 1-325. 
35. Boersma E, Maas ACP, Deckers ]\YI, Simoons ML. Early thrombolytic treatment in acute 
myocardial infarction: reappraisal of the 'golden hour'. Lancet 1996; 348: 771-75. 
36. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with 
altepiase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-66. 
37. Topoi EJ, Califf RM, Vandormael M, et al. A randomised trial of late reperfusion therapy 
of myocardial infarction. CirC/llation 1992; 85: 2090-99. 
38. Schröder R, Neuhaus KL, Linderer T, Bruggeman T, Tebbe U, Wegscheider K. Impact of 
late coronary artery reperfusion on left ventricular function one month af ter acute 
myocardial infarction (results from tlte ISAM study). Am] Cardio11989; 64: 878-84. 
39. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a 
randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase 
and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute 
myocardial infarction. Lancet 1992; 339: 753-70. 
40. \Ylhite HD. Thrombolytic therapy for patients with myocardial infarctÎon presenting af ter 
six hours. Lancet 1992; 340: 221-22. 
66 CHAPTER4 
41. Beek AM, Verheugt FWA, Meyer A. Usefulness of electrocardiographic findings and 
creatine kinase levels on admission in predicting the accuracy of the interval between 
onset of chest paill of acute myocardial infarctÎon aud initiation of thrombolytic therapy. 
Am] Cardio! 1991; 68: 1287-90_ 
42. SiulOons:ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial 
haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523·28. 
43. Gore JM, Granger eB, Simoons ML, et aL, for the GUSTO-I investigators. Stroke after 
thrombolysis: mortality aud functional outcomes in the GUSTO-I trial. Circulation 1995; 
92: 2811-18_ 
44. Gruppo Italiano per 10 Studio della Sopravvivenza nell'Infarto miocardico. GISSI·2: A 
factorial randomised trial of altepiase versus streptokinase and heparin versus 110 heparin 
among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71. 
45. The International Study Group. In-hospital mortality and clinical course of 20,891 
patients with suspected acute myocardial infarction randomised between altepiase and 
streptokinase with or without heparin. Lancet 1990; 336: 71-75. 
46. The GUSTO investigators. An international randomized trial comparing four 
thrombolytic strategies for acute myocardial infarction. N Engl ] Med 1993; 329: 673-82. 
47. Califf RM, \Vhite HD, Sadowski Z, et al., for the GUSTO-I investigators. One year 
results from the Global Utilization of Streptokinase and tPA for Occluded Coronary 
Arteries (GUSTO-I) trial. Ciwt/ation 1996; 94: 1233-38. 
48. \X'erf van de F, TopoI EJ, Lee KL, et al., for the GUSTO investigators. Variations in 
padent management and outcomes for acute myocardial infarction in the United States 
and other countries.]AMA 1995; 273: 1586-91. 
49. Mark DB, Hlatky MA, Califf RM, et al. Cost effeetiveness of thrombolytic therapy with 
tissue plasminogen actÎvator versus streptokinase for acute myocardial infarction: results 
from the GUSTO randomizcd trial. N Engl] Med 1995; 332: 1418-24. 
50. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin and fibrinolytic therapy in 
suspected acute myocardial infarction. N Engl] Med 1997; 336: 847-60. 
51. Grines CL, Browne KP, Marco J, et al., for the Primary Angioplasty in Myocardial 
Infarction Study Group. A comparison of immediate angioplasty with thrombolytic 
therapy for acute myocardial infarction. N EnglJ Med 1993; 382: 673-79. 
52. Zijlstra F, Boer de MJ, Hoorntje JCA, Reiffers S, Reiher JHC, Suryapranata H. 
Comparison of immediate coronary angioplasty with intravenous streptokinase in acute 
myocardial infarction. N Eng!] Med 1993; 328: 680-84. 
53. Gibbons R}, Holrnes DR, Reeder GS, et al., for the Mayo Coronaf}' Care Unit and 
Catheterization Laboratory Groups. Immediate angioplasty compared with the 
administration of a thrombolytic agent followed by conservative treatment for myocardial 
infarction. N Eng!] Med 1993; 328: 685-91. 
54. O'Neill \Yf\Y/, Boer de MJ, Gibbons R}, et al. Data from three prospectÏve randomized 
clinical trials of thrombolytic versus angioplasty therapy of acute myocardial infarction. 
Preliminaf}' results from a pooled analysis. Submitted. 
55. The GUSTO-IIb angioplasty substudy investigators. A clinical trial comparing primary 
coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N 
Eng!] Med 1997; 336: 1621-28. 
56. Boer de M}, Hout van B, Liem AL, Suryapranata H, Hoorntje ], Zijlstra F. A cost· 
effective analysis of primary coronary angioplasty versus t1uombolysis for acute 
myocardial infarction. Am] Cardio/1995j 76: 830-33. 
57. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. 
CirCidation 1990; 82: 1510-13. 
A SEARCH FOR CONSENSUS 67 
58. Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute 
myocardial infarction: concepts and controversies. ] Am Col! CardiQ{1990j 16: 223-31. 
59. Selker HP, Beshansky JR, Schmid eH, et al. Presenting puIse pressure prediets 
thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive 
Instrument (rPI) project results. CirCl(lation 1994; 90: 1657-61. 
60. Boersma E, Van der Vlugt M, Arnold AER, Deckers }W, Simoons ML. Estimated gain in 
life expectancy. A simple taal to select optimal reperfusion treatment in individual 
patients with evolving myocardial infarction. Ellr Heart J 1996; 17: 64-75. 
61. Arnold AER. Benefits and risks of thrombolysis for acute myocardial infarction. Thesis. 
Rotterdam 1990. 
62. Selker HP, Griffith JL, Beshansky JR, et al. Patient·specific predictions of outcomes of 
thrombolytic therapy for real-time emergency use: the thrombolytic predictive 
instrument. Antz Int Med 1997; in press. 
ApPENDIX 
Participants 
F. Van der Werf (Belgium, Leuven, University Hospital Leuven), A. Vahanian 
(France, Paris, Hemadynamie Laboratory Cardiology Service Hospital 
Tenon), D.C. Gulba (Gennany, Berlin, University Hospital 'Rudolf 
Virchow'), J. Müller (Germany, Marburg, Behringwerke Aktiengesellschaft), 
A.E.R. Arnold (The Netherlands, Alkmaar, Medical Center Alkmaar), F. Bär, 
F. Vermeer (The Netherlands, Maastricht, University Hospital Maastricht), 
F.W.A. Verheugt (The Netherlands, Nijmegen, University Hospital 
Nijmegen), H. Boersma, G.A. Van Es, J.W. Deckers, T. Lenderink, M.L. 
Simoons, E. Steyerberg, C. Van der Zwaan (The Netherlands, Rotterdam, 
University Hospital 'Dijkzigt'), M.J. de Boer, F. Zijlstra (The Netherlands, 
Zwolle, Hospital 'De Weezenlanden'), R.D. Wilcox (U.K., Nottingham, 
Department of Medicine, Queens Medical Center), R. Collins, P. Sleight 
(U.K., Oxford, Cardiac Department), H.P. Selker (U.S.A., Boston MA, New 
England Medical Center), R.M. Califf, C. Granger, K.L. Lee, M.E. Ohman 
(U.S.A., Durham NC, Duke University Clinical Center), D.W. Weaver 
(U.S.A., Detroit MI, H. Ford Hospitai), T. Love (U.S.A., San Francisco C, 
Genentech Inc.), H. White (New Zealand, Auckland, Green Lane Hospital) 
Writing committee 
H. Boersma, R. Califf, R. Collins, J.W. Deckers, M.L. Simoons 
68 CHAPTER4 
ACKNOWLEDGEMENTS 
We thank Anneke Kooijman and Lilian Oelius for transcribing the lectures 
and for their help with the preparation of the manuscript. The meeting on 
February 20 and 21, 1995 was supported by grants from the Dutch Heart 
Foundation (l'lederlandse Hart Stichting), Genentech Inc., Boehringer 
Ingelheim and hospital 'De Weezenlanden' in Zwolle. 
PRACTICAL DECISION MODELS 

Chapter 5 
A TREA TMENT SCHEME TO GUIDE DECISION MAKING IN 
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SUMMARY 
Background 
Currently several modes of reperfusion therapy for acute myocardial infarction are 
available. Streptokinase, accelerated altepiase and direct angioplasty are the most 
frequently used. These options are increasingly effective, but also increasingly complex 
and costly. Since, unfortunately, physicians are often restricted by budget limitations, 
choices must be made in clinical practice to provide optimal therapy to individual 
patients. 
Metbods and findings 
In order to guide such decision making, we developed a model to predict the expected 
benefit of therapy in terms of gain in life expectancy. Patients' life expectancy wil! 
decrease after infarction. Part of this loss can be prevented by eady reperfusion 
therapy. This clinical benefit of therapy ranges from negligible gain in patients with 
small infarcts treated relatively late to an expected gain of more than 2 years in patients 
with extensive infarction treated within 3 h of onset of symptoms. 
The expected benefits are presented in a set of tables and depend on age, previous 
infarction, estimated infarct size, treatment delay and intracranial bleeding risk. With 
the help of these tab les, resources will be allocated in such a manner, that patients who 
wil! benefit most wil! receive the most effective therapy. Patients with similar expected 
treatment benefit wil! be offered the same mode of therapy. Puture life years were 
discounted at 5% per year. The arbitrary thresholds currently applied for decision 
making at the Thoraxcentre are: no reperfusion therapy when the estimated gain in 
discounted life expectancy was < 1 month, streptokinase for 1-4 months and 
accelerated altepiase for a gain ~5 months. Direct angioplasty is recommended in 
patients with all estimated gain ;;::12 months, and in patients with an increased risk of 
intracranial bleeding. In this way, approximately 80% of our patients will be treated 
with thrombolytics (40% streptokinase and 40% accelerated altepiase), while in 10% 
direct angioplasty wil! be initiated. Patients with small infarcts presenting late wil! not 
receive reperfusion therapy. 
Conclusions 
These threshold values have been chosen arbitrarily, and different thresholds may be 
selected in other centres. However, the developed model would guarantee that 
treatment decisions are made in a consistent mannef, to provide optimal therapy for 
patients with evolving myocardial infarction, in spite of limited resources. 
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INTRODUCTION 
The necessity of early reperfusion to improve survival in acute myocardial 
infarction patients has clearly been demonstratedP-12l Such reperfusion can be 
achieved using one of several regimens of thrombolytic drug therapy, or by 
direct percutaneous transluminal coronary angioplasty. Various 
pharmacological strategies have been compared in separate trials. The regimens 
studied in the GISSI-2 and ISIS-3 studies appeared to be equally effective: 
streptokinase, anistreplase, altepIase rt-PA and dutepIase, each administered with 
aspirin and either without or with subcutaneous heparin started a few hours 
after thrombolysis.[8,13l In addition, a bolus injection with reteplase was shown 
to be equivalent to streptokinaseP4l In contrast, the GUSTO trial demonstrated 
improved survival by accelerated administration of tt-PA with aspirin and 
immediate intravenous heparin: one additional survivor at 30 days and at one 
year for 100 patients treated with accelerated tt-PA in comparison with 
streptokinasePS,t6l The combined results of three recently presented studies 
indicated superior survival following direct angioplasty compared with 
thrombolysis. The 42-day mortality rates were 2.2% [95% Cl: 0.6-3.8) and 5.8% 
[3.3-8.3), respectively.[17-19l Furthermore, fewer intracranial haemorrhages and a 
lower rate of recurrent infarction were repotted in the angioplasty group. 
The gradient of efficacy of the three accepted and most widely used modes 
of reperfusion therapy (streptokinase, accelerated tt-PA and direct angioplasty) 
runs parallel to a gradient of costs and complexity. For example, the initial, 
direct costs of treatment of a patient with tt-PA in The Netherlands are 
approximately five times higher than if streptokinase were used (Df]. 2,000 vs. 
Dfl. 400, respectively), while an angioplasty procedure requires more complex 
organisation and is even more expensive: approximately Dfl. 5,000 to 8,000. 
Other regimens for reperfusion therapy are being evaluated, including 
combined thrombolytic and anti-thrombotic therapyPO-22l and thrombolytic 
therapy with platelet fibrinogen receptor blockers.[23l The clinical benefits of 
these and other approaches have yet to be determined. Again, more effective 
therapy will often be more costly than current available therapy. 
A gradient of treatment benefit is also apparent when subsets of patients 
with evolving myocardial infarction are compared. The benefit of reperfusion 
therapy depends on age, the area at risk, treatment delay and the risk of 
intracranial bleeding.[I,S,"-29l Accordingly, in clinical practice physicians must 
choose the most suitable mode of therapy for individual patients. 
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Unfortunately, this choice is aften limited by a budget, such that the most 
effective therapy cannot be offered to all patients. Given this constraint, it is 
appropriate to offer more effective, more expensive and more complex modes of 
therapy to patients who are likely to benefit most from treatment, and to 
provide slightly less effective, but considerably less expensive modes of therapy 
to patients whose expected benefits from treatment are lower. Ta facilitate such 
decision making, we present a model which predicts the benefit of reperfusion 
therapy in individual patients through assessment of the gain in life expectancy. 
An earlier model expressed treatment benefit in terms of number of cardiac 
deaths prevented in the first year.[29J However, that model did not account for 
differences in life expectancy in different age categories. For example, elderly 
patients may have considerable initial benefit from intensive therapy, but their 
life expectancy remains limited, and the cost-efficacy ratio may be 
unsatisfactory. In contrast, a smaller initial benefit in younger or middle-aged 
patients with a langer life expectancy may result in a more favourable cost-
efficacy ratio. 
In the proposed model, life expectancy was estimated from age- and 
gender- specific mortality and follow-up data from different groups of patients 
after myocardial infarction. The influence of various parameters in the model 
was evaluated by a sensitivity analysis using data from a recent cohort of 500 
consecutive patients admitted with evolving myocardial infarction. Finally, a set 
of simple tables is presented, which provides an overall estimate of the effects of 
reperfusion therapy in patient subgroups to assist clinical decision making in a 
consistent manner. The present model may be used to choose between four 
currently available treatment options: na reperfusion therapy, streptokinase, 
accelerated tt-PA with intravenous heparin and direct angioplasty. It may be 
adapted to other treatment regimens when these become available in the future. 
DESIGN OF THE MODEL 
A cost-efficacy analysis, comparing outcome and casts of each regimen in 
different subsets of patients is a formal way to choose between different 
treatment regimens in an individual patientpoJ This would require assessment of 
the initial and subsequent casts assocÎated with the different modes of treatment 
as weil as survival analysis. However, a complete cost-efficacy model applicable 
to individual patients would need extensive computations with an appropriately 
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programmed computer system, and would be difficult to handle for immediate 
decision-making in clinical practice. Also the design of such a detailed model 
would require precise knowledge of differences (if any) in long-term effects of 
various treatment modalities, knowledge that is not currently available. 
Therefore we sought an alternative approach, which provides an overall estimate 
of the effects of reperfusion therapy in patient subgroups, presented in a set of 
tables. 
The chosen approach is based on the assumption that differences in 
expected benefits between treatment regimens are greater in groups of patients 
with a greater overall benefit from reperfusion therapy. lndeed, currently 
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Figure 1: Estimated one-year mortality in different patiellt subgroups 
40% 50% 
44.3% 
Results are based on a multivariate analysis of data from 3,179 patients from three 
studiesP9] Risk factors for one-year mOltality were: advanced age, previous infarctioll, 
anterior infarction, inferior 10cation with right ventricular involvement, heart failure and 
bundie branch block. Patients are devided iuto groups according to their increasing 
number of risk factors, either without or with extensive ST segment deviation. The length 
of each bar represents estimated mortality without reperfusion therapy (no treatment). 
Early treatment (within 3 h of symptom onset) is assumed to reduce mortality in each 
group by 50% (grey area), while only 12.5% mortaliry reduetion is aehieved by late 
treatment (6-12 h of symptom onset, white area). 
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1. Mortality in the first year after infarction can be predicted from age, history of 
infarction, infarct location and indicators of infarct size. 
2. Mortality reduction by reperlusion therapy is proportional to predicted mortality 
and related age, and to time to treatment. 
3. Differences in efficacy of various modes of reperfusion therapy are proportional to 
the overall mortality reduction. 
4. The risk of intracranial haemorrhage ean be predicted from age, blood pressure, 
body weight and the mode of reperlusion therapy. 
5. Survival curves of myocardial infarction patients without and with reperfusion 
therapy run parallel after the first year, and exceed mortality rates of the 'normal' 
reference populations with a constant difference. 
6. Late mortality rates are proportional to one-year mortality after infarction: patients 
with a large infarct have both greater initial and greater suhsequent mortality rate 
(i.e. larger differences relative to the reference population). 
7. The utility of luture life years is discounted at 5% per year. 
Table 1: Assumptions made in the modeIs to .ssess the benefit of reperfusion ther.py 
in patients with evolving myocardial infarction 
available data indicate that bath the benefit of reperfusion therapy compared to 
conventional therapy, as wel! as the incremental benefit of more intensive 
therapy (for example accelerated rt-PA versus streptokinase) are proportional to 
the mortality risk in patient subgroups. Thus, to identify patients whose 
additional benefit from intensive therapy would be considerable, it would be 
sufficient to identify the subgroups with the highest overal! one-year mortality 
risk (figure 1). In these groups, classified according to the initial mortality risk, 
the expected benefit of reperfusion therapy wil! be expressed as gain in life 
expectancy (years or months). 
In the following paragraphs the model wil! be developed and explained in a 
stepwise manner. The model assumptions have been summarised in table 1. 
INITIAL TREATMENT BENEFIT 
Initial treatment benefit can be expressed as the 'numbers of lives saved' within 
the first year af ter myocardial infarction. As described previously, treatment 
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benefit is related predominantly to mortality risk without therapy and to the 
time to interventionp,5,29] Factors determining mortality risk include age, 
previous infarction and indicators of the expected infarct size: infarct location, 
the total amount of ST-segment deviation in the EeG, the presence or absence 
of heart failure and presenee or absence of bundie branch block (figure 1).[1,29] 
THE RISK FOR INTRACRAMAL HAEMORRHAGE 
The initial benefit of thrombolytic therapy is lost in some patients who have an 
increased risk of intracranial haemorrhage.[311 On the other hand, the risk of 
embolie stroke is diminished. No increase in total stroke was observed in large 
studies with streptokinase,[2,51 while a smaIl excess of intracranial haemorrhage 
and stroke was observed after administration of accelerated rt-PA. Nevertheless, 
excess stroke after accelerated rt-PA is only 10% of the additional survival 
benefit.[15] Previous studies have identified risk factors for intracranial 
haemorrhage: increased age, elevated blood pressure at admission, low body-
weight and the use of rt-PA vs. streptokinase.[32-34] Patients with other risk 
factors for intracranial haemorrhage were generaIly excluded from trials: those 
with a known history of cerebrovascular disease or other intracranial 
abnormalities and patients with a recent head trauma. These contraindications 
for thrombolytic therapy should be respected in clinical practice, and direct 
angioplasty should be considered in patients with increased bleeding risk. 
LIFE EXPECTANCY OF THE REFERENCE POPULAnON 
Using age- and sex-specific mortality data from The Netherlands in 1990, life 
expectancy was estimated of an imaginary, average reference person in the 
normal population. Since 80% of the infarct patients admitted to coronary care 
units in The Netherlands are male, mortality risks were weighted according to 
this sex distribution. Reference life expectancies calculated for different age 
categories were 30.9 years at the age of 45, and 22.0,14.3 and 8.4 years at ages 55, 
65 and 75 respectively (figure 2a). Yearly mortality of a 55 year old reference 
subject would be approximately 1.0% to 1.5% during the first 5 years. 
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Figure 2(e): Life expeetaney of a 55 year old patient with extensive myoeardial 
infarction patient af ter eonventional as weil as reperfusion therapy 
Figure 2: Life expeetaney (a) in a referenee poplliation as weil as in myoeardial 
infarction patients af ter (b) eonventional and (e) reperfllsion tlierapy 
(a) Referenee life expeetancies for different age eategories. (b) Survival curves of a SS year 
old reference subject as weIl as the curves of two conventionally treated patients of the 
same age. After a small infarction, life expeetaney (the area under the curve) will be 
reduced from 22.0 to 19.1 years, a 105s of 2.9 years (35 months). An extensive infarction 
would result in a 1055 of 13 years and a remaining liEe expectancy of only 9 years «c), see 
also table 2(a». Part of this loss ean be regained by reperfusion therapy, as shown by the 
survival curve of a patient whose large myocardial infarction was treated early. Assuming 
no risk factors for intracranial haemorrhage, reperfusion tllerapy within 3 h of onset of 
symptoms regains 3.6 Iife years (43 months): from 9.0 to 12.6 years. The benefit of 
treatment initiated between 6 and 12 h would be 0.8 year (10 months): from 9.0 to 9.8 
years. In the presence of risk factors for intracranial haemorrhage the treatment benefit in 
similar patients would be redueed by approximately 0.1 years (1 month). 
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Figure 3: Estimated and observed long-term mortality effects of reperfusion ther.py 
in myocardial infarctioll 
Computed survival curves according to rhe proposed model were compared with observed 
survival in the combined data from 1,254 patients in trials by the Inter-universi~ 
Cardiology Institute of The Netherlands and the Europe.n Cooperative Study Group.IJ5.J 
The mean age of the patients was 55 years; the ane-year mortality rate without 
thrombolysis was 12.5%. This corresponds to the mortality of a patient in the model of 
the same age with an anterior infarction and a total ST segment deviation exceeding 2.0 
mV. Indeed, the estimated survival curves (dotted line) are superimposed on the observed 
curves (straight line) in the trials. 
LIFE EXPECTANCY AFI'ERMYOCARDIAL INFARCTION 
To assess life expectancy aftel' myoeardial infaretion, with or without 
reperfusion therapy, follow up data were analysed from different trials of 
thrombo-lytie therapy. In all trials the reduction in mortality aftel' one year was 
maintained during follow-up, for at least during 3 to 8 years.[29,35-37] Survival 
curves of patients without or with thrombolytic therapy were approximately 
parallel. This implies a sustained absolute survival benefit and a similar or 
slightly lower relative mortality aftel' thrombolytic therapy compared with 
conventional treatment. 
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In the early study of intracoronary streptokinase conducted by the Inter-
university Cardiology Institute of The Netherlands (rCIN), mortality rates after 
the first year were 3.2% and 2.1% in conventionally treated and reperfused 
treated patients respectivelyPSI In the Western Washington intracoronary 
streptokinase studies these figures were 3.3% and 4.8%, respectively, and in the 
studies by the European Cooperative Study Group (ECSG) 2.0% and 1.8%P6,37] 
The mean age of the patients in these studies was approximately 55 years. A 
recent observational study in a London district general hospital revealed a yearly 
mortality rate after the first year of follow-up of 4.2% in conventionally treated 
and 3.8% in thrombolysis treated patients at a median age of 62 years.[381 Thus, 
mortality in survivors of a myocardial infarction is in the range of 2% to 5% per 
year, which is 0.5% to 4.0% higher than mortality in the reference population as 
presented above. Late mortality rates are similar among patients with and 
without reperfusion therapy. We assumed that an average excess in mortality 
rate of approximately 1.5% will also occur in other age categories, and that this 
will be maintained beyond the reported follow-up. The accuracy of this 
estimation for a 55 year old patient is illustrated in figure 3, in which computed 
and observed survival curves are presented. 
Survivors of a small infarct will have a better prognosis than those patients 
surviving a large infarction. In fact, predictors of late mortality are similar to 
factors determining early mortalityP7J We analysed late mortality rates in 
subgroups of patients with low, middle or high tertiles of initial mortality risk, 
employing the combined data of the ICIN and ECSG trials. In the low risk 
group, late mortality rate was 1.9% [95% Cl 1.4-2.4] per year, whereas these 
figures were 2.5% [1.7-3.4] and 4.1% [2.5-5.6] in the medium and high risk 
groups, respectively. To account for these differences in our model, we assumed 
an excess in mortality of 1.0%, 2.0% and 3.0% compared with the reference 
population, for patients with a one-year mortality risk of less than 10%, between 
10% and 30% and more than 30%, respectively (figure 1). 
OVERALL BENEFIT OF REPERFUSION THERAPY 
Part of the potentialloss in life years from myocardial infarction can be regained 
by timely reperfusion therapy. The expected gain from reperfusion therapy in 
different subgroups of patients is presented in table 2(a) taking into account age, 
estimated infarct size and its modification by reperfusion therapy, and treatment 
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Table 2(a): Estimated gain in life expectancy Table 2(b): Gain in discounted life expectancy 
Estimated gain in life expectancy (a) in different patient subgroups depending on age, indicators of increased mortality risk (risk 
indicators, see figure 1) and tota! ST segment deviation in the 12 standard EeG leads. Reference life OÀ-pectancies in tbe different age 
groups are 30.9, 22.0, 14.3 and 8.4 years, respectively. The expected benefit of reperfusion tberapy is estimated depending on baseline 
risk and treatroent delay. See tex! for further explanation. The double line (in tbe right-hand column) separates patients whose 
expected benefit is less than the 50tb percentile (above tbe line) from tbose exceeding the 50tb percentile (below the line). The single 
line indicates patients witb a very limited expected treatment benefit: less tban tbe lOth percentile. The value of reperfusion therapy 
in such patients may he questioned. The underscored numbers indicate patients in whom the e':pected treatment benefit would he 
lost if risk factors for intracranial haemorrhage were present (apart from age): high blood pressure, low body weight and treatroent 
with alteplase.[341 Discounting future life years at 5% per year results in values as presented in (b). The 50th percentile and lOtb 
percentile lines are indicated as in (a). Note the similar position of tbe double lines in (a) and (b), with only a one position shift 
downward for earl y treatment in the youngest age group. 
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delay. In patients between 50 and 59 years of age the expected gain varied from 
less than 1 month to more than 2 years, respectively, in those with smal! infarcts 
arriving late and those with extensive infarction treated within 3 h of symptom 
onset. In al! subgroups at younger age the expected gain in life years was 
somewhat greater, due to their longer life expectancy. The expected gain was 
also greater in patients between 60 and 69 years of age, as a result of the greater 
initial benefit due to the high mortality risk without therapy. In the elderly 
patients, aged 70 years or over, reperfusion therapy was less effective, and 
consequently the expected gain decreased. It should be appreciated that the 
available data['9] did not a!low a more comprehensive analysis of expected 
benefits in patients at advanced age with extensive infarctions (multiple 
mortality risk factors) since such patients have a low life expectancy anyhow. 
The reduction of expected gain by intracranial bleeding was less than 1 month 
in the youngest age groups, and less than 1.6 and 2.2 months in patients aged 60-
69 and 70-79 years, respectively. 
In cost·efficacy analysis it is customary to discount future life years, to 
account for the greater value given to the near future, when compared with the 
value of the more uncertain, more distant futUt"ePO] Discounting also 
compensates for the lesser accuracy of predicted long·term survival. In table 2(b) 
the discounted life expectancies (discounting factor 5% per year) are presented 
for different patient groups. In patients with the longest life expectancy - those 
in the youngest age group - values are reduced relative to elderly patients 
(compare tables 2(a) and (b)). The loss in discounted life expectancy from 
increased bleeding risk was less than 0.7, 0.6, 1.1 and 1.7 months in the 
respective groups of patients with increasing age. 
The proposed model (tabIe 2(a) and (b)) provides ascale to rank patients 
with greater or smaller expected treatment benefit. In order to analyse the 
distribution of patients with different levels of expected treatment benefit in 
clinical practice, data were co!lected from a series of 500 consecutive patients 
with myocardial infarction admitted to different hospitals (tabIe 3). One third of 
these patients were above the age of 70, and only one sixth were less than 50 
years of age. The distribution - in percentiles - of expected gain in life years 
among the different age groups is presented in figure 4(a). Patients with the 
greatest expected benefit were predominantly represented in the younger age 
groups. The 25% of patients with the greatest predicted benefit were within 
those younger than 70 years of age. Computation of discounted life expectancies 
resulted in some shift of the 50th percentile of expected benefits towards the 
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elderly. The greatest expected benelit according to the discounting principle was 
observed in patients between 60 and 70 years ol age (ligure 4(b)). This shift 
towards greater expected bene fit in the elderly was even more pl'Onounced if 
decisions were based on the initial treatment effect: reduction in one-year 
mortality. The distribution in figure 4(c) indicates that the 50% of patients with 
greatest expected benefit, who would warrant the most intensive mode of 
therapy, would be mainly among those above the age of 60 according to this 
approach, although none ol the elderly would be above the 90th percentile. 
Baseline characteristics Number (%) 
Male sex 373 (75) 
Mean age (years) 63 
Age (years) 
<50 73 (15) 
50 - 59 124 (25) 
60 - 69 145 (29) 
;'70 158 (32) 
Prior infarction 119 (24) 
Localisation 
anterior 205 (41) 
infetîor and right ventricle 120 (24) 
QRS time> 120 msec 31 (6) 
Congestive heart failure 61 (12) 
Symptom onset (h) 
<3 330 (66) 
3-6 117 (23) 
6 - 12 53 (11) 
ST deviation ;'2.0 m V 195 (39) 
Mean RR at admission ;'160/90 mmHg 140 (28) 
Body weight < 70 kg 151 (30) 
Mean number of MI risk factors 1.1 
Mean number of ICH risk factors 0.6 
Table 3: Baseline characteristics of 500 patients with evolving myocardial infal'ction 
admitted consecutively to su hospitals in The Netherlands dUrÎl1g predefined periods 
in 1993 and 1994 
MI = myocardial infarctionj ICH = intracranial haemorrhage 
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Figure 4: Distriblltion of patients with different levels of estimated treatment benefit 
in clinical practice 
Three different modeIs were applied to data from 500 consecutive patients from six 
different hospitals (tabIe 3). The bars represent the actual patient numbers in four age 
groups. The different shadings represent patients with estimated benefit within the 
specified percentiles of the distribution. Note: (I) A marked shift of the centre of the 
distribution - 50th percentile - of modeIs accounting for life expectancy (a) and (h) vs. 
reduction of one-year mortality (c). (ll) The 25% of patients with greatest predicted benefit 
according to the fulllife expectancy model (a) was found in those younger than 70 years of 
age. (lIl) Discounting Iife years resulted in same shift of the 50th percentile of expected 
benefits towards the e1derly (compare (a) and (h)). (rV) The greatest expected benefit 
according to the discounting principle was observed in patiellts between 60 and 70 years of 
age. 
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DISCUSSION AND SENSITIVITY ANALYSIS 
The purpose of the current analysis was to develop a simple tooi for clinical 
decision making in patients with evolving myocardial infarction. In most 
hospitals in Europe, as weil as in other continents, physicians have to select the 
best available reperfusion therapy for individual patients, given that (1) several 
modes of therapy are available, which differ in efficacy, costs and complexity, 
while (2) resources are limited, which implies that the most effective therapy can 
not be offered to all patients. Since (3) the expected benefit differs among 
various groups of patients - smaller vs. larger infarcts, younger vs. elderly 
patients, early vs. late treatment (tabie 2) - it wil! be appropriate to offer the 
most effective (costly) therapy to those with the greatest expected benefit. At the 
same time, patients with similar expected benefits should be treated in a similar 
manner. Selection criteria, mainly based on age, financial situation or social 
status - better therapy for the younger, wealthy and powerful - are considered 
undesirable. 
In order to choose the optimal therapy following this principle, the 
physician must be able to assess the expected treatment benefit, and to rank 
patients according to this expected benefit. Table 2, as presented in this report, 
provides such measures of expected benefit expressed in 'gain of (discounted) life 
years'. Since the available follow-up data are limited, a model had to be 
developed to estimate the expected gain in life years (or months) for different 
groups of patients which can easily be identified in clinical practice. The 
assumptions made in the model (tabie 1) will be discussed below and the effects 
of alternative assumptions on the outcome (i.e. ranking of patients according to 
the expected treatment benefit) wil! be presented where appropriate (sensitivity 
analysis). 
Initial benefit: one-year sllrvival 
Predictors of one-year survival were obtained by multivariate logistic regression 
analysis in a series of 3,179 patients from different trialsP'] More recently a 
detailed analysis was performed by the GUSTO investigators, predicting 30-day 
mortality from patient characteristics as available upon admission, and by the 
Fibrinolytic Therapy Trialistsp·39] In all thl'ee studies the characteristics which 
appeared to predict mortality were similar, which supports the validity of the 
proposed model for initial benefit of reperfusion therapy. 
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The duration of coronary occlusion preceding reperfusion is a major 
determinant of the extent of myocardial necrosis and infarct mortality. In the 
model it was assumed that initiation of reperfusion therapy within 3 h would 
reduce mortality in the first year by 50%, and therapy aftel' 3·6 hand 6-12 h by 
25% and 12.5%, respectively. This represents a simplification of the curvilinear 
relation between time to treatment and myocardial salvage as observed in 
experimental studies as weIl as clinical studies measuring infarct size (figure 
5).f40,4!J Within each time interval, the re/ative benefits of reperfusion therapy 
were assumed to be constant, thus the absolute benefits depend on, and are 
proportional to the mOltality risk in patient subgroups. This is consistent with 
findings in all larger trials comparing thrombolytic therapy vs. placebo Ol' 
controls, and with the GUSTO dataP-lO,!SJ 
Overall benefit: lifè expectdncy 
Life expectancy in subgroups of patients was assessed from a survival table of the 
reference population in The Netherlands, with adjusted (higher) yearly 
mortality rates aftel' myocardial infarction. The major determinants of life 
expectancy were initial - one-year - survival rates (as discussed above) and the 
difference between reference mortality and late mortality rates aftel' infarction. 
Benefit of reperfusion therapy was defined as the number of regained future life 
years (months) which otherwise would have been lost aftel' infarction. The 
effects of late mortality on prediction of treatment benefit in several age 
categories was evaluated for different model assumptions. 
In the model, increased late mortality was related to mortality in the first 
year: 1.0%, 2.0% and 3.0% higher than the reference group, respectively, in 
three groups of patients with low, intermediate and high one-year mortality. 
This reDects the notion that patients with a large infarct will have both 
increased early (one year) and late mortality due to impaired ventricular 
function. In addition a more simple model was tested assuming similar late 
mortality rates, independent of infarct size, 1.5% greater than reference 
mortality. These two approaches yielded similar distributions of the expected 
gain (the data of the second model not shown). A shift in late mortality rates 
within the models had litde effect, neither on the estimation of treatment 
benefit nol' on the ranking of patients according to the expected treatment 
benefit. 
There was a modest reduction in estimated treatment benefit in patients at 
increased risk for intracranial haemorrhage. However, this hardly affected the 
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Figure 5: Relationship between treatment delay and mortality reduction as reported 
in clinical trials 
The exact relationship is still debatable. The dolted curvelinear line presents the assumed 
relationship based on animal experiments.[41] Although no statistical curve fitting was used, 
the line appears to match data from different patient studies as indicated. 
ranking of patients groups with increasing treatment benefit (tabie 2). The 
ranking of patients according to expected treatment benefit was determined 
predominantly by the introduction of life expectancy vs. reduction in one-year 
mortality in the model (compare figures 4(a) and (c)). Furthermore, the centre of 
the distribution (50th percentiIe line) was slightly affected by the discounting 
factor of 5% per year (compare figures 4(a) and (b)). The top end of the distri-
bution (90th percentiIe) also shifted slightly, implying greatest benefit in patients 
between 60 and 70 years of age using the latter concept. The identification of 
patients with the smallest expected benefit (below 10th percentiIe) was also 
influenced by the design of the model (figure 4). 
ESTIMATED GAIN IN LIFE EXPECTANCY 91 
A PROPOSED DECISION RULE 
The model which has been developed estimates the gain in 1ife expectancy by 
reperfusion therapy depending on patient characteristics, predicted infarct size 
and time to treatment (tabIe 2). This resulted in a gradient of expected benefits 
ranging from a negligible benefit < 1 month in patients with small infarcts 
treated late, to an increased life expectancy of more than 2 years in patients with 
large infarctions treated within 3 h of symptom onset, Ol' within 6 h in the 
youngest age group. 
Each physician or each hospital must select the best available therapy for 
each patient. If a choice were made to treat all patients with one mode of 
therapy (e.g. streptokinase as being the less expensive drug, or rt-PA, it being the 
most effective), decisions in individual patients can be avoided. In clinical 
practice, however, individual decisions are usually required because of budgetary 
and/or organisational (direct angioplasty) constraints. At the Thoraxcentre we 
elected to allocate the resources as follows: 5% to 10% of the patients will not 
receive thrombolytic therapy, if estimated benefit is very small or even absent 
(e.g. in those with a small infarct, presenting late); 5% to 10% of patients with a 
large expected treatment benefit will be treated with direct angioplasty, 
including patients with a markedly increased risk for intracranial haemorrhage. 
In the remaining 80% to 90% of patients, half willreceive streptokinase and the 
other half accelerated rt-PA. The life expectancy model (tabIe 2(b)) is used to 
rank patients according to expected treatment benefit, while discounting future 
!ife years. The model with discounting was chosen, because it seems to be the 
best theoretical approach, and because of its intermediate position between the 
expected one-year benefit (figure 4(c)) and life expectancy without discounting 
(figure 4(a), table 2(a)). It should be appreciated, that the latter choice has only 
modest influence on the distribution of the use of the two thrombolytic 
regimens (tabIe 2). According to the chosen model (tabIe 2(b), figure 4(b)), direct 
angioplasty will be offered only to patients younger than 70 years of age. 
The use of the two thrombolytic regimens in patient groups of similal' size 
has been based on the recent cast effectiveness analysis of the GUSTO tl'ial.[42] 
In that analysis, based on U.S.A. data, the incremental costs per !ife year gained 
by using accelerated lt-PA vs. streptokinase were estimated at $27,400. After 
adjustment for differences in price levels between the U.S.A. and The 
Netherlands the incremental casts of lt-PA pel' year of life gained amounts to 
approximately Dfl. 25,000. We elected to use this more effective but more 
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expensive therapy in half of the patients: those with the greatest expected gain in 
life years. In these patients the incremental costs will be less than Dfl. 25,000. 
Patients in whom incremental costs for rt-PA would be in excess of Dfl. 25,000 
were recommended to be treated with streptokinase. 
The thresholds currently applied for decision making at the Thoraxcentre 
are (based on the model of our choice as described above): no reperfusion 
therapy when the gain in discounted life expectancy was < 1 month, 
streptokinase for 1-4 months and accelerated rt-PA for a gain ;0,5 months. Direct 
angioplasty is recommended in patients with an increased intracranial bleeding 
risk and in those with estimated gain d2 months. Indeed, application of this 
decision rule to the 500 patients resulted in 54 patients (10.8%) being 
recommended conventional therapy, 197 (39.4%) SK, 199 (39.8%) accelerated rt-
PA and 50 (10%) direct angioplasty. It should be appreciated that this choice for 
allocation of recourses is wholly arbitrarily. Other centres may elect to apply 
another model, or to provide the available therapies in different proportions and 
use, for example, direct angioplasty more frequently or never. This would imply 
other threshold values, while the same principles could still be applied. 
CLINICAL IMPLICATIONS : ARBITRARY BUT CONSISTENT DECISIONS 
Currently available follow-up after reperfusion tllerapy is limited, and lacks 
power to allow a definite choice between the approaches presented above. 
However, the physician often has to make his choices, at night, with little time 
for reflection. Patients previously treated with streptokinase or anistreplase 
preferably should not receive such drug a second time because of development 
of streptokinase antibodies.[4Jl Patients in cardiogenic shock should be offered 
direct angioplasty, when available. For most patients, however, models like the 
one presented here may guide the physician to be consistent, and to offer the 
same mode of therapy to patients with similar expected treatment benefits. 
Benefit always will be greatest in patients with extensive infarction, treated early 
after the onset of symptoms. All efforts should be made to promote early 
treatment by whichever regimen available, whether it be streptokinase, 
accelerated rt-PA or direct angioplasty.[4Jl 
Patients with the greatest expected treatment benefit deserve the most 
effective therapeutic regimen, regardless of costs and complexity. If such 
decision were based predominantlyon the initial treatment benefit, then such 
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intensive and expensive therapy would be reserved mainly for elderly patients 
(figure 4(c». However, the most intensive therapy should be given to younger 
patients if the decision is weighted by the expected long-term survival after 
successful intervention (figure 4 (a». This reasoning mayalso be reversed : A 
physician who, intuitively, applies direct angioplasty (the assumed most effective 
therapy) to predominantly younger patients logically assumes a significant long 
term benefit of the intervention. 
At the Thoraxcentre, we have opted for the intermediate approach (tabie 
2(b), figure 4(b», but others may be inclined to base their decisions on other 
modeIs. It should be appreciated that our preferenee will change when new, 
more effective treatment regimens become available in which either the risk of 
intracranial haemorrhage or the costs would be lower. Nevertheless, a model as 
described above does ensure that treatment decisions are made in an organised 
and consistent mannel', to provide optimal treatment for patients with evoh'ing 
myocardial infarction, given the existing financial - and organisational 
restrictions. 
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INTRODUCTION 
Large randomised trials have demonstrated the benefit of reperfusion therapy 
in treatment of patients with evolving myocardial infarctionp,2l Reperfusion 
therapy dissolves (pharmacological approach) or removes (mechanical 
procedure) the occluding coronary th rombus, thus recovering blood flow and 
oxygen delivery to the jeopardised myocardium. If such therapy is initiated 
within 6 h from coronary occlusion, which event usually coincides with onset 
of chest pain, part of the viabIe myocardial tissue will be preserved,[3l which 
has favourable impact on patient's prognosis. 
Results of randomised investigations apply by necessity to a patient 
poplllation, whose characteristics are defined by the trial in- and exclusion 
criteria. In clinical practice, however, physicians will treat individllal patients, 
in whom the benefits, risks and cost! effectiveness of reperfusion therapy are 
not always clear at once, let alo ne differences in efficacy between specific 
reperfusion strategies. Since benefits of therapy rapidly fall off with time,l4l 
oppartunities for reflectian are limited at the moment of presentation of the 
patient. Therefore, it might be wise to determine in advance which patient 
will receive which therapy (if any), and to reflect decisions in treatment 
guidelines. In th is paper, we summarise the key aspects which should be 
considered in this respect. 
REPERFUSION THERAPY OPTIONS 
Over the last 15 years several reperfusion treatment strategies have been 
developed. Table 1 summarises the properties of the most relevant options. 
Streptokinase and aspirin 
The clinical effectiveness of intravenous streptokinase has been demonstrated 
by the GISSI-1 (N=11,802), ISAM (N=1,741) and ISIS-2 (N=17,187) 
investigations.[5.7] In these trials patients were randomised to either a 
streptokinase infusion of 1.5 MU units over 1 h or placebo treatment (open 
control in GISSI). Short term mortality among the streptokinase patients was 
20% reduced compared to those allocated control therapy (35-day mortality 
9.6% vs. 12.1%; P < 0.0001). This beneficial effect of streptokinase is 
maintained far at least 4 years.[8l The smaller rCIN trial (N = 533) of 
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Streptokinase Reteplase Altepiase Angioplasty 
Recommended 1.5 MU over 1 h 2 boluses of 10 15 mg bolus; Does not apply 
dose MU given30 0.75 mg/kg over 
min apart 30 min; 
0.5 mg/kg over 
next 60 min 
(total dose 5100 
mg) 
Aeeompanying Aspirin(i) Aspirin and Aspirin and Aspirin and 
medication intravenous intravenous intravenous 
Heparin(l) Heparin Heparin 
Prke(') $250 - $270 Not on the $1,260 - $2,220 $5,040 - $6,200 
market yet 
Pateney(') 57% 83% 81% 98% 
Intracranial 0.5% 0.7% 0.7% <0.1% 
bleeding 
Complexity Allergie reaction Relative high Relative high Complex proce-
Hypotension reocclusion rate reocclusion rate dure, need excel-
(oeed heparin, (need heparin, lent medical 
see above) see above) staff; only in 
hospitals with 
catheterisation 
laboratory 
Strength Effeetive Bolus High early Angioplasty not 
thrombolytic administration pateney rate only removes 
drug with low aecluding 
compJication thrombus, but 
rate and broad also treats 
applicability underlying 
coronary artery 
disease 
Tahle 1: Chal'acteristics of the most relevant reperfusion treatment strategies 
(1) Aspirin dose 160-325 mg/day for at least 1 month; (2) heparin dose 5000U bolus; 
1000-1200U/h far 3·5 days; (3) the lowest values represent European prices,'45) whereas 
the highest values correspond with US &rices[Hlj (4) represents the percentage of patients 
with TIMI-grade 2 or 3 flow at 90 min. 6.56,57J 
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intracoronary streptokinase reported a sustained effect even at 10 years follow-
Up.[9l The stroke rate was in balance between the two groups (0.79% vs. 
0.74%). There was a difference in the rate of intracranial bleeding 
complications, which event was documented in 22 out of 15,356 streptokinase 
patients, 17 of whom died, and in none of the 15,378 controls. It should be 
realised, however, that these numbers represent only part of the true incidence 
of intracranial haemorrhage, since most of the strokes we re not classified as 
either ischaemic or embolic. 
In ISIS-2 patients were further randomised to either oral aspirin (162.5 
mg daily for one month) or placebo. Mortality among patients randomised to 
both streptokinase and aspirin was 39% reduced compared with both placebo 
(8.0% vs. 13.2%; P < 0.0001), whereas the incidence of cerebral complications 
was almost halved (0.58% vs. 1.05%; P < 0.0001), thus demonstrating the 
clinical efficacy of combined thrombolytic and antiplatelet therapy to reopen 
the occluded coronary artery and keep it open. 
Acce/erated a/tep/ase and intl'avenOlls hepal'in 
A disadvantage of streptokinase is the production of antibodies, which limits 
it's efficacy and applicability on repeated use. Recombinant tissue-type 
plasminogen activator (rt-PA), on the other hand, is a non-antigenic agent, 
which directly activates the lytic process, and is potentially more powerful 
than streptokinase. The relative efficacy of rt-PA (100 mg infusion over 3 h) 
over streptokinase was studied in the GISSI-2 (N ~20,768) and ISIS-3 
(N ~41,299) trials, but no clinical benefit was observedpO-12l In contrast, in the 
GUSTO-1 trial (N ~41,021), the combination regimen of acce/el'ated rt-PA 
(100 mg infusion over 1.5 h) and intravenous heparin yielded a statistically 
significant (p~0.001) 14% relative reduction in 30-day mortality compared 
with 'standard' streptokinase (combined with either subcutaneous or 
intravenous heparin) from 7.3% to 6.3% on the absolute scale. The difference 
was still present at one year.[IJ.Hl The rate of intracranial complications was 
slightly, but significantly (p < 0.001) increased from 1.29% to 1.55%, which 
was mainly caused by a difference in cerebral bleeding complications. 
Retep/ase 
Recombinant plasminogen activator (reteplase, r-PA) is a mutant of rt-PA with 
a markedly increased half-life, which allows bolus administration. 
Angiographic evaluations of the r-PA regimen of 2 boluses of 10 MU given 30 
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min apart showed relatively high early coronary patency rates compared with 
rt_PA.[15,16l Two large mortality studies with r-PA have been reported. The 
INJECT trial (N =6,010) demonstrated that the reteplase regimen is at least 
equivalent to 'standard' streptokinaseP'l Mortality at one month was 9.0% 
and 9.5% in patients randomised to r-PA and streptokinase, respectively, 
whereas stroke rates were 1.23% and 1.00% (these differences were not 
significant, while it should be realised that INJECT was designed to show 
equivalence, and not superiority of reteplase). The GUSTO-3 study 
(N=15,060) compared r-PA with the GUSTO-l accelerated tt-PA regimenPSl 
This trial has a power of 70% (90%) to demonstrate a 15% (20%) relative 
reduction in 30-day mortality aftel' r-PA. However, no significant difference 
was observed: mortality was 7.2% after accelerated rt-PA and 7.4% after r-PA. 
Stroke rates were also comparable: 1.83% and 1.67%, respectively. These 
results suggest that the clinical effects of r-PA are in between 'standard' 
streptokinase and accelerated rt-PA. 
Othel' agents 
Other thrombolytic regimens based on agents from the class of plasminogen 
activators are currently being studied. Angiographic investigations with 
saruplase and lanoteplase indicated that the efficacy and safety profile of these 
drugs is comparable with alteplase.[19,20l More promising results have been 
reported from staphylokinase. In a small randomised trial (N = 100) 
staphylokinase appeared to be at least as effective for early recanalisation as 
accelerated rt-PA, while it was significantly more fibrin-specificP1l The 
improved fibrin specificity will avoid a systemic fibrinolytic state, and may 
very weil reduce the risk of haemorrhages. Largel' studies are necessary to 
determine the clinical properties of th is drug. 
Angiop/asty 
Another wa}' to repair the perilous coronary occlusion is an immediate 
mechanical intervention. Direct coronary angioplast}' has been compared with 
several thrombolytic regimens in a couple of randomised trials. Among the 
patients enrolled in all of these trials (N = 2,606) short term mortality af ter 
primary angioplasty was 33% reduced compared with thrombolysis (4.4% vs. 
6.5%; P =0.018).[2l The risk of stroke was also significantly reduced (0.70% vs. 
1.98%; p=0.007; intracranial haemorrhage: 0.07% vs. 1.14%; p=0.0005). So 
far, there are no reports on long term outcome. It should be realised, that the 
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major part of the observed reduction in cerebral bleeding complications is 
already accounted for in the Il).ortality results, since 50% to 70% of cerebral 
bleeds will lead to death. [22,23] This indicates, that direct angioplasty is 
especially an alternative for, and probably superior to thrombolysis in patients 
with high risk for cerebral bleeding complications. 
Several trials (N"'7,000) investigated the value of systematic additional 
angioplasty af ter thrombolytic therapy.l24] No benefit of this approach was 
observed if the combined endpoint of mortality and non-fatal reinfarction at 6 
weeks was considered, as compared with thrombolysis alone (12.1% vs. 11.6%; 
NS). Among the 6 weeks survivors, however, angioplasty seemed to be 
associated with a lower one-year mortality rate (2.1% vs. 2.6%, which implies 
a 19% relative reduction; NS). Longer follow-up is necessary to determine 
whether this survival difference will emerge. So far, however, it is not 
recommended to perform rol/tine angioplasty as an adjunct to thrombolytic 
therapy. On the other hand, results of the DANAMI trial (N = 1,008) indicate 
that angioplasty or coronary bypass surgery is warranted and beneficial in 
patients with recurrent ischaemia prior to discharge.l25] 
Only few randomised investigations evaluated the merits of ,-escue 
angioplasty after failed thrombolysis. The limited data indicate that such 
approach might have some benefit (mortality at 6 weeks was 5.4% among 93 
patients randomised to rescue angioplasty vs. 12.9% among 85 controls; 
p=0.078),l24] but more evidence is definitely needed. 
Antithrombotic agents 
Antithrombotic treatment as an adjunct to thrombolytic and antiplatelet 
(aspirin) therapy was evaluated in the GISSI-2 and ISIS-3 trialspO-12] Both trials 
together, 62,067 patients were randomised to either subcutaneous heparin or 
control therapy. Mortality at one month was slightly, but not significantly 
reduced in the heparin group (8.8%) compared with controls (9.2%), whereas 
stroke rates were slightly higher (1.22% and 1.15%, respectively). In the 
GUSTO-l study no significant difference was observed between subcutaneous 
and intravenous heparin in patients treated with streptokinase.l13] Thus, it can 
be concluded that neither subcutaneous nor intravenous heparin adds much to 
the outcome in streptokinase patients. The additional value of intravenous 
heparin added to accelerated rt-PA (one of the GUSTO-l treatment arms) 
cannot be quantified with data from existing randomised controlled clinical 
trials. There are, however, strong indications from angiographic studies that 
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intravenous heparin considerably contributes to sustained infarct-artery 
patencyP6] 
As opposed to heparin, hirudin direcdy acts on platelet bound thrombin 
and might therefore be expected to be more effective. However, two 
randomised trials in patients with evolving myocardial infarction (lIMI-9a, 
N ~757 and GUSTO-2a, N ~2,564y27,28] did not show a significant advantage 
of intravenous hirudin over intravenous heparin in combination with 
thrombolysis, while the high dose of hirudin used in these trials resulted in an 
unacceptable high rate of intracranial haemorrhage. The subsequently used 
low dose largely avoided these complications, but had litde (GUSTO-2b, 
N ~ 12,142) or no (lIMI-9b, N ~3,002) effect on survival.[29,30] Studies with 
other thrombin inhibitors, such as hirulog and argatroban, in combination 
with thrombolytic therapy are ongoing. 
Flltllre directions: glycoprotein IIb/lIIa receptor blockers 
Current investigations focus on the development of reperfusion strategies 
which may result in more rapid (new fibrinolytic agents), more complete 
(direct angioplasty) and more sllstained (intracoronary stents) coronary 
patency compared with existing optionsP1] The introduction of platelet 
glycoprotein nb/Illa receptor blockers may improve treatment of patients 
with evolving myocardial infarction in all three aspects. glycoprotein IIb/IIIa 
forms the final common pathway in platelet aggregation, which may lead to 
the formation of a 'white', platelet-rich thrombus. Use of glycoprotein IIb/IIIa 
receptor blockers williead to extensive or even full inhibition of this process, 
and may thus facilitate clot lysis and prevent early reocclusion. 
The first agent developed for clinical use, abciximab, has been shown to 
be beneficial in the prevention of thrombotic complications following 
coronary angioplasty in patients at high risk for acute vessel closure, including 
those with evolving myocardial infarctionP2,33] Results of the CAPTURE trial 
(N ~ 1,265) indicate, that abciximab can stabilise patients to such level that 
subsequent coronary intervention might be postponed or even cancelled.[33] 
The clinical efficacy of another glycoprotein IIb/IIIa receptor blocker, 
eptifibatide, has been evaluated in the recent large PURSUIT randomised trial 
(N ~ 10,948). In patients with unstable angina or suspected non-Q-wave 
myocardial infarction eptifibatide showed a significant 10% relative reduction 
in the combined endpoint death or non-fatal myocardial (re)infarction at 30 
days compared with placebo (14.2% vs. 15.7%; p~O.042; 17.8% vs. 19.8% in 
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the myocardial infarction patients)P41 Similar results have been shown for 
tirofiban and lamifiban in several studies reported recently.[35.371 A small dose-
ranging study in patients with acute myocardial infarction suggested that the 
incidence and speed of reperfusion can be enhanced when eptifibatide is 
combined with accelerated rt-PA, aspirin and heparin.[381 Large randomised 
trials assessing the clinical value of such treatment will be launched soon. 
TIME PROM ONSET OP SYMPTOMS TO TREA TMENT 
The beneficial effect of reperfusion therapy depends on time from symptom 
onset, although the nature of the treatment benefit/ delay relationship is 
subject to discussion.[1,4,391 Generally, it is agreed, that initiation of therapy 
within 6 h of symptom onset will directly save left ventricular muscIe cells, and 
consequently improve survival. Treatment within 6 to 12 h from continuous 
coronary occlusion will have indirect salutary effects on left ventricular 
function (reduction of left ventricular remodelling and dilatation)[401 and 
improved survival af ter such delays is therefore less pronounced. Considering 
the results of experimental studies, combined with randomised comparisons 
between pre- and in-hospital thrombolysis on about 6,600 patients, and larger 
randomised clinical trials, we are convinced of the importance of reperfusion 
treatment within 1 to 2 h from onset of symptoms, the time window in which 
cell death just commences. In the first hour a 50% mortality reduction is 
conceivable,l41 whereas this figure is approximately 30%, 25% and 12.5% in the 
respective :2:1-3, ~3-6 and ~6-12 h intervaIs. In an earlier study,[411 a 50% 
reduction was assumed for treatment in the first 3 h period, which was based 
on an analysis of 3,362 patients,[421 but this seems overoptimistic in view of 
current evidence from clinical trials. 
COMPLICATIONS 
While early thrombolytic therapy considerably reduces mortality in patients 
with evolving myocardial infarction, some complications may occur. The 
most feared complication is intracranial haemorrhage, which happened in 
between 0.3% and 1.0% of patients who participated in randomised trials, and 
led to death in more than half of those cases, while only about 10% recovered 
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without significant disability.[22.23J It should be appreciated, that these deaths 
were reckoned in the overall mortality figures, which were clearly in favour of 
thrombolytic therapy compared with conservative treatment. Furthermore, 
the rate of embolic strokes was reduced due to thrombolytic therapy, so that 
the overall rate of cerebrovascular complications as a whole was only 
marginally increased. Among each 1,000 patients with ST elevation or new 
Bundie Branch Block treated within 6 h of symptom onset, thrombolytic 
therapy will prevent approximately 30 deaths compared with control therapy, 
due to early reperfusion of the occluded coronary artery, and cause about 2 
deaths as weIl as lasting disability in another 2 patients, due to cerebral 
complicationsP9] Thus, the benefits of thrombolytic therapy far exceed the 
risks in these patients. 
Rates of haemorrhage other than intracranial as reported in randomised 
trials of thrombolysis are difficult to interpret, because of varying definitions, 
different intensities of data collection and differences in use of invasive 
revascularisation procedures. Overall in the placebo-controlled trials, there is a 
two to three fold increased incidence of severe haemorrhage after 
thrombolytic therapy (0.4% among controls vs. 1.1% among patients 
randomised to active treatment)PJ 
Immunologic reactions may occur if streptokinase is applied, which drug 
is derived from group C streptococci. Determination of the true incidence of 
these reactions is difficult, since symptoms of allergy, such as fever, 
hypotension and shortness of breath are of ten indistinguishable from 
symptoms that may be caused by the myocardial infarction itself. 
Nevertheless, in several trials, mild allergic reactions were reported in 
approximately 4% of patients treated with streptokinase. True anaphylactic 
shock is very rare, perhaps occurring in 0.1%. Hypotension may occur in 
about 6%?3] 
Reperfusion therapy mayalso induce ventricle fibrillation, especially if 
treatment is initiated in an early stage of the infarction.[43J This complication 
should therefore be watched, particularly in pre-hospital thrombolysis 
programs. Thrombolytic treatment is only warranted if first aid (defibrillator) 
is immediately available. 
..... 
0 
'" 
Feature Fibrinolytic Therapy Tria!ists' Collaborative Group GUSTO-l randomised tria! 
No. patients Deaths during fust 35 days No. patients Deaths during first 30 days 
Fibrin Contr Fibrin Contr Benefit Ace SK Ace t-PA SK Benefit 
per 1,000 t-PA per 1,000 
(SD) (SD) 
Location 
inferÎor 6,556 6484 493 ( 7.5%) 542 ( 8.4%) 8 ( 5) 5931 11575 277 ( 4.7%) 592 ( 5.1%) 4 ( 3) 
anterior 6,587 6642 868 (13.2%) 1120 (16.9%) 37 ( 6) 4019 7829 352 ( 8.8%) 822 (10.5%) 17 ( 6) 
Hours from onset 
0-1 1,678 1,670 159 ( 9.5%) 217 (13.0%) 35 (11) 239 505 18 ( 7.5%) 24 ( 4.8%) -28 (20) 
:2:1-3 8,297 8,315 683 ( 8.2%) 889 (10.7%) 25 ( 5) 5,204 10,369 238 ( 4.6%) 619 ( 6.0%) 14 ( 4) 
8-6 8,294 8,195 802 ( 9.7%) 945 (11.5%) 19 ( 5) 4,255 7,912 318 ( 7.5%) 637 ( 8.1%) 6 ( 5) 
0-6 18,269 18,180 1,644 ( 9.0%) 2,051 (11.3%) 23 ( 3) 9,698 18,786 574 ( 5.9%) 1,288 ( 6.9%) 9 ( 3) 
:2:6-12 6,478 6,404 719 (11.1%) 813 (12.7%) 16 ( 6) 330 715 30 ( 9.1%) 66 ( 9.2%) 1 (19) 
Age (years) 
<55 8,082 8,158 278 ( 3.4%) 373 ( 4.6%) 11 ( 3) 3,232 6,389 58 ( 1.8%) 126 ( 2.0%) 2 ( 3) 
55-64 9,911 9,678 709 ( 7.2%) 864 ( 8.9%) 18 ( 4) 2,989 5,792 108 ( 3.6%) 275 ( 4.8%) 11 ( 4) 
65-74 8,487 8,496 1,144 (13.5%) 1,372 (16.1%) 27 ( 5) 2,789 5,553 230 ( 8.3%) 575 (10.4%) 21( 7) 
~5 2,835 2,953 689 (24.3%) 748 (25.3%) 10 (13) 1,326 2,394 254 (19.2%) 490 (20.5%) 13 (14) 
Gender 
male 22,353 22,412 1,835 ( 8.2%) 2,258 (10.1%) 19 ( 3) 7,721 15,049 383 ( 5.0%) 884 ( 5.9%) 9 ( 3) (") 
female 6,962 6,873 985 (14.1%) 1,099 (16.0%) 18 ( 6) 2,622 5,090 270 (10.3%) 587 (11.5%) 12 ( 7) :r: ;.. 
" >ol 
'" ::0 
'" 
SBP 
(mmHg) 
<100 1,263 1,182 365 (28.9%) 415 (35.1%) 62 (18) 959 1,973 162 (16.9%) 362 (18.4%) 15 (15) 
100-149 17,979 18,063 1,731 ( 9.6%) 2,081 (11.5%) 19 ( 3) 7,301 14,112 394 ( 5.4%) 895 ( 6.3%) 9 ( 3) 
150-174 7,907 8,005 569 ( 7.2%) 694 ( 8.7%) 15 ( 4) 1,777 3,454 84 ( 4.7%) 167 ( 4.8%) 1 ( 6) 
2:175 2,166 2,035 155 ( 7.2%) 167 ( 8.2%) 11 ( 8) 304 603 13 ( 4.3%) 47 ( 7.8%) 35 (16) 
HR(bpm) 
<80 12,922 12,965 926 ( 7.2%) 1,097 ( 8.5%) 13 ( 3) 6,488 12,593 314 ( 4.8%) 723 ( 5.7%) 9 ( 3) 
80-99 6,268 6,221 579 ( 9.2%) 706 (11.3%) 21 ( 5) 2,913 5,684 197 ( 6.8%) 454 ( 8.0%) 12 ( 6) 
dOO 3,095 3,126 537 (17.4%) 646 (20.7%) 33 (10) 942 1,864 142 (15.1%) 294 (15.8%) 7 (14) 
Prior MI 
no 22,468 22,635 ,993 ( 8.9%) 2,467 (10.9%) 20 ( 3) 8,596 16,798 463 ( 5.4%) 1,050 ( 6.3%) 9 ( 3) 
yes 5,719 5,577 717 (13.6%) 784 (14.1%) 15 ( 6) 1,726 3,294 180 (10.4%) 399 (12.1%) 17 ( 9) 
Diabetes 
no 19,423 19,424 1,697 ( 8.7%) 1,981 (10.2%) 15 ( 3) 8,828 17,075 504 (5.7%) 1,100 ( 6.4%) 7 ( 3) 
yes 2,236 2,260 1,981 (10.2%) 391 (17.3%) 37 (11) 1,498 3,024 140 ( 9.4%) 343 (11.3%) 20 ( 9) 
All patients 29,315 29,285 2,820 ( 9.6%) 3,357 (11.5%) 18 ( 3) 10,348 20,162 653 ( 6.3%) 1,475 ( 7.3%) 10 ( 3) 
Table 2: Short-term mortality observations from randomised clinical trials of thrombolytic therapy versus placebo/control 
and of more effective therapy (accelerated rt-PA) versus 'standard' therapy (streptokinase) 
Fibrin = tibrinolytic ther.py; Contr = control or placebo; Ace t-PA = accelerated t-P A; SK = streptokinase; SBP = systolie blood 
pressure; HR = heart rate; :MI = myocardial infarction 
Observations are derived from the Fibrinolytic Therapy Trialists' Coll.bor.tive analysis[lJ and an analysis of tbe GUSTO_l[13J data. 
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FTT Collaborative Group 
Fibrinolytic better Control better 
inferÎor Infarct location anterior -e--t -
0-1 • 
Hours from onset d-3 • 
i 
2>3-6 • 2>6-12 la 
i 
<55 • 
i 
i 
Age (years) 55·64 .: 
65-74 
-2>75 
i 
i 
i 
Gender male ... female '. i i 
<100 
---
Systolie BP (mmHg) 100-149 150-174 , 
d75 
i 
<80 .. 
Heart rate (bpm) 80-99 .. i dOO 
-
Previous N11 na 
--t. yes 
i 
Diabetes na .-yes • i 
i 
ALL PA TIENTS • i i I 
0.5 1.0 1.1 
Fignre 1: Relative effects of thrombolytic therapy compared with con trol, and of 
more effective therapy (aceelerated rt-PA) eompared with 'standard' tI.erapy 
(streptokinase) on short-term mortality in several sllbgrollps of patients 
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Data represent odds ratio's and corresponding 95% confidence intervals. The areas of the 
black squares are proportional to the arnount of 'statistical information' contributed hy 
the trialsPJ Observations are derived from the Pibrinolytic Therapy Trialists' 
CoIlaborative analysispJ which included patients randomised up to 24 h after onset of 
symptoms, and an analysis of the GUSTO-l data/DJ in which most patients were 
randomised withill 6 h. 
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COSTS 
Besides differences in clinical efficacy between the reperfusion strategies 
discussed above, there are major differences in costs. Streptokinase therapy 
initially requires about $250, whereas rt-PA treatment costs approximately 
$2000 (USA prices, see table 1).l44,45] A cost-effectiveness analysis of the 
GUSTO-1 data showed, that these initial differences will not be recovered by 
savings during follow-up (the incremental cost-effectiveness ratio was about 
$27,400 per year of life saved by rt-PA compared with streptokinase).l44] 
Immediate angioplasty is even more expensive, with initial costs around $6000. 
Investigations of data from randomised trials indicated that these costs are 
recovered in part by a decrease in subsequent revascularisation procedures 
compared with thrombolysis.l45,46] Observational data, however, contradict 
these findings.l47] 
The considerable higher costs of rt-PA and angioplasty compared with 
streptokinase will limit their availability, especially in an era of shrinking 
health care budgets, while angioplasty is by nature limited to hospitals with a 
catheterisation laboratory and excellent trained and experienced medical staff. 
Therefore, these options should be applied, when available, in patients who 
are expected to benefit most from therapy. 
TREA TMENT EFFECTS IN SUBGROUPS OF PA TIENTS 
Table 2 and figure 1 present the effects of thrombolytic therapy on 35-day 
mortality compared with control as observed in an analysis of all trials that 
randomised at least 1,000 patients (altogether 58,600 patients).ll] No apparent 
deviations from the average l'elative mortality reduction are observed, except 
for subgroups according to time from symptom onset (as discussed above) and, 
to alesser extent, age.l1 ,39] Consequently, the absoillte number of deaths 
avoided by thrombolytic treatment appears to be greater in those groups with 
a higher mortality. The relative and absolute reductions were maintained 
during follow-up, but there was no further divergence observed. As far as age 
is concerned, there was a significant trend towards largel' relative mortality 
reductions among younger patients. However, absoillte reductions were 
comparable, since mortality greatly increases with age. 
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Table 2 and figure 1 also demonstrate detailed data on 30·day mortality of 
30,510 GUSTO·l patients randomised to either streptokinase (with either 
subcutaneous or intravenous heparin) or accelerated rt·PA.[13] Again, there is 
no significant heterogeneity between the relative mortality reductions in the 
different subgroups of patients studied. Thus, also the additional effect of more 
intensive and effective therapy (rt·PA) up on 'standard' therapy (streptokinase) 
is most pronounced in the patient groups at high mortality risk.l48] The 
GUSTO·2b angioplasty substudy (1,138 patients) presented some subgroup 
analyses, which indicated, that this argumentation also holds for angioplasty 
vs. accelerated rt·PA, although it should be appreciated that the latter data is 
fairly limited.[49] 
BENEPITS ANO RISKS IN INOIVIDUAL PATIENTS 
Prom the above it is apparent, that reperfusion therapy generally reduces 
mortality after myocardial infarction. The absolute effect of therapy compared 
with control treatment, as weil as the additional effect of more effective 
therapy upon 'standard' therapy is most prominent in subgroups of patients 
with high mortality rates. Nevertheless, it should be realised that reperfusion 
therapy (especially thrombolytic therapy) may lead to life·threatening cerebral 
bleeding complications, which would not have occurred without treatment. 
Accordingly, to evaluate treatment efficacy in an individllal patient, the risk 
reduction of cardiac death (i.e. death not due to haemorrhagic stroke) should 
be weighed against the introduced risk for adverse cerebral bleeding 
complications. 
Determinants of mortality not dlle la hdemorrhagic stroke 
Analysis of the GUSTO·l data showed that patient's 30·day mortality risk 
after thrombolysis is largely determined by the independent presenting 
features: age (most important), systolic blood pressure, Killip class, heart rate, 
infarct location and history of myocardial infarction.[50] A young, 
haemodyamically stabIe patient with a small inferior infarction is at low risk, 
while an elderly patient presenting with signs of heart failure and an extensive 
anterior infarction is at high risk of early death.[9,51] 
In the GUSTO·l trial 268 patients suffered from a primary intracranial 
bleeding complication, and 160 (60%) of them subsequently died within the 
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5 4.83 5 4.57 
4 4 
3 3 
2 2 
1 1 
0.26 
0 0 
<50 50-59 60-69 70-79 <:80 <80 80-99 100-119 <:120 
Age (years) Systolic BP (mmHg) 
6 5.76 
5 
4 3.94 
3 3 2.62 
2 1.63 
1,--:-=-= <:80 -
(years) 
I II -III-IV- <80 80-99 100-119 <:120 
Killip class Heart rate (bpm) 
2 2 1.52 2 
1.27 1.14 
1 
0 0 0 
Înferior anterior no yes <4 <:4 
Infarct location PreviousMI Leads with STt 
Figure 2: Graphical representation of the independent contriblltion of several 
presenting features to determine cardiac mortality af ter reperfusion therapy in 
patients with evolving myocardial infarction 
Mortality (in odds farm, see appendix) of an average patient is indexed at value 1. Ta 
calculate the mortality index of a particular patientJ characterised by given presenting 
features, deviations from this average should be multiplied. 
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Figure 3: Graphical representation of the independent contribution of several 
presenting features to determine the risk of haemorrhagic stroke af ter thrombolytic 
therapy in patients with evolving myocardial infarction 
The haemorrhagic stroke rate (in odds form, see appendix) of au average patient is 
indexed at value 1. To calculate the haemorrhagic stroke index of a particular patiellt, 
characterised hy given presenting features, deviations from this average should be 
multiplied. 
30·day follow-up periodP'J To estimate the magnitude of the above mentioned 
risk factors in predicting cal'diac death, we performed a subsequent 
multivariate logistic regression analysis on the GUSTO-1 data, excluding 
patients with fatal cerebral haemorrhage. Results of this analysis are 
summarised in figure 2 (see also the appendix). 
The developed regression model may, strictly speaking, only be applied 
to estim.te patient's individual 30-day probability of cardiac death in a 
'GUSTO-1 alike' population. However, since the model appeared to be 
practically independent from the population mortality (appendix), it mayalso 
be used in populations with different (higher) mortality rates. Furthermore, 
although all GUSTO-1 patients received thrombolytic therapy, the model ean 
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be employed to estimate the risk for dying without reperfusion therapy, since 
the relative effect of such therapy is almost equal for each patient (see above), 
and, consequently, the ratio between the individual- and the population risk 
will not be influenced by therapy. Finally, the model may be applied to assess 
individual one-year mortality rather than 30-day mortality, because almost all 
of the infarct-related mortality occurs in the first month, whereas the hazard 
of mortality remains stabie after this period.[14,52l 
DetermÎnants of intracranÎal haemorrhage 
In general cerebral events are hard to predict, although there are some weil 
recognised predictive factors for intracranial haemorrhage after thrombolytic 
therapy, including advanced age, low body weight, elevated blood pressure at 
time of presentation and use of rt-PA instead of streptokinase.[53l To quantify 
the individual contribution of these risk factors in prediction of the adverse 
bleeding complication, we again performed a multivariate logistic regression 
analysis in the GUSTO-1 dataset. Results are presented in figure 3 (see also the 
appendix). The developed regression model estimates patient's individual risk 
for intracranial haemorrhage af ter initiation of thrombolytic therapy. Since 
cerebral bleeding complications are very rare «0.1%) among myocardial 
infarction patients who do not receive thrombolysispl the model mayalso be 
used to estimate the excess bleeding risk caused by therapy. 
Life expectancy 
Due to increased mortality risk, life expectancy (appendix) of a myoeardial 
infaretion patient is decreased compared with an 'average' person of the same 
community at the same age. With the help of reperfusion therapy part of this 
potential loss can be regained. The impact of changes in early survival on 
patient's life expectancy is age dependent.l41l For example, a one-year mortality 
reduction from 12% to 10% in a 45 year old patient will save approximately 4 
months, while a similar early mortality reduction yields less than 2 months in 
a 75 year old (these savings reflect so-called 'discounted' values, see appendix). 
Therefore, we prefer to eoncentrate on the effects of treatments on life 
expeetancy rather than on one-year mortality, sinee the long-term perspeetive 
may be most appropriate for medical decision makingp4l 
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Integration of benefits and risks in individllal patients 
Table 3 may help to integrate benefits and risks in potential candidates for 
reperfusion therapy. The average (population) probability of dying within one 
year af ter a conventional treated myocardial infarction (i.e. without 
reperfusion therapy) is assumed to be 12.5%. Dependent on the described 
presenting features (figure 2) patient's individu al mortality risk without 
therapy may vary from less than 2% to even more than 50% (upper panel in 
table 3). Consequently, remaining life expectancies range from almost 14 years 
in young patients at low risk to about 4 years in the elderly at high risk. Due 
to reperfusion therapy cardiac mortality at one year wi!! deet·ease. The 
magnitude of this reduction depends on the time expired from onset of 
symptoms (see paragraph about time to treatment). Consequently, remaining 
life expeetaney wi!! inerease. Most benefits of reperfusion therapy are to be 
expeeted in young, high-risk patients treated within 1 haf ter symptom onset 
(ave rage gain up to 39 months). 
The risk for cerebral bleeding eomplications can be estimated using the 
lower panel of table 3. We presumed a 0.75% population probability for 
intracranial haemorrhage after thrombolytie therapy. In individu al patients 
this may range from a negligible < 0.2% to even 3.5%. The probability of 
intracranial haemorrhage should be weighed against the expeeted reduetion in 
cardiac death. If both are (almost) equal, one should refrain from reperfusion 
therapy, although in some case immediate angioplasty sti!! might be an option. 
Advantage of the described model 
Over the years several models have been developed to identify which patients 
benefit most from reperfusion therapy,l9,14,41,48,511 and some of these are 
incorporated in treatment protocols which are applied in clinical practice,[9,411 
Therefore, the question is justified as to what is the advantage of the current 
model. Does it lead to 'better' estimations of treatment effects in individual 
patients than existing ones? 
The problem with answering this question is, that there is no uniform 
starting'point in the different models and also no clear definition of 'better', 
The effects of reperfusion therapy are quantified in terms of one-month 
mortality,l481 one-year mortality,[91 as wel! as life expeetaney,[411 Is the latter 
approach 'better' than the first one? We do take th is view (see paragraph about 
life expeetaney), but agree that a focus on the more short term effects is also 
Mortality No reperfusion ther.py Benefit from reperfusion ther.py: months .dded (absolute ..... ..... cr-
index mortality reduction in %) 
Oneyear Life expec- 0-1 h 1-3 h 3-6 h 6-12 h 
mortality (%) tancy (years) 
Age < 50 years 
0.125 2 13.6 3 ( 0.9) 2 ( 0.5) 1 ( 004) o ( 0.3) 
0.25 3 1304 4 ( 2.5) 2 ( 1.5) 2 ( 1.3) < 1 ( 0.8) 
0.5 7 13.1 7 ( 4.1) 4 ( 2.5) 3 ( 2.0) 1 ( 1.2) 
0.75 10 12.7 10 ( 5.6) 6 ( 3.3) 5 ( 2.8) 2 ( 1.7) 
1.0 12.5 10.8 15 ( 7.6) 8 ( 4.5) 7 ( 3.8) 3 ( 2.3) 
1.5 18 10.1 20 (11.1) 11 ( 6.7) 10 ( 5.6) 5 ( 3.3) 
2.5 26 7.7 30 (1704) 17 (10.5) 15 ( 8.7) 7 ( 5.2) 
5.0 42 6.7 39 (23.6) 22 (14.2) 19 (11.8) 9 ( 7.1) 
Age 50-59 years 
0.125 2 11.6 2 ( 0.9) 1 ( 0.5) <1 ( 004) o ( 0.3) 
0.25 3 11.5 3 ( 2.5) 1 ( 1.5) 1 ( 1.3) o ( 0.8) 
0.5 7 11.2 5 ( 4.1) 3 ( 2.5) 2 ( 2.0) <1 ( 1.2) 
0.75 10 10.9 7 ( 5.6) 4 ( 3.3) 3 ( 2.8) 1 ( 1.7) 
1.0 12.5 904 10 ( 7.6) 6 ( 4.5) 5 ( 3.8) 2 ( 2.3) 
1.5 18 8.8 14 (11.1) 8 ( 6.7) 7 ( 5.6) 3 ( 3.3) 
2.5 26 6.8 21 (1704) 13 (10.5) 11 ( 8.7) 5 ( 5.2) 
5.0 42 5.9 27 (23.6) 16 (14.2) 13 (11.8) 6 ( 7.1) 
Age 60-69 years Cl 
0.5 7 8.8 2 ( 4.1) 1 ( 2.5) < 1 ( 2.0) o ( 1.2) :I: >-
"' 0.75 10 8.6 3 ( 5.6) 1 ( 3.3) 1 ( 2.8) o ( 1.7) >-l 
'" 1.0 12.5 7.6 6 ( 7.6) 4 ( 4.5) 3 ( 3.8) 1 ( 2.3) ::0 
cr-
1.5 18 7.1 8 (11.1) 5 ( 6.7) 4 ( 5.6) 1 ( 3.3) 
2.5 26 5.6 12 (17.4) 7 (10.5) 6 ( 8.7) 3 ( 5.2) 
5.0 42 4.9 16 (23.6) 10 (14.2) 8 (11.8) 3 ( 7.1) 
Age 70·79 years 
1.0 12.5 5.5 2 ( 7.6) 1 ( 4.5) < 1 ( 3.8) o ( 2.3) 
1.5 18 5.1 3 (11.1) 1 ( 6.7) 1 ( 5.6) o ( 3.3) 
2.5 26 4.2 5 (17.4) 3 (10.5) 2 ( 8.7) < 1 ( 5.2) 
5.0 42 3.6 7 (23.6) 4 (14.2) 3 (11.8) 1 ( 7.1) 
IeR index 0.125 0.25 0.5 1.0 1.5 2.5 5.0 
IeR complications 
Probability (%) 0.1 0.2 0.4 0.8 1.1 1.9 3.6 
Death (%) ±0.1 ±0.1 0.2·0.3 0.4-0.6 0.6-0.8 1.0·1.3 1.8·2.5 
Table 3: Estimated benefits and risks of reperfusion tberapy in individual patients witb evolving myocardial infarction 
The upper panel shows one year mortality rates and life e.xpectancies in several categories of panents in case reperfusion therapy is 
not installed. Also the expected, time-dependent benefits from such therapy are presented. The average one year mortality 
without reperfusion therapy is estimated at 12.5%. Patient's individual mortality index can be determined with help of figure 2; 
the individual mortality probability follows by multiplication of this index with the average mortality (in odds form, see 
appendix). 
The lower panel presents the risk for intracranial haemorrhage after reperfusion therapy. The average probability is estimated at 
0.75%. Patient's intracraniaI haemorrhage index can be determined with help of figure 3; the individual probability follows by 
multiplication of this index with the average probability (in odds form). 
IeR - intracranial haemorrhage 
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valid, and may very weil match with physician's first aim: discharge a patient 
in a good clinical condition. 
On the other hand, models which apply more detailed information (e.g. 
age and blood pressure as continuous valuesjl'sl may better distinguish low risk 
from high risk patients than models using more rough data (e.g. age 
categorised as < 65 or ~65 years, and blood pressure as 'hypertension' or 'no 
hypertension,).[4Il Further, since multivariate analyses were performed on a 
very large data set (GUSTO-l), parameter estimates are more precise than 
those used in an earlier version of the life-expectancy model, which was based 
on a much smaller data set.[42l Another advantage is, that the quantified 
positive and negative aspects of reperfusion therapy are presented separately 
(tabIe 3), which may lead to a more accurate weighing in individual patients. 
The modeIs presented contain well-known and readily-available patient 
characteristics and are expected to be valid for new patients. The effects of 
reperfusion therapy on mortality and intracranial haemorrhage were 
considered separately from the influence of these patient characteristics, which 
makes our approach transparent and suitable for clinical use. 
WHICH TREATMENT POR WHICH PATIENT? 
To satisfy the requirements of cost-effective clinical practice, costly therapy 
should be reserved for patients with substantial expected benefit, while relative 
cheap, but slightly less effective therapy might be allocated to those with 
lower expected profits. Now that an instrument has been developed to 
estimate the effect of reperfusion therapy, the question still remains as to what 
is 'low' and what is 'high' benefit? Which thresholds should be used to 
equitably allocate scarce reperfusion resources? 
Patient·driven decision making 
Some physicians opt for an allocation policy which can be called 'patient-
driven'. In such situation, patients in whom expected benefits from 
reperfusion therapy do not exceed the threshold of certain X I months to be 
gained will receive streptokinase, being an effective and relative cheap 
treatment option (obviously, in those with a negligible gain no reperfusion 
therapy will be initiated). Patients with an expected benefit in the range XI to 
Y j months might be treated with rt-PA, which is slightly more effective, but 
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also more expensive than streptokinase (also r-PA might be considered in such 
patients). If the expected gain goes beyond Y 1 months immediate angioplasty 
might be performed. Angioplasty might also be considered in patients with 
more modest gain in life expectancy, but increased risk for intracranial 
haemorrhage. The essence of this policy is that the fixed thresholds Xl and Y 1 
are determined in advance by the team of treating cardiologists on the basis of 
their insight in what is cost·effective t,·eatment of their individllal myocardial 
infarction patient. 
Blldget·driven decision making 
The advantage of the patient-driven policy is that decision thresholds are 
determined by the professional group on account of their knowIedge. 
However, a major problem arises when reperfusion resources are limited to 
such extent that at some point in time the preferred option is not available. 
This situation may very weil happen in case of closed (e.g. yeady) budgets, and 
is very undesirable, since it is at varianee with the ethical rule of 'equivalent 
treatment in equivalent cases,.[55] Therefore, others defend a 'budget-driven' 
allocation-policy. Point of departure is the available amount of separate 
reperfusion treatment options (slIpply), and the expected number of patients 
that will consurne these resources (the population, e.g. all myocardial 
infarction patients that will be admitted on the coronary care unit in a certain 
year; demand). Availability of reperfusion resources is detennined in 
consultation with health care policy makers, representatives of insurance 
companies, hospital boards and treating cardiologists. Characteristics of the 
population can be obtained from analyses of data from the recent past. These 
former patients can be ordered according to what their gain in life expectancy 
from reperfusion therapy would have been. Based on this order, it is possible 
to reliably agree upon treatment allocation in future patients. Patients 
belonging to the lower X,%, middle X,% to Y/l'o or upper 100%-Y2% of 
estimated gain will be allocated streptokinase, rt-PA or angioplasty, 
respectively, in which X2 and Y2 are dependent on the ratio of demand and 
supply (e.g. in the Thoraxcentre Rotterdam X2-SO and Y2-90). Thus, the 
budget-driven poliey eoneentrates on cost·effective treatment of a certain 
poplIlation of myocardittl infa1"Ction patients rather than individual patients. 
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CONCLUDING REMARKS 
In the first part of th is paper the most important results are summarised as 
observed in randomised trials of reperfusion therapy in patients with evolving 
myocardial infarction for different treatment strategies. Benefits and 
complications are described, and the direction for future investigations is 
indicated. In the second part it has been discussed in which way this 
information can be applied for decision making in individual patients. A set of 
tables is presented which might be applied on a coronary care unit. It should 
be realised, however, that the intention of this article is to arrange thoughts 
rather than to dictate the 'final' solution to the question of equitable allocation 
of scarce reperfusion resources. \Y/ e definitely appreciate the importance of an 
attentive treating cardiologist, who cannot be replaced by a 'paper clinician'. 
Conversely, we are also convinced of the usefulness of guidelines or protocols 
in clinical practice, especially if rapid decision making is of vital importance. 
These views, however, are not mutually exclusive. Individual patients as weIl 
as the community wiII profit from skilful physicians who use treatment 
guidelines in asensibIe way. 
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ApPENDIX 
Logistic regression model for prediction of 30-day cardiac mortality 
Probability of cardiac death within 30 days = (1 + exp(a) ITi exp(-/3ûr\ where 
a = 5.406; 
/31 = 0, 0.569, 1.290, 2.138 or 2.919 if age < 50, 50-59, 60-69, 70-79 or ;:,80 
years; 
/3, = 0,0.447,1.162 or 1.825 if systolic blood pressure ;:,120,100-119,80-99 or 
<80mmHg; 
/3l = 0,0.635 or 1.898 if Killip class is I, TI or mIIV; /33 = 1.519 or 1.094 if 
Killip class is m/IV and age 70-79 or ;:,80 years (age is an effect modifier for the 
relation between Killip class and mortality); 
/3, = 0,0.484,0.987 or 1.239 if heart rate <80,80-99,100-119 or ;:,120 bpm; 
/35 = 0 if infarct location is non-anterior or 0.436 if location is anterior; 
/36 = 0 if there is no history of infarction or 0.518 in case of previous 
infarction; 
/37 = 0 if total ST elevation < 0.4 m V or 0.295 if ST elevation ;:,0.4 mV. 
This model is developed in 38,814 GUSTO-l patients with complete data on 
mortality, intracranial haemorrhage, age, blood pressure, Killip class, heart 
rate, infarct location, infarct history, electrocardiographic infarct size and 
weight. 
Probability and odds 
Given a probability (risk) of X%, the odds is defined as X% I (100% - X%). 
Two patients with equal risk profile for early cal'diac death, except for one 
predictive varia bIe (e.g. age) wil! have different odds. The ratio of these odds is 
cal!ed odds ratio, and can be interpreted as a relative risk. The components 
exp(/3i) in the cardiac mortality model represent independent odds ratio's 
corresponding with the different predictive features. For each feature, the 
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index-group is determined by ~i = O. For example, a patient in the age 
category 50-59 years has an odds ratio of exp(0.569) = 1.8, which implies an 
almost two fold risk of cardiac death compared to an, otherwise comparable, 
patient of less than 50 years (the index-group). A patient aged 80 years has a 
exp(2.919) = 18.5 times higher risk. 
Mortality index 
Cardiac death within 30 days occurred in 2,493 of the 38,814 patients, which 
implies a population risk (probability) of 6.4% and an odds of 0.069. In other 
words: each patient of the population has a prior odds of 0.069. With help of 
the mortality model, the risk (and thus the odds) of an individual patient can 
be determined. The ratio of th is so-called postel'iOl' (individual) odds and the 
prior (population) odds is the likelihood ratio (we avoid mentioning this term 
in the text and do call it mortality index). Thus, the index-value with regard to 
the likelihood ratio is related to an avel'age patient from the population, 
whereas the index-value in the mortality model is related to the patient with 
the best perspectives Qowest mortality probability). 
The likelihood ratio an also be considered as a multiplicative composition 
of factors corresponding with the different independent predictive features. 
These factors are presented in figure 2, and can be determined as follows. 
Consider each presenting feature Fi (i = 1, .. , 7) separately. Fi has k (k= 1, .. ,K;) 
mutually exclusive categories. There are Nk patients in category k, who each 
have a probability of cardiac death Pk estimated by (1 + exp(a;) exp(-~ilJ)"l, 
with ~ik as described above, and ai such that ~\ Nk Pk = 2,493 (the total 
number of cardiac deaths in the population) . The ratio between Pk and the 
population probability (in odds form) gives the factor at issue. 
We assume that the relative risks corresponding with the described 
features (exp (~;)) are independent from the population risk. In that case, 
mortality indices appeared to be insensible for moderate changes in the 
population risk, and may thus be applied in populations with higher 
underlying mortality. In figure 2 a 12.5% mortality probability is assumed. 
Logistic I'egl'ession model fol' prediction of the risk of intl'acl'anial hdemorrbdge 
Probability of intracranial haemorrhage = (1 + exp(a) I1i exp(_~;))"l, where 
a = 6.919; 
~1 = 0, 0.857, 1.567, 2.111 or 2.224 if age < 50, 50-59, 60-69, 70-79 Ol' ~80 
years; 
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13, ~ 0 in case of normal tension (systolic blood pressure < 165 and diastolic 
blood pressure <95 mmHg) or 0.881 in case of hypertension (systolic blood 
pressure d65 or diastolic blood pressure ~95 mmBg); 
133 ~ 0 or 0.660 if weight ÛO or < 70 kg. 
This model is developed in 38,814 GUSTO-1 patients with complete data on 
mortality, intracranial haemorrhage (N ~251), age, blood pressure, Killip class, 
heart rate, infarct location, infarct history, electrocardiographic infarct size 
and weight. 
Haemorrhagic bleeding indices can be calculated with help of figure 3 (see 
paragraph about mortality index for the theoretical background). The 
underlying population risk is estimated at 0.75%. 
Life expectancy and discollnting principle 
Life expectancy of an average reference person in the normal population is 
based on age and sex specific mortality data from The Netherlands in 1990. 
Compared with this average person, life expectancy after myocardial infarction 
is decreased due to (a) a higher mortality risk at one year, which can be 
calculated with help of the model in figure 2, and (b) a higher subsequent 
mOltality risk; we assumed a yearly mortality excess of 1.0%, 2.0% and 3.0% for 
patients with a one-year mortality risk of < 10%, 10% - 30% and ~30%, 
respectively. 
In cost-effectiveness analyses it is customary to discount future life years, 
thus accounting for the greater value given to treatment effects in the near 
future compared with the more distant future. Discounting also compensates for 
the moderate accuracy of predicted long term survival. The presented life 
expectancies in this manuscript are discounted by 5% per year. 
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Chapter 7 
BENEFITS AND RISKS OF POSSffiLE PRE-HOSPITAL 
THROMBOLYSIS STRATEGIES 
Boersma E, Maas ACP, Grijseels E\'\fM, Deckers JW, 
Hartman JAM, Simoons ML 
The benefits of thrombolytic therapy exceed the risks, even in patients with 
somewhat IIncertain diagnosis of myocardial infarction. 
Implications for pre·hospital programs 
Submitted 
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SUMMARY 
Background 
Effeetiveness and safety of pre-hospital thrombolysis in myocardial infarction 
patients depends on possibilities for rapid and correct diagnosis. The Rotterdam pre-
hospital treatment program utilises an automated electrocardiogram for 
confirmation of infarction. Ta prevent inaccurate diagnosis and inappropriate 
treatment, cunent electrocardiographic criteria are very strict. \Yfe investigated 
whether these criteria could safely be widened, to increase the number of patients 
eligible for pre-hospital therapy. 
Methods and findings 
The benefit of pre-hospital thrombolysis is defined as the number of lives saved in 
ttue infarctions compared with in-hospital therapy (approximately 10 to 20 per 
1,000 treated). The risk is determined by the number of cerebral bleeds caused in 
inappropriately treated patients without infarction (5 to 10 per 1,000 inappropriate 
treatments). 
Automated 12-lead electrocardiograms were recorded in 1,072 consecutive 
patients with symptoms- suggestive of acute coronary syndrome. Myocardial 
infarction was diagnosed in 371 (35%) cases, 128 (35%) of whom were confirmed by 
the current criteria for pre-hospital therapy (total ST-deviation d.O m V). False 
positive diagnosis occurred in 6 non-infarctions. This corresponds with a 
benefit/risk ratio ranging from 21 to 85. The criteria usually applied for in-hospital 
confirmation of infarction were satisfied hy 214 infarctions and 49 non-infarctions 
(benefit/risk ratio 4 to 17). The maximal net benefit per 1,000 patients screened (1.6 
to 3.7 lives saved) was observed at a ST-elevation level of 0.6 (0.4) m V in probable 
anterior (inferior) infarctions (benefit/risk ratio 5 to 22). 
Conclusions 
The benefits of rapid, pre-hospital thrombolysis far exceed the risks, even in patients 
with somewhat uncertain dia gnosis of myocardial infarction. Therefore, initiation of 
such ther.py should be considered in a greater amount of patients. 
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INTRODUCTION 
The sequelae of myocardial infarction, particularly heart failure and death, are 
largely avoided by very early reperfusion therapyp,2l Such therapy, whether 
by thrombolysis or angioplasty, is recommended in all patients with a 
diagnosis of evolving myocardial infarction, especülly in those with ST 
segment elevation or a new Bundie Branch Block,[I,Jl Physicians are reluctant, 
however, to initiate thrombolytic therapy in patients in whom the diagnosis 
'evolving infarction' is somewhat uncertain. This reluctance is caused by fear 
for bleeding complications, above all intracranial haemorrhage. 
Pre-hospital thrombolytic therapy is particularly effective since it allows 
very early therapy. In the pre-hospital 'REP AIR' program (REPerfusion for 
Acute Infarction in Rotterdam) 73% of patients recognised with large 
infarctions are treated within 2 hours aftel' onset of symptom onset, resulting 
in high survival rates.[4,Sl In this program, initiated in 1988, an automated 12-
lead ECG analysis is used for conlirmation ol evolving myocardial infarction 
in patients with chest pain, to support the General Practitioner in decision 
making. Paramedics on the scene are allowed to start thrombolytic therapy in 
eligible patients in the absence ol a physician.[4,6l In the early stage of the 
program the limited diagnostic facilities in the pre-hospital setting were 
appreciated and considerations ol patient safety prevailed. At that time the 
protocol was designed to identify patients with extensive evolving myocardial 
infarction, in whom the additional benelit of very early therapy would be 
large,l7l and to mini mise the risk of intracranial haemorrhage. Accordingly, 
ECG criteria to conlirm evolving myocardial inlarction were very strict and 
pre-hospital therapy was restricted to patients less than 70 (until 1991) or 75 
(since 1991) years of age, with extensive ST segment elevation (total ST 
deviation over all 12 leads d.O mV).[6l Consequently, the number of patients 
who benelit Irom out of hospital therapy was limited, averaging 120 per year, 
which is approximately 40% to 50% ol patients who ultimately received 
thrombolytic therapy. 
Currently, pre-hospital thrombolysis has proven to be safe, without 
major complications outside the hospita!.[4,6l In the REPAIR program, over 
1,000 patients have been treated, in only 1% ol whom infarction was not 
conlirmed by subsequent ECG evolution and enzyme elevations in hospita!. 
One-year survival was 97% and 5-year survival 92%.[4] In view of this 
experience it would be appropriate to offer immediate, pre-hospital therapy to 
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a larger proportion of patients with evolving infarction. Therefore, we 
investigated whether the criteria for enrolment and immediate thrombolytic 
therapy could be widened, to increase the number of patients to be treated 
without excessive risk. 
The occurrence of ST·segment deviation (ST-segment elevation and 
concomitant depression) on the ECG is the most specific electrocardiographic 
measure for confirmation of evolving myocardial infarction.[8] The percentage 
of myocardial infarctions to be confirmed (sensitivity) and of non-infarctions 
to be excluded (specificity) is related to the selected thresholds for ST-
deviation. The choice of these thresholds for pre-hospital thrombolysis is 
arbitrary and depends on the perceived benefits of appropriate and risks of 
inappropriate treatment. A quantitative analysis is performed to estimate 
benefit/risk ratio's at several ST-deviation thresholds. Results are applicable 
not only to the pre-hospital setting, but also to the emergency room in many 
hospitaIs. 
METHODS 
Patients and elect1"Ocardiographic data 
From January 1992 to April 1994 standard 12-lead ECG's were recorded prior 
to hospital admission in 1,072 patients with chest pain suggestive of acute 
coronary pathology, transported by the ambulance service in the Rotterdam 
region (tabIe 1). Patients above the age of 80 years and those with chest pa in 
existing for more than 6 h were excluded from our analysis. For each lead 
amplitude and time measurements were computed and interpreted by 
Siemens' Sicard P + ECG analysis system.[9] These measurements were 
subsequently stored for oH-line analysis. Thrombolytic therapy was initiated 
on site in patients with symptoms of evolving myocardial infarction, without 
contraindications, in whom this pattern was confirmed by the automated 
ECG interpretation (tabIe 2). All chest pain patients were hospitalised. Final 
diagnoses were gathered from the hospital medical records. Definite 
myocardial infarction was diagnosed by enzyme rise and/ or evolving Q waves 
on the ECG in 371 patients (tabIe 1). 
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Number of patients 
Male sex 
Mean age, years (range) 
History of coronary artery disease(t) 
History of myocardial infarction 
Time from symptom onset 
< 1 hour 
1-3 hours 
3-6 hours 
Diagnosis 
Myocardial infarction 
Anterior 
InferÏor 
Unknown 
Unstable angina pectoris 
Stabie angina pectoris 
ECG criteria for pre-hospital thrombolysis satisfied 
Myocardial infarction 
Unstable angina pectoris 
Stabie angina pectoris 
Other diagnosis 
Immediate thrombolytic therapy in infarctions 
Thrombolysis initiated in.hospital in infarctions 
Immediate thromholytic therapy in non-infarctions 
1,072 
622 (58) 
63 (30-80 
531 (50) 
291 (27) 
182 (17) 
681 (64) 
209(19) 
371 (35) 
149 (40) 
176 (47) 
46 (12) 
187 (17) 
90 ( 8) 
134 (13) 
128 (96) 
o ( 0) 
2 ( 1) 
4 ( 3) 
84 (23) 
25 ( 7) 
1 ( 0) 
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Table 1: Characteristics of chest pain patients admitted within 6 h from symptom 
onset. The age limit in the analysis was 80 years. The numbers between brackets 
represent percentages 
(1) Myocardial infarction, angina pectoris, bypass surgery or percutaneous transluminal 
coronary angioplasty. 
Benefit/risk analysis 
In Western Europe and the USA pre-hospital initiation of thrombolytic 
treatment reduces the call-to-needle-time with about 1 h compared to in-
hospital therapyPO-1J1 Pooled analyses of all trials that compared pre-hospital 
and in-hospital thrombolysis indicated that th is gain of time results in about 15 
to 21 additional survivors at 30 days per 1,000 treated.[2,lO,1J1 The gain of earl ier 
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Indications 
• chest pain ~30 minutes and < 6 hours duration suggestive of myocardial infarction 
• no relief by uitro-glycerine 
Main contraindications 
• age ;:::75 years; for wamen < 55 years to avoid auy bleeding risk during menstru-
atian or pregnancy 
• cardiac massage, history of cerebrovascular accident, major trauma or surgery in 
the previous 3 months 
EeG criteria 
• ;"0.3 mV ST elevation in ;,,2 leads ofVl-V6, or 
;"0.2 m V in ;,,2 leads of U/uI! a VF 
• total ST elevation d.O m V 
• excluded: left bundIe branch bloek, Wollf-Parkinson-White pattern, intraventri-
cular conduction delay and pacemaker rhythm 
Table 2: In- and exclusion criteria for pre-hospital thrombolytic therapy in patients 
with evolving myocardial infarction according to the Rotterdam triage protocol 
therapy is time-dependent. The average gain per hour earl ier treatment is 
approximately 60, 10 and 2 lives saved per 1,000 treated patients in the 
respeetive 0-1 h, > 1-3 hand> 3-6 h intervals after onset of symptomsPl Sinee 
most patients in our series were visited within 3 h of symptom onset (tabie 1), 
mortality reduetion in definite myoeardial infarction patients - the benefit of a 
pre-hospital thrombolysis program - ean reliably be estimated at 10 to 20 lives 
saved per 1,000 treated. 
In same patients an intraeranial bleeding may oecur as a eonsequenee of 
thrombolytie therapy, whieh williead to death in more than half of the cases 
and to severe disability in another quarter.[Hl The risk for intraeranial haemorr-
hage ean be estimated at 5 to 10 per 1,000 patients treated.[I.Hl In patients with 
evolving myoeardial infarction this risk is partIy campensated by areduction 
of the risk for embolie stroke (strokes of any type oeeur in approximately 4 to 
8 per 1,000 treated patients).[I,Hl Moreover, the expeeted mortality reduetion 
far exeeeds the expeeted risk of intraeranial haemorrhagePl However, in 
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Total anterior (inferior) ST-deviation (rnV) 
Figure 1: Sensitivity and specificity in eonfirmation of myoeardial infaretion at 
several thresholds of ST-deviation on the presenting electrocardiograms 
All 263 (~214+49) patients in this figure met the classical criteria for in-hospital 
eonfirmation of infaretion (;-2 leads ofVI-V6 show ;-0.2 mV ST-elevation or ;-2 leads of 
I1,m,a VF show ;-0.1 rn V ST-elev.tion). 
ST-deviation is defined as: (a) in case of anterior ST-elevation: the total sum of ST-
elevation in VI-V6 plus ST-depression in I1,I1I,a VF and (b) otherwise (said to be 
inferior): the total surn of ST-elevation in I,I1,I1I,aVF,.VL,V5,V6 plus ST-depression in 
VI-V4. 
'Current' represents the strict criteria as applied in the original Rotterdam program. 
patients without infarction who (erroneously) reeeive thrombolytie therapy 
the benefits are absent, while the bleeding risk prevails. Hence, the risk of a 
pre-hospital thrombolysis program ean be estimated at 5 to 10 intracranial 
bleeding eomplieations per 1,000 treated non-infaretions. 
We evaluated the benefitl risk relation of initiation of thrombolytie 
therapy at several levels of ST deviation on the autom.ted EeG's. Reported 
are the number of myoeardial infarction patients and non-infaretions that 
reaeh eertain ST-deviation thresholds, the eorresponding sensitivity and 
speeifieity, the benefit/risk ratio and the estimated net benefit. The latter is 
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Figure2: Expected net benefit per 1,000 patients screened at several thresholds of ST-
deviation on the presenting electrocardiogram 
Only the 263 patients that met the classical in-hospital criteria (ligure 1) for 
confirmation of infarction are potential candidates for pre-hospital thrombolysis. These 
patients contribute in the benefit/risk estimations. See figure 1 for definition of ST-
deviation. 
defined as the difference between estimated benefit and risk, and is to be 
interpreted as the additional number of lives saved by pre-hospital therapy 
without additional cerebral bleeding complications. In order to emphasise that 
estimates of benefits and risks are necessarily imprecise, results are presented 
by a bandwidth, based on above described estimates, rather than point 
estitnates. 
REsULTS 
The current pre-hospital program identified extensive ST-segment elevation in 
128 out of 371 patients with definite myocardial infarction (sensitivity 35%; 
figure 1), .nd thrombolytic therapy was initiated immediately in 84 of these 
(21 patients were excluded due their age: 14 patients were > 75 years .nd 7 
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Figure 3: Expected benefit per 1,000 patients treated at several thresholds of ST-
deviation on the presenting electrocardiograms 
Only the 263 patients that met the classical in-hospital criteria (figure 1) for 
confirmation of infarction are potential candidates for pre-hospital thrombolysis. These 
patients contribute in the benefit/risk estimations. See figure 1 for definition of ST-
deviation. 
women were < 55 years; 23 patients met other exclusion criteria). Large ST 
elevation was also observed in 6 patients in whom myocardial infarction was 
not confirmed (specificity 99%). Only 1 of these patients was actually treated 
with thrombolytics. In-hospital thrombolytic therapy was installed in 99 
additional patients, so that overall 183 (49%) infarctions received reperfusion 
therapy. 
The classical criteria for in-hospital electrocardiographic confirmation of 
evolving myocardial infarction comprehend ;:'0.2 m V of ST-elevation in two 
or more contiguous precordialleads (Vl-V6; anterior location) or ;:'0.1 m V in 
two or more limb leads (II,III,a VF; inferior location)PS,161 These criteria were 
met in 214 patients with confirmed infarction, implying a sensitivity of 58% 
(figure 1). The benefit of pre-hospital thrombolytic treatment of these patients 
would be in the range of 10 to 20 lives saved per 1000 patients treated one 
hour earl ier (see methods), corresponding to 2.1 to 4.3 additionallives saved in 
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Figure 4: Expected benefit/risk ratio at several thresholds of ST-deviation on the 
presenting electrocardiograms 
Only the 263 patients that met the classical in-hospital criteria (figure 1) for 
confirmatÏon of infarction are potential candidates for pre-hospital thrombolysis. These 
patients contribute in the benefit/risk estimations. See figure 1 for definition of ST-
deviation. 
this series (214/1,000 times 10 to 20 lives expected to be saved ). The criteria 
were also satisfied in 49 non-infarctions (specificity 93%), so the risk of 
installing pre-hospital therapy at the mentioned ST-elevation thresholds would 
be 0.25 to 0.49 intracranial bleeding complications (49/1,000 times a risk of 5 
to 10 expected intracranial haemorrhages). Consequently, the expected net 
benefit would range from 1.6 ~owest benefit minus highest risk) to 4.0 
(highest benefit minus lowest risk). The estimated net benefit per 1,000 patients 
sCl'eened ranges from 1.5 to 3.8 (multiplication factor 1,000/1,072; figure 2), 
and per 1,000 patients treated from 6 to 15 (multiplication factor 
1,000/(214+49); figure 3). 
For each 4 infarctions that met the classical ST-thresholds one non-
infarction did so, resulting in a benefit/risk ratio of 4 to 17 (figure 4). This 
ratio can be improved by introducing additional criteria for total ST-deviation, 
which simultaneously increase specificity but reduce sensitivity for confir-
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mation of myocardial infarction. Consequently, the expected net benefit of 
pre-hospital thrombolytic therapy per 1000 patients tl'eated will increase (figure 
3). However, the benefit per 1000 patients screened wil! decrease (figul'e 2), due 
to the decreasing number of confirmed infarctions that satisfy the more strict 
criteria (decreasing sensitivity). The benefit/risk ratio can also be improved if 
more strict criteria for ST-elevation in separate leads would be employed (e.g. 
~0.3 m V for precordial leads and ~0.2 m V for limb leads). In this situation 
sensitivity is low Oess than 38%) and specificity high (99%), resulting in a 
relative high benefit/risk ratio (more than 14) and low net benefit per 1,000 
patients screened (between 1.1 and 2.6). 
DISCUSSION 
Physicians have been educated with the principle 'primum non nocere' ('first 
do no harm', 'better be safe than sorry'). This principle does apply te most 
modes of therapy, however, such attitude may be too strict in patients with 
possible evolving myocardial infarction. Myocardial infarction is a life 
threatening disease. The high mortality-rate can be considerably reduced by 
early (particularly very early) reperfusion therapy.[l,'l In patients with ST-
elevation or Bundie Branch Block this benefit is estimated at 30 fewer deaths 
per 1,000 patients treated early aftel' symptom onset compared with 
conventional therapyPl Yet, most myocardial infarction patients do not 
timely receive such life saving therapy, partly because diagnosis is initiaUy 
'uncertain, and partly because significant delays occur in those who ultimately 
appeared te be eligible. Treatment delays can be reduced by immediate, pre-
hospital initiation of thrombolytic treatment,l4,1~l2l though pre-hospital 
diagnosis may be somewhat uncertain. The current analysis implies, however, 
that thrombolytic therapy could be, and should be, initiated even in patients 
with some diagnostic uncertainty! 
Thrombolytic therapy carries some risk for cerebral haemorrhage 
(estimated at 5 to 10 per 1,000 treated patients). Pre·hospital thrombolysis 
carries additional risk, sin ce, due to limited diagnostie faeilities, such treatment 
might be instaUed in patients without infarction and subsequently cause a 
cerebral bleed in some if them. Given this risk, the question arises whether all 
patients should be withheld pre-hospital therapy? If not, what would be an 
aceeptable benefit/ risk ratio? First of aU, it should be accepted that the risk of 
causing cel'ebral haemorrhage in somebody without infarction ean never be 
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Final diagnosis 
Myocardial infarction(2) 
Unstable angina pectoris 
Pericarditis 
Aortie dissection 
Other cardiae diseasefl) 
Noncardiac disease 
PatÏents that satisfy 
'opt\mal' ST thresholdfl) 
(N ~246) 
208 (84.5%) 
19 ( 7.7%) 
2 ( 0.8%) 
o ( 0%) 
15 ( 6.1%) 
2 ( 0.8%) 
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EMIP[lOl 
(N ~5,469) 
4,892 (89.4%) 
390 ( 7.1%) 
21 ( 0.4%) 
9 ( 0.2%) 
57 ( 1.0%) 
100 ( 1.8%) 
Table 3: Final diagnosis among 246 patients that satisfy extended eleetroeardio· 
graphic criteria compared with the 5,469 patients from the EMIP[IOl trial 
(1) At the 'optimal' threshold (0.6 mV anterior or 0.4 mV inferior total ST.deviation) 
the net benefit per 1,000 patients screened reached it's maximum; (2) including patients 
with diagnosis 'probable infarction' (EMIP); (3) including patÏents with final dia gnosis 
'atypical chest pain'. 
eliminated completely, even not in-hospital by an experienced cardiologist. 
The dia gnosis of myocardial infarction cannot be made with complete 
certainty at an early stage.rI7,IS] Enzyme rise and new Q-waves on the 
electrocardiogram appear only hours af ter symptom onset, at a stage where 
thrombolytic therapy has lost most of its value. 
In the pre-hospital setting, the balance between apprapriate and 
inapprapriate treatment depends on the available diagnostic tooIs. Automated 
electrocardiography on site might be very useful, since clinical symptoms of 
evolving myocardial infarction usually are accompanied by manifest ST 
elevations. Our investigation focused on these electrocardiographic measures. 
It should be realised, however, that the decision whether or not to install 
thrombolytic therapy was only considered in patients with manifest 
symptoms of evolving myocardial infarction, which were systematically 
checked by the visiting physician by means of a standardised questionnaire. 
The electra·cardiogram was used to confinn clinical signs of acute coranary 
pathology. 
It has been argued by others, that an acceptable benefit/ risk ratio for in-
hospital thrambolysis would be obtained if such therapy is initiated in all 
patients with symptoms suggestive of evolving myocardial infarction, 
accompanied by classical ST abnormalities In the presenting 
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electrocardiogramPSl In the present series this implies a positive predictive value 
of 81% (214 out of 263 ECG's that satisfy the classical in-hospital 
electrocardiographic criteria were infarct-related, see figure 1), which can be 
considered the directive for a pre-hospital diagnostic system_ However, as figure 
2 suggests, a better threshold seems to be 0_6 m V ST deviation in case of anterior 
and 0.4 m V in inferior infarction, as at that point the lower estimate of the net 
benefit per 1,000 patients screened seems to reach its maximum value, though it 
is appreciated that differences in this lower estimate are smaIl_ Table 3 shows 
hospital diagnoses of all 246 patients that satisfy this more strict threshold_ In 
208 patients (85%) myocardial infarction was confirmed, which is slightly lower 
than in the large EMIP trial of pre-hospital thrombolytic therapyPOl Among the 
38 non-infarction patients, 18 showed significant anterior ST elevation, with 
total ST elevation ranging from 0.4 to even 2.4 m V_ Inferior ST elevation were 
observed in the remaining 20 patients, with totals in the range 0.3 to O. 9 mV. 
One of the false positives with extensive anterior ST elevations received 
thrombolytic therapy in-hospita!. Since no enzyme elevations occurred, the 
final diagnosis was unstable angina pectoris, but actuaIly, in this patient an 
evolving infarction was aborted. Only very few (0.8%) patients were suffering 
from cardiac disorders with an increased life-threatening bleeding risk, such as 
pericarditis. In the present series there were no cases of aortic dissection, while 
in EMIP 0.2% of treated patients appeared to suffer from this disease. It should 
be noticed, that aortic dissection may weIl be associated with evolving 
infarction, so the diagnosis might also be overlooked in-hospita!. 
The initial electrocardiographic criteria in the Rotterdam pre-hospital 
program were clearly risk-avoiding (the estimated benefit/risk ratio is in the 
range 21 to 85), and were satisfied only by 35% of the myocardial infarction 
patients. Consequently, the expected net benefit per 1,000 patients screened is 
relatively low. In our opinion, we are now at the stage that a less risk-avoiding 
strategy would be acceptable, and electrocardiographic criteria might be 
widened. Using the described 'optimal' thresholds, estimated benefits are 5 to 22 
times higher than the risks, thus for each intracranial bleed caused in non-
infarction patients at least 5 lives are expected to be saved in true infarctions. In 
patients with a reduced risk for intracranial bleeding (e.g. the younger patients 
and those with a normal blood pressurep9l an even higher number can be 
expected. These insights have been translated into an revised program, which is 
currently being evaluated. 
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Administration of thrombolytic therapy to patients who do not have an 
evolving infarction carries unnecessary costs in addition to the risk involved. In 
our opinion these costs are acceptable, paiticlllarly when using streptokinase as 
thrombolytic drug in the pre·hospital setting (REP AIR). 
Despite the awareness of the importance of rapid thrombolysis, 25% of 
treatment delay is caused by time·consuming in-hospital procedures, including 
time spend by nursing, emergency physician evaluation and cardiologist bedside 
consultation.[20] One way to reduce this delay is to improve diagnostic tools in 
the emergency room, for example by using automated an l2-lead ECG system, 
and to allow nurses to initiate life-saving thrombolytic therapy in typical 
myocardial infarction patients. The results described above are derived from 
ECG's in the pre-hospita! setting, but are similarly appIicable in the emergency 
room situation, to the benefit of many patients with evolving myocardial 
infarction in whom treatment delay might be reduced, and with litde risk to 
other patients without a final diagnosis of infarction. 
CONCLUSION 
Although the question of the optimal ratio between benefits and risks in pre-
hospita! thrombolysis can not be answered unambiguously, the quantitative 
analysis as presented in this paper does contribute to a better understanding of 
the choices. In general, additional mortality reduction among patients with 
extensive myocardial infarction - due to the simple fact that they are treated in 
time - far outweighs the risk of causing major complications in erroneously 
treated non-infarct patients. Therefore, initiation of thrombolytic therapy prior 
to hospital admission should be considered in a greater amount of patients. At 
the same time, in-hospital logistics should be improved by introducing of 
automated diagnostic tools in the emergency room. 
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Chapter 8 
PRACTICAL AND ETHICAL CONSEQUENCES OF 
MEDICINE ACCORDING TO PROTOCOL 
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INTRODUCTION 
'All effective treatment must be free' was the slogan of Archie Cochrane, 
eminent founder of evidence based medicine, when he was a medical student 
in the 1930spl About four decades later he developed this perception in his 
book 'Effectiveness and Efficiency: Random Reflections on Health Services' ,lil 
Cochrane's principles were straightforward: since resources are always limited, 
they should be applied to provide eqllitttbly those forms of health care which 
had been shown effictive in properly designed investigations. Clearly, two 
major questions arise: what is 'effective' medical treatment? and what is an 
'equitable' distribution of resources? Actually, these problems occur both at 
society (macro) and hospitalor department (micro) level. The first decision to 
be made at the macro-level is how much of the Gross National Product should 
be allocated to health carePl After the general health care budget has been 
settled, it has to be detennined what percentage should be allocated for 
preventive care, acute care, long-term care, and for specific patient 
populations. Given the financial scope for treatment of a specific disease, at 
micro-level decisions are to be made as to which patients will receive which 
mode of available therapies. 
The problem as dealt with in th is thesis is an example of medical decision 
making on micro-level. Myocardial infarction is an acute life-threatening 
disease which can be treated with several modes of reperfusion therapy. The 
properties of these treatment options and the effècts on mortality and 
morbidity are studied and discussed in the 'Premises' . Based on these materiais, 
in the part 'Practical decision models' treatment guidelines are developed for 
eqllitttble allocation of scarce reperfusion resources in daily clinical practice. In 
this final chapter premises are briefly recapitulated, and ethical principles and 
practical consequences of evidence based medicine are discussed. 
PREMISES 
MeaslI1'ements of evidence 
The first issue is that of evaluating to what extent different reperfusion 
treatment options improve clinical prognosis of individual myocardial 
infarction patients. It is commonly accepted, that clinical evidence can be 
measured objectively by means of a randomised controlled investigationPl In 
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such setting, patients are allocated based on random numbers to one of several 
treatment options. Preferably, neither the physician nor the patients know 
which of the treatments is being given ('double blind' randomisation). This 
technique guarantees that baseline characteristics in all treatment arms are 
comparable (if not, differences are per definition due to chance) and eliminates 
the possibility of observer bias. Thus, differences in outcome bet ween the 
treatment arms can entirely be accredited to the treatment itself. Almost all of 
the evidence as stated in this thesis is derived from randomised comparisons. 
Sometimes additional non·randomised comparisons of groups of patients and 
experimental observations are used to make the point (chapter 3). 
Reperfilsion therapy in evolving myocardial infantion 
Since it became accepted that myocardial infarction is generally caused by an 
acute thrombotic obstruction of a coronary artery, several pharmacological 
and mechanical interventions were introduced that aimed at rapid and 
sustained restoration of local blood flow (chapter 2). Nowadays, intravenOlls 
infusion of streptokinase (1.5 MU over 1 h) is the cheapest (and most widely 
used) therapeut ic alternative. Randomised investigations involving more than 
30,000 patients indicate that mortality at one month is 23% reduced if such 
therapy is initiated within 6 h from onset of symptoms.[4.7] In combination 
with aspirin an even higher (almost 40%) mortality reduction can be 
achieved.[6] Streptokinase therapy does increase the rate of intracranial 
haemorrhage. On the other hand, embolic stroke rates are slightly reduced. 
Overall, the excess of any stroke (haemorrhagic or embolic) with thrombolytic 
therapy in the large trials (in 90% the agent in concern was streptokinase) 
appeared to be small compared with the achieved mortality reduction: about 4 
strokes caused as against 30 fewer deaths (including 2 fatal strokes) per 1,000 
myocardial infarction patients treated within 6 h.[S] 
Recombinant tissue-type plasminogen activator (rt-PA) is a thrombolytic 
agent which directly activates the lytic process, and is therefore potentially 
more powerful than streptokinase. However, rt-PA is also more expensive. 
Randomised clinical investigations that compared effects of streptokinase with 
rt-PA showed contradictory results. In two trials the relative slow infusion of 
rt-PA (100 mg infusion over 3 h) appeared not to be more effective than 
streptokinase in terms of short-term mortality reduction (in these 
investigations 38,000 patients were randomised within 6 h).l9.11] On the other 
hand, combination therapy of so-called accelerated rt-PA (100 mg infusion 
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over 1.5 h) and intravenous heparin resulted in a 14% mortality reduction at 
one month compared with streptokinase in combination with heparin (results 
are based on 30,600 randomised patients).[12] Both rt-PA regimens produced a 
higher rate of haemorrhagic strokes than streptokinase. Investigators in 
question did not reach consensus as to whether there was a net difference in 
clinical outcome between the two different thrombolytic agents (chapter 4).[8] 
One group argued that, to avoid selective emphasis on particular trial results, 
all randomised investigations on rl-PA versus streptokinase should be 
considered together.[13] Such analysis does not indicate superiority of rt-PA 
over streptokinase. Others stated, that the combination therapy of accelerated 
rl-PA and intravenous heparin is an apparently different regimen than 'slow' 
rl-PA alone, and combined analysis is therefore inappropriate. In this thesis 
the last opinion is preferred (chapters 5 and 6). 
Recombinant plasminogen activator (reteplase, r-PA) is a mutant of rt-PA 
with an increased half-life, which allows administration via bolus injection. So 
far, the r-PA regimen of 2 boluses of 10 MU given 30 min apart has been 
evaluated in two large randomised trials.[14.15] The results of these 
investigations indicate that the clinical effects of r-PA are in between 'standard' 
streptokinase and accelerated rt-PA. 
Direct coronary angioplasty is another way to treat the coronary 
occlusion. This technique has been compared with several thrombolytic 
regimens in a couple of randomised trials, including ab out 2,600 patients.[16] 
Short term mortality af ter primary angioplasty was 33% reduced compared 
with thrombolysis, while the risk of stroke was also remarkably decreased. In 
view of the relative small amount of available data, these observations should 
be interpreted cautiously. Nevertheless, direct angioplasty is an alternative for 
thrombolysis, especially in patients with increased risk for cerebral bleeding 
complications. The initial costs related with the invasive procedure are high 
and it is yet uncertain whether these are counterbalanced by a decrease in 
revascularisation procedures during foIlow_up.[17·19] 
Perspectives 
As far as future developments in treatment of myocardial infarction patients 
are concerned, investigations focus on strategies which will result in more 
rapid and sustained coronary patency compared with existing options. This 
includes introduction of new thrombolytic agents as weIl as application of 
coronary stents to optimise the result of direct angioplasty. Also platelet 
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glycoprotein IIb/rna receptor blockers are nowadays subject of examination. 
Drugs from this dass inhibit the process of platelet aggregation, and may thus 
prevent the occurrence of ocduding 'white', platelet-rich thrombi. Promising 
results are observed in a small dose-ranging studyPO] 
Time /rom symptom onset to treatment 
The beneficial effect of reperfusion therapy depends on time from symptom 
onset. The nature of the treatment benefit/ delay relationship is subject to 
discussion (chapter 4).[8] In this thesis the importance of very early reperfusion 
treatment is emphasised (chapters 3 and 7).[21] The beneficial effect of such 
therapy is thought to be substantially higher in patients presenting within 2 h 
aftel' symptom onset compared to those presenting later (chapters 3, 5, 6 and 
7). 
Treatment effects in sl/bgrol/ps of patients 
The risk of death from acute myocardial infarction can be predicted at the 
time of hospital admission. Most important mortality determinants are: age, 
blood pressure, Killip dass, heart rate, history of infarction and site of the 
current infarct (dlapters 4, 5 and 6). Systematic overview of the large 
randomised trials showed that there was no significant heterogeneity between 
the proportional mortality reductions in the different subgroups of patients 
studied.[22] Consequently, the absolute number of deaths avoided by 
reperfusion treatment appears to be greater in those groups with a higher 
baseline mortality risk. Also the additional benefit of more intensive therapy 
up on 'standard' therapy is most pronounced in patients at high baseline risk 
(chapter 6). 
Long term effects of reperfl/sion therapy 
Most randomised investigations planned only evaluation of the short-term 
(one month) effects of reperfusion therapy. Some trials reported also results at 
long term follow-up (up to 10 years; 4 year data is available in ab out 18,300 
randomised patients), and showed a sustained survival benefit of reperfusion 
therapy (chapters 4 and 5).[23-25] The larger absolute benefits observed at one 
month in patients at higher risk of death were also sustained. 
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PRACTICAL DECISION MODELS 
Ethical princip/es with respect to allocation of scarce reso/lrces 
Medical resources are often scarce in relation to human wantsp6] which 
implies that a physician may not always be able to pursue patient's best 
interests. At the bedside these individual interests may come into conflict with 
the social benefits from fairly resource allocation. To arrive at an equitable 
resource allocation, three general ethical principles should be considered.f27] 
The first principle focuses on maximising patient welfare, which can be 
quantified with help of (quality adjusted) life years. The fact that a certain 
treatment option produces greater increase in patient welfare than another is a 
reason to choose that option. The other way around, patients in whom greater 
welfare increase can be expected from certain treatment are more suitable 
candidates than others with a more limited gain. The second principle 
indicates that patients with equal benefit from therapy should be given an 
equal chance. The third principle says that the aim of health care is not to 
produce as many quality adjusted life years as possible (in that case all stakes 
should be thrown on fertility programs).f28] Sometimes the acute medical need 
justifies interventions which will not be cost·effective. 
Eq/litab/e allocation of reperj/lsion reso/lrces among patients with evolving 
myocardial infa1"Ction 
As has been outlined above, there are several modes of reperfusion therapy for 
patients with evolving myocardial infarction. These options are increasingly 
effective, but also increasingly costly and complex. In most hospitals in 
Western-Europe and the United States reperfusion resources are limited 
(especially, direct angioplasty is only possible in hospitals with catheterisation 
laboratory and excellent trained and experienced medical staff). To equitably 
allocate these resources, in this thesis a two-step approach is described 
(chapters 5 and 6). 
In the first step, based on patient's presentation features, one year 
mortality risks are determined, both with and without reperfusion therapy. 
Subsequently, life expectancies are calculated, using Dutch life tables. The 
difference between patient's life expectancy with and without treatment is 
defined to be the treatment benefit. No quality of life adjustments are 
performed, except for the occurrence of intracranial haemorrhage. This event 
may be caused by thrombolytic therapy, and wil! lead to death in more than 
MEDICINE ACCORDING TO PROTOCOL 151 
half of the cases. Therefore, the probability of intracranial bleeding due to 
treatment has been judged as undesirable as the occurrence of death after 
refrained treatment. The concept of life expectancy is refined by introduction 
of the discounting principle (chapter 5). With help of th is technique a greater 
value can be given to treatment results in the near future, compared with the 
more distant future, which is in concordance with physician's opinion of good 
clinical practice. For several categories of patients the estimated benefits of 
reperfusion therapy - gain in future life years, both 'crude' and discounted - are 
presented in sets of tables (chapters 5 and 6). 
In the second step, treatment allocation policies are discussed, with the 
estimated gain in life-expectancy in individual patients being the bench mark. 
Patients with a negative or negligible gain wil! not be offered reperfusion 
therapy (treatment wil! likely be harmful). In those with a relative small 
expected gain 'standard' therapy is the preferred option (nowadays: 
streptokinase), whereas more effective, but more expensive options (in rising 
order: reteplase, accelerated rt-PA and angioplasty) are recommended in 
patients with higher awaited benefits. The question as of what is 'smalI' and 
'high' benefit cannot be answered unambiguously. Some physicians defend a 
so-called 'patient-driven' treatment definition. In such case, treating 
cardiologists determine fixed decision-thresholds on the basis of their insight in 
what is cost-effective treatment in individual patients. They do not aim in the 
first place at cost-effective treatment of the popu/ation of myocardial infarction 
patients. Others opt for a more 'budget-driven' definition. Thresholds are 
determined in consultation with hospital boards and treating cardiologists on 
the basis of the expected demand (patients to be treated) and supply (available 
resources). In the Thoraxcentre Rotterdam this Iatter policy is preferred, and 
current thresholds are chosen in such way that approximately 50% of patients 
wil! receive 'standard' therapy and 50% more advanced therapy (chapter 5). 
The developed decision model generally answers the first and second 
ethical principles outlined above. In some cases, however, application of the 
model may yield spurious results. Patients with a high underlying mortality 
risk usually benefit most from reperfusion therapy (also in terms of expected 
life years to be gained), and are consequently candidates for intensive 
treatment. However, in a patient presenting in a terminal stage (e.g. an elderly 
patient with extensive infarction complicated by severe heart failure, low 
blood-pressure and increased heart rate) , who has also an extreme high 
mortality risk, reperfusion therapy wil! not be useful, and good terminal care 
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should be considered instead. U ndeserved initiation of reperfusion treatment 
as suggested by the model (chapters 5 and 6) in such patient may be to the 
disadvantage of those who will really benefit. At the other hand one might 
argue that in this typical situation the acute need requires some action (third 
ethical principle). Obviously, the decision model can not replace the 
physician's clinical judgement, and should consequently not be used 
compulsively. In individual cases protocol deviations are allowed for sure, 
although these variations are not encouraged. 
Doing more good tban harm 
Another dilemma discussed in this thesis is, whether it is allowed to initiate 
thrombolytic therapy in patients with somewhat uncertain dia gnosis of 
myocardial infarction (chapter 7). Thrombolytic therapy is especially effective 
very early af ter onset of symptoms, and therefore several attempts are made to 
initiate treatment prior to hospital admission. Since thrombolysis also carries 
some risk for life-threatening cerebral bleeding complications, correct 
diagnosis is essential, to prevent inappropriate treatment of non-infarction 
patients. No diagnostic tooi, however, has a specificity of one hundred 
percent. Thus the question arises as to what is an optimal balance between 
sensitivity and specificity. 
Generally, it is appreciated that medicine may do harm as weil as good, 
and only medical treatments of which one can be reasonably sure of doing 
more good than harm are agreed to be permitted.[29l This principle refers to 
treatment of patients who definitely suffer from a certain disease. In the 
described situation, however, diagnosis is uncertain. Treatment will be very 
beneficial in patients with true infarctions, but can only be harmful in the 
non-infarctions. It is questionable whether the 'more good than harm' 
principle still holds. Actually, no entirely satisfactory solution can be given in 
this situation. The decision not to treat patients before hospital admission 
because of diagnostic uncertainty may be fatal for approximately 1% to 2% of 
those with true infarction (mind that the focus is on very early treatment). On 
the other hand, a generalised treatment decision may lead to cerebral bleed in 
about 0.5% to 1.0% and subsequent death in 0.3% to 0.7% of patients without 
infarction. In this thesis it is argued that the diagnosis of myocardial infarction 
cannot be made with complete certainty at an early stage, even not in-hospital 
by an experienced cardiologist. 'To treat or not to treat' depends on the 
expected ratio between true- and false positive diagnoses. Treatment was 
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judged permissible and indispensable in case estimated benefits are at least 5 
times higher than the risks. 
FINAL REMARKS 
This thesis is a typical product of the modern scientific method. On the basis 
ofaxioms, observations, experimental results (randomised clinical trials), 
mathematical techniques (calculation of life expectancy) and rational reasoning 
an answer is formulated to the problem of optimal, equitable allocation of 
scarce resources in reperfusion treatment of patients with evolving myocardial 
infarction. So far, observations, results and techniques are extensively 
discussed, while axioms are underexposed. Nevertheless, it might be useful to 
pay some attention to the underlying fundamental assumptions. 
The most conspicuous and dominating assumption is that the natural 
course of a disease, the effects of medical interventions and the distribution of 
resources can be determined according the theory of probabilities. A particular 
myocardial infarction patient was thought to run a certain 'risk' (or 
'probability') of early death. Results of 'randomised' clinical trials indicate a 
'risk-reduction' after reperfusion therapy, with different effects of distinct 
treatment options. Treatment effe cts are summarised in terms of 'life-
expectancy' (a measure constructed with help of estimated future mortality 
probabilities). Finally, resource allocation is based on 'distribution' of 
estimated treatment benefit within a certain patient population. This 
narrowing of reality was essential for solution of the central problem, but 
passes over patient's experience of the disease (e.g. the faith that God does 
guide his life) and his endured emotions (e.g. uncertainty about the final 
outcome, doubt whether the goal he hoped to achieve is still attainable). To 
overcome this gap in the 'scientific solution' a good, human patient-doctor 
relationship is essential (also pastoral support may be considered in this 
respect). The listening ear of an observant treating physician can therefore not 
be replaced by the developed treatment protocol. The combination of both, 
however, may lead to equitable allocation of medical resources and improved 
patient care. 
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INTRODUCTION 
Chapterl 
Several modes of reperfusion therapy for evolving myocardial infarction have 
been developed, which differ in terms of effectiveness, complexity and costs. 
Resources are of ten restricted by budgetary constraints or logistic circumstances, 
and therefore cost-benefit considerations wil! play a prominent part in the 
decision as to which therapy to provide to an individual patient. Since the first 
hours of symptom onset are of vital importance, time to estimate and weigh 
benefits, risks and costs of different options is fairly limited. In this situation a 
decision model which integrates all relevant aspects might be very useful. The 
present thesis reflects the development of such clinical decision models. The 
foundation is laid in the 'Premises' and the upshot given in the part on 
'Practical decision models' . 
PREMISES 
Chapter 2 
The clinical effects of various reperfusion treatment strategies, especially 
streptokinase, accelerated altepiase and direct coronary angioplasty have been 
studied in a number of randomised trials. This chapter presents a survey of the 
most relevant results observed in these investigations. Reperfustion therapy of 
suspected myocardial infarction within 6 h of onset of symptoms does avoid 
approximately 25 deaths per 1,000 patients compared with control therapy. 
On the other hand, thrombolytic treatment wil! cause a slight excess in 
cerebrovascular complications: 4 per 1,000 treatments, 2 of these are fatal (and 
are al ready accounted for in the mortality result). Thus, reperfusion therapy is 
clearly beneficial in these patients. There are moderate, but significant 
differences in outcome between several reperfusion strategies: direct 
angioplasty being most effective, followed by accelerated altepiase (with 
intravenous heparin) and streptokinase. In clinical practice, however, most 
emphasis should be on rapid installation of some reperfusion therapy without 
worrying overmuch about which option to choose. 
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Chapter 3 
Mortality-reduction by reperfusion therapy is related to the time elapsing 
bet ween onset of symptoms and commencement of treatment. In this chapter 
the nature of this relationship is studied, using tabulated data from randomised 
trials reported within the 1983-1993 period which compared fibrinolytic 
therapy with control (including a total of 50,246 randomised patients). The 
absolute as weil as the proportional mortality reduction by thrombolytic 
therapy was significantly higher in patients treated within 2 h compared to 
those treated later. The relation between treatment delay and mortality 
reduction was expressed significantly better by a non-linear than a linear 
regression equation. This analysis emphasises the importanee of early (pre-
hospital) thrombolytic therapy. 
Chapter4 
In Pebruary 1995, a colloquium involving several groups of investigators was 
organised to discuss several questions with regard to selection of reperfusion 
therapy for individual myocardial infarction patients. This chapter provides a 
summary of that discussion. There was a consensus on most topics, and the 
most important conclusions were: 
• Almost all patients with evolving myocardial infarction presenting up to at 
least 12 h from symptom onset wil! benefit from reperfusion therapy. 
• The proportional improvement in short-term survival produced by 
reperfusion therapy is generally similar in different subgroups of patients. 
Consequently, in absolute terms, high-risk patients will benefit most from 
such therapy. 
• The absolute mortality reduction produced by reperfusion therapy is 
sustained af ter the first year. 
• The beneficial effect of reperfusion therapy depends on the time expired 
from the onset of symptoms. 
Consensus could not be reached with respect to two issues: 
• There was no agreement about the shape of the association between 
treatment delay and treatment benefit. 
• Some investigators were convinced that the use of accelerated altepiase with 
intravenous heparin yields a significant net clinical benefit over 
streptokinase, while others considered that whereas the hazard with rt-PA is 
definite any excess of benefit over hazard is uncertain. 
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The occurrence of these contrasting viewpoints can partly be explained by 
differences in emphasis on pathophysiological concepts and results of large 
trials. These differences, however, do not lead to major differences in routine 
treatment strategies. 
PRACTICAL DECISION MODELS 
Chapter 5 
Patients' life expectancy will decrease after myocardial infarction. By early 
reperfusion therapy part of this loss can be prevented. The magnitude of the 
clinical benefit depends on several factors, among which patient's age, the infarct 
size and treatment delay are the most important. In this chapter, treatment 
benefit is quantified in terms of 'gain in life expectancy' for several categories of 
patients and presented in a set of tables. These can be used for allocation of 
reperfusion resources in clinical practice. For cost-effectiveness reasons, patients 
in whom the largest benefits are awaited, will receive the most effective 
(expensive) therapy. Medical ethics require, that patients with similar expected 
treatment benefit will be offered the same mode of therapy. 
Currently at the Thoraxcentre in Rotterdam streptokinase is installed 
when the estimated gain in life expectancy is 1-4 months and accelerated 
altepiase for a gain ;0,5 months (future life years were discounted with 5% per 
year). Direct angioplasty is recommended in patients with an estimated gain ;0,12 
months, and in those with an increased risk of intracranial bleeding. In this way, 
approximately 80% of the patients will be treated with thrombolytics (40% 
streptokinase and 40% accelerated altepiase), while in 10% direct angioplasty 
will be initiated. These threshold values have been chosen based on the actual 
situation in the Thoraxcentre. Different thresholds may be selected in other 
centres. Nevertheless, the developed model guarantees that treatment decisions 
will be made in a consistent manner, and that, within the margins of the 
available budget, optimal therapy will be provided for individual patients. 
Chapter 6 
In this chapter an alternative model for the estimation of treatment benefit is 
presented, which is mainly based on an analysis of the GUSTO-1 randomised 
trial. Since more detailed information is applied as compared with the model 
presented in chapter 5, this alternative potentially better distinguishes low 
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risk- from high risk patients. A further advantage is, that the quantified 
positive and negative aspects of reperfusion therapy are presented separately, 
which generally willlead to a more accurate weighing in individual patients. 
ebapter 7 
One way to avoid unnecessary treatment delay, is initiation of thrombolytic 
therapy prior to hospital admission. The effeetiveness and safety of pre-
hospital thrombolysis depends on possibilities for rapid and correct dia gnosis. 
The Rotterdam pre-hospital treatment program utilises a standardised and 
computer-interpreted electrocardiogram for confirmation of infarction. To 
prevent false positive dia gnosis and inappropriate treatment, current 
electrocardiographic criteria are very strict: a total ST-deviation ?:1.0 m V is 
required among other things. In this chapter it is investigated whether these 
criteria can safely be widened, to increase the number of patients eligible for 
pre-hospital therapy. 
Myocardial infarction was definite in 371 (35%) out of 1,072 studied 
patients with symptoms suggestive of acute coronary syndrome. In 128 (35%) 
of these cases the pre-hospital electrocardiogram satisfied the current criteria 
for immediate thrombolysis, which was also the case in 6 (1%) of the non-
infarctions. This corresponds with a benefit/ risk ratio of at least 20. The 
maximal net benefit per 1,000 patients screened is reached if pre-hospital 
thrombolysis would be installed above the 0.6 (0.4) m V ST-elevation level in 
probable anterior (inferior) infarctions. In that case, the benefit/ risk will be 
approximately 5. On the basis of these results, pre-hospital thrombolysis 
should be considered in a greater amount of patients. 
GENERAL DISCUSSION 
Chapter 8 
This final chapter provides a general discussion of the results described in this 
thesis. Practical and ethical consequences of medicine according to protocol 
are addressed. Finally it is stated, that the use of a clinical decision model by an 
attentive treating physician may lead to both an equitable allocation of 
medical resources and improved patient care. 
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INLEIDING 
Hoofdstllk 1 
Voor de behandeling van patlenten met een zich ontwikkelend myocard 
infarct zijn diverse reperfusie therapieën ontwikkeld, die verschil vertonen in 
effectiviteit, complexiteit en kostbaarheid. Om budgettaire en organisatorische 
redenen zijn in de klinische praktijk meestal niet alle opties onbeperkt 
voorhanden, zodat de kosten-baten verhouding een belangrijke rol speelt in 
het opstellen van een behandel-plan voor de individuele patiënt. Aangezien het 
van levensbelang is de reperfusie behandeling zo snel mogelijk na het onstaan 
van de klachten te beginnnen, is er weinig tijd om de baten, risico's en kosten 
van verschillende opties in te schatten en tegen elkaar af te wegen. In deze 
situatie kan het bijzonder zinvol zijn, gebruik te maken van een beslismodel 
dat alle relevante aspecten integreert. Dit proefschrift beschrijft de 
ontwikkeling van zulke klinische beslismodellen, waarbij de basis wordt 
gelegd in de 'Premissen' en de uitwerking volgt in het gedeelte over 
'Praktische beslismodellen' . 
PREMISSEN 
Hoofdswk 2 
De klinische effecten van verschillende rep er fusie therapieën, met name 
streptokinase, altepIase en directe corona ria-angioplastiek, zijn bestudeerd in 
diverse gerandomiseerde studies. In dit hoofdstuk wordt een overzicht 
gepresenteert van de belangrijkste resultaten zoals die in deze onderzoeken 
zijn behaald. Reperfusie behandeling van elke 1.000 patiënten met een 
vermoedelijk myocard infarct binnen 6 uur na het onstaan van de klachten 
leidt tot een reductie van ongeveer 25 sterfgevallen in vergelijking met 
controle-behandeling. Daartegenover staat een geringe toename van het aantal 
cerebro-vasculaire complicaties: 4 per 1.000 behandelingen, waarvan er 2 fataal 
zijn (deze zijn reeds verwerkt in het sterfte-cijfer). Dus, reperfusie therapie is 
duidelijk nuttig in deze groep patiënten. Er zijn kleine, maar significante 
verschillen in uitkomst tussen de verschillende reperfusie therapieën: directe 
angioplastiek is het effectiefst, gevolgd door altepIase (in zogenaamd 'versneld' 
toegediende vorm en in combinatie met intraveneuze heparine) en 
streptokinase. In de klinische praktijk echter, moet de nadruk liggen op het zo 
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snel mogelijk beginnen van enige reperfusie therapie. De vraag wélke optie te 
kiezen, komt pas in tweede instantie aan de orde. 
Hoofdstuk 3 
De sterfte-reductie die bereikt wordt door reperfusie therapie is gerelateerd aan 
de tijd die verstreken is sinds het ontstaan van de klachten. In dit hoofdstuk 
wordt de aard van deze relatie bestudeerd aan de hand van getabuleerde 
gegevens van gerandomiseerde studies uit de periode 1983-1993 waarin 
thrombolytische therapie werd vergeleken met controle-behandeling (totaal 
50.246 gerandomiseerde patiënten). De absolute zowel als de proportionele 
sterfte-reductie ten gevolge van thrombolytische therapy was significant groter 
onder patiënten die binnen 2 uur werden behandeld dan onder hen die later 
werden geholpen. De relatie tussen behandelings-vertraging en sterfte-reductie 
kon significant beter worden beschreven met een niet-lineaire dan met een 
lineaire regressie vergelijking. Deze analyse benadrukt het belang van vroege 
(pre-hospitale) thrombolytische therapie. 
Hoofdstuk 4 
In februari 1995 is er een colloquium georganiseerd, waarin verschillende 
groepen onderzoekers met elkaar van gedachten wisselden over vragen met 
betrekking tot de selectie van reperfusie therapie in patiënten met een zich 
ontwikkelend myocard infarct. In dit hoofdstuk wordt een samenvatting van 
die discussie gegeven. Over het antwoord op de meeste vragen bestond 
overeenstemming. De belangrijkste conclusies waren: 
• Nagenoeg alle patiënten met een zich ontwikkelend myocard infarct die 
binnen 12 uur na het ontstaan van de klachten behandeld worden, hebben 
baat bij reperfusie therapie. 
• De proportionele verbetering in korte-termijn overleving ten gevolge van 
reperfusie therapie is nagenoeg gelijk in diverse subgroepen van patiënten. 
In absolute zin is de sterfte-reductie dus het grootst onder patiënten met een 
hoog onderliggend sterfte-risico. 
• De absolute sterfte-reductie ten gevolge van reperfusie therapie blijft ook na 
het eerste jaar behouden. 
• De omvang van het heilzame effect van reperfusie therapie is afhankelijk 
van de tijd die verstreken is sinds het onstaan van de klachten. 
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Twee vragen konden niet eensluidend worden beantwoord: 
• Er was geen overeenstemming over de aard van de relatie tussen 
behandelings-vertraging en behandelings-effect. 
• Sommige onderzoekers waren ervan overtuigd dat de combinatie van 
'versneld' toegediende altepiase en intraveneuze heparine tot een significant 
beter resultaat leidt dan behandeling met streptokinase. Anderen, 
daarentegen, waren van mening dat het onzeker is of het onweerlegbaar 
toegenomen risico uiteindelijk opweegt tegen de baten. 
Het bestaan van deze tegenstrijdige standpunten kan gedeeltelijk worden 
verklaard door verschillen in het omgaan met pathofysiologische concepten en 
resultaten van grote gerandomiseerde studies. In de klinische praktijk hebben 
deze verschillen van inzicht echter geen grote consequenties. 
PRAKTISCHE BESLISMODELLEN 
Hoofdsttlk 5 
De levensverwachting van een patient zal afnemen ten gevolge van een 
doorgemaakt myocard infarct. Door vroegtijdige reperfusie therapie kan dit 
verlies in levensjaren gedeeltelijk worden voorkomen. De omvang van het 
behandelings-effect is afhankelijk van diverse factoren, waaronder de leeftijd 
van de patiënt, de omvang van het bedreigde myocard weefsel en de tijd die 
verstreken is sinds het ontstaan van de klachten de belangrijkste rol spelen. In 
dit hoofdstuk wordt voor diverse categorieën van patienten de 'winst in 
levensverwachting' na reperfusie therapie uitgerekend en gepresenteerd in een 
aantal tabellen. Deze kunnen worden gebruikt voor het verdelen van 
beschikbare middelen in de klinische praktijk, waarbij om redenen van kosten-
effectiviteit de effectiefste (kostbaarste) optie wordt toegewezen aan patiënten 
waarin de grootste winst kan worden verwacht. Om ethische redenen dienen 
patiënten met een onderling vergelijkbare winst voor dezelfde behandeling in 
aanmerking te komen. 
Momenteel worden in het Thoraxcentrum in Rotterdam patiënten met 
een geschatte winst in levensverwachting in de orde 1-4 maanden behandeld 
met streptokinase, terwijl 'versnelde' altepiase wordt toegediend bij een winst 
ó maanden (hierbij zijn toekomstige levensjaren met 5% per jaar gekort). 
Directe coronaria-angioplastiek wordt aanbevolen in patiënten met een 
geschatte winst ~12 maanden en in patiënten met een verhoogd risico op een 
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cerebrale bloeding. Op deze manier wordt ongeveer 80% van de populatie 
behandeld met een thrombolyticum (40% streptokinase en 40% 'versnelde' 
altepiase), terwijl 10% een directe angioplastiek ondergaat. Genoemde 
drempelwaarden zijn gekozen op basis van de huidige situatie in het 
Thoraxcentrum. Andere centra komen mogelijk tot afwijkende drempels. 
Desondanks garandeert het ontwikkelde model dat er consistente keuzes 
worden gemaakt, en dat, binnen de marges van het beschikbare budget, 
patiënten optimaal worden behandeld. 
Hoofdstllk 6 
In dit hoofdstuk wordt een alternatief model beschreven voor het schatten van 
het effect van reperfusie therapie, voornamelijk gebaseerd op een analyse van 
de GUSTO-l studie. Aangezien de gegevens die hierin worden gebruikt 
gedetailleerder zijn dan die in het model uit hoofdstuk 5, leidt dit alternatief 
tot een betere onderscheiding van laag- en hoog-risico patiënten. Een 
bijkomend voordeel is, dat de geschatte positieve en negatieve gevolgen van 
reperfusie therapie gescheiden worden gepresenteerd, hetgeen over het 
algemeen zal leiden tot een nauwkeuriger afweging in individuele gevallen. 
Hoofdstllk 7 
Een manier om onnodige behandelings-vertraging te voorkomen, is het 
toedienen van een thrombolyticum voor opname in het ziekenhuis. De 
effectiviteit en veiligheid van zo'n procedure is afhankelijk van de 
mogelijkheden voor snelle en correcte diagnose. In het Rotterdamse 
programma voor pre-hospitale thrombolyse wordt voor de bevestiging van het 
myocard infarct gebruik gemaakt van een gestandaardiseerd en computer-
geïnterpreteerd electrocardiogram. Ter voorkoming van een vals positieve 
diagnose en ongepaste thrombolytische behandeling zijn de huidige 
electrocardiografische criteria erg streng: onder andere is een totale ST-deviatie 
21,0 m V vereist. In dit hoofdstuk wordt onderzocht of deze criteria op een 
veilige wijze kunnen worden versoepeld teneinde meer patiënten reeds voor 
ziekenhuisopname te kunnen behandelen. 
Myocard infarct was de definitieve diagnose in 371 (35%) van de 1.072 
bestudeerde patiënten met symptomen passend bij een acute corona ria 
aandoening. Van 128 (35%) patiënten uit deze groep voldeed het pre-hospitale 
electrocardiogram aan de huidige criteria voor directe thrombolyse, hetgeen 
ook het geval was bij 6 (1%) patiënten met een uiteindelijke diagnose anders 
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dan myocard infarct. De hiermee corresponderende baten-risico verhouding 
was groter dan 20. De maximale winst per 1.000 geëvalueerde patiënten wordt 
behaald indien pre-hospitale thrombolytische therapie zou worden toegediend 
aan hen met een totale ST-deviatie 20,6 (0,4) m V bij een mogelijk voorwand 
(onderwand) infarct. De baten-risico verhouding is dan ongeveer 5. Op grond 
van dit onderzoek zou een groter aantal patiënten voor pre-hospitale 
behandeling in aanmerking kunnen komen dan nu het geval is. 
ALGEMENE DISCUSSIE 
Hoofdstuk 8 
Dit laatste hoofdstuk bevat een algemene discussie van de in dit proefschrift 
beschreven resultaten. Aandacht wordt besteed aan praktische en ethische 
consequenties van protocollaire geneeskunde. Uiteindelijk wordt gesteld, dat 
een klinisch beslismodel in handen van een terzake kundige arts een goed 
middel kan zijn om tot een rechtvaardige verdeling van beschikbare middelen 
te komen, waarbij tegelijkertijd de kwaliteit van de patiëntenzorg wordt 
verbeterd. 
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